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 Abstract 
Much work has been done to elucidate the role of costimulatory molecules in 
CD4+ T cell responses. However the advent of major histocompatibility class II 
tetramers now allows endogenous polyclonal populations to be tracked from the 
naive pool through the primary response to the memory phase. I have utilised 
this method to dissect the role of OX40, ICOS and CD28 in the 2W1S:I-Ab+ CD4+ T 
cell response. Additionally I have developed a model of local immunisation in 
photoconvertible Kaede transgenic mice, allowing the migration of antigen-
specific memory cells to be tracked from a given site.  
Following infection with Listeria monocytogenes expressing 2W1S peptide, OX40 
ligation specifically expanded T effector (Teff) cells which resulted in a memory 
cell pool skewed towards T effector memory (Tem) cells, while T follicular 
helper (TFH) cell and germinal centre formation was abrogated. ICOS was 
required only for the formation of TFH cells in the primary response and the 
subsequent generation of both T central memory and Tem cells. However signals 
through OX40, ICOS and CD28 were dispensable for the persistence of memory 
cells once formed. Upon secondary challenge again OX40 and ICOS were 
specifically required for the proliferation of Teff and TFH cells respectively while 
CD28 had a more general role in the optimal expansion of all T cell subsets. Thus 
a complex set of temporally separated costimulatory molecule interactions are 
required for optimal CD4+ memory T cells responses in vivo. My results indicate 
that amongst this CD4+ memory T cell pool, a secondary lymphoid tissue resident 
population reside. 
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CHAPTER 1: INTRODUCTION 
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1.1 The Adaptive Immune system 
The immune system has evolved to combat the wide range of pathogenic 
organisms in the environment in which we reside.  The key feature of the 
immune system is its ability to distinguish self from non-self and therefore 
eliminate potential threats without harming self-tissues. This is achieved 
through two arms of the immune system: innate and adaptive. The complexity of 
pathogenic microbes has prompted the evolution of increasing complex immune 
defence mechanisms against these. Central to its function is the ability to detect 
structural features of pathogens that mark them as threats. Broadly these can be 
divided into innate and adaptive recognition mechanisms. Innate mechanisms 
rely upon the identification of molecular patterns that are common to many 
microbes by receptors encoded in the germ line. Adaptive mechanisms are able 
to detect a virtually infinite variety of antigens, as a result of gene rearrangement 
(Chaplin, 2010).  
Adaptive immune mechanisms evolved more recently than innate mechanisms 
and are present only in vertebrates. Unlike innate immunity, which is 
characterised by swift responses, the development of adaptive immunity takes 
several days. This is because the adaptive system is composed of small 
populations of cells, which collectively are able to recognise a vast range of 
pathogens, which must proliferate upon recognition of their cognate antigen 
(Chaplin, 2010). A key function of the adaptive immune system is its ability to 
generate long-lived cells, which upon reencounter of their cognate antigen are 
able to respond more rapidly and robustly and therefore eliminate the threat 
 
 
 
 
3 
before it has taken hold of the host (Figure 1.1). Due to the long-term persistence 
of this population these cells are able to respond to re-infection years after their 
initial formation. This feature, termed immune memory, was thought to be 
specific to adaptive immune responses, however more recently mechanisms of 
innate immune memory have been described. Natural killer (NK) cells, a 
component of innate immunity, were found to exhibit surprising longevity 
following initial priming and enhanced responses upon re-exposure to antigen 
(Sun et al., 2014, Boehm, 2012).   
Antigen receptors expressed by T and B cells are key to the diverse range of 
pathogens that the adaptive immune system can recognise. These receptors 
undergo somatic gene rearrangement to produce randomly generated receptors 
that can respond to a large and diverse array of antigens. Although the innate 
and immune arms are described as separate entities they work in concert to 
effectively target pathogens. Innate cells respond rapidly to infection while 
adaptive cells proliferate to produce large effector populations. Many of the 
adaptive immune responses rely on contribution from innate cells for their 
activation (Chaplin, 2010). For example dendritic cells (DC) undergo maturation, 
upregulating MHC molecules and costimulatory ligands, to become effective 
antigen presenting cells (APC) in response to signals from pattern recognition 
receptors (PRR) (Joffre et al., 2009). The remainder of this thesis will focus on 
adaptive immune responses, specifically those brought about by T cells.  
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Figure 1.1: Kinetics of the immune response following antigen exposure. 
Upon antigen recognition, proliferation of adaptive immune cells takes several 
days before the pathogen is eliminated. Upon secondary exposure memory cells 
respond more rapidly and robustly to eliminate the pathogen before any 
deleterious effects on the host. 
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1.2 T lymphocytes 
T lymphocytes, or T cells, are a vital component of the adaptive immune system; 
they provide specificity for antigens, target pathogens for destruction and 
provide help to other cells to activate humoral and cellular arms of the immune 
response. A major function of T cells is the recognition and destruction of 
infected cells to prevent the multiplication of pathogens within them.  T cells can 
be divided into classes with different functions; cluster of differentiation 8+ 
(CD8+) T cells primarily recognise and destroy infected cells, while CD4+ T cells 
coordinate and activate other cell types to regulate immune responses. Both 
CD8+ and CD4+ T cells recognise antigens when they are displayed on the cell 
surface by a family of major histocompatibility (MHC) molecules. CD8+ T cells 
recognise antigen displayed by MHC class I (MHC I) molecules and CD4+ T cells 
by MHC class II (MHC II) (Chaplin, 2010). These T cell subsets will be discussed 
in more detail in section 1.7. NK-T cells are a minor class of αβ T cells that 
express the receptor NK 1.1 and are negative for both CD4 and CD8 co-receptor 
expression. Unlike CD4+ and CD8+ T cells they recognise glycolipid antigens 
presented by CD1d and secrete immunoregulatory cytokines (Godfrey et al., 
2004). 60 % to 70 % of T cells in the blood and secondary lymphoid tissue are 
CD4+ while 30-40% are CD8+ T cells (Chaplin, 2010). 
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1.3 Generation of TCR diversity 
T cells are defined by their expression of an antigen-specific T cell receptor 
(TCR), which enables them to target responses against specific pathogens 
through recognition of cognate antigen. The major class of T cells have a TCR that 
consists of an alpha and a beta subunit (αβ T cells), joined by disulphide bonds. 
Another minor class of T cells have a TCR that consists of a gamma and a delta 
chain (γδ T cells) which is structurally similar to the αβ TCR but varies in the 
mechanism by which antigen is recognised (Vantourout and Hayday, 2013). 
Although both T cell classes develop from a common progenitor in the thymus it 
is unknown what drives their lineage commitment at present (Kreslavsky et al., 
2010). Discussion of T cells will focus on αβ T cells from this point onwards. Each 
α and β chain of the TCR consists of a constant (C) and a variable (V) region 
(Saito et al., 1984). The variable region encodes 3 complementarity determining 
regions (CDR) of the receptor and therefore governs antigen specificity (Figure 
1.2). CDR3 is the main region responsible for determining variation in the 
antigen receptor. TCR genes that encode the α and β chains are located on 
chromosomes 14 and 7 respectively. The gene segments that encode the β chain 
are variable (V), diversity (D) and joining (J), which exist in a non-functional 
state in the germ line until they are assembled by recombination (Schatz and Ji, 
2011). The α chain is encoded by V and J gene segments only. The process of 
V(D)J recombination takes places in the thymus to generate the wide diversity of 
TCR that allow T cells to recognise such a large number of foreign antigens. 
These gene segments are rearranged during the process of somatic  
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Figure 1.2: Vβ genes of the T cell receptor (TCR). The Vβ chain of the TCR 
contains genes encoding the variable (V), diversity (D) and joining (J) segments 
as well as the constant (C) region. The complementarity determining region 3 
(CDR3) contains genes from each of these segments and governs the diversity of 
the TCR.  
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recombination to form functional genes. Recombination activating gene 1 
(RAG1) and RAG 2 produce a protein complex termed RAG recombinase (RAG), 
which initiates this process. RAG introduces double stranded DNA breaks that 
allow the rearrangement of these genes, which are subsequently re-joined. V(D)J 
segments are subsequently joined to C regions to produce messenger ribonucleic 
acid (mRNA) from which α and β chain proteins will be transcribed. Further 
diversity is produced by the introduction of nucleotides, imperfect gene splicing 
and frame shifts (Gilfillan et al., 1993, Delves and Roitt, 2000). Although this 
process produces a wide variety of receptors, some of the genes produced are 
non-functional. Selection in the thymus eliminates these non-functional 
receptors and ensures they are not released into the periphery.  
 
1.4 T cell development in the thymus 
The thymus is a primary lymphoid organ that supports the development and 
maintenance of the diverse T cell repertoire found in the periphery (Miller and 
Osoba, 1967). With age the thymus undergoes atrophy and consequently the 
development of newly formed T cells is impaired. The role of the thymus also 
includes educating the T cell repertoire to become tolerant to self through the 
presentation of self-antigens and deletion. The development of CD4+ and CD8+ T 
cells from haematopoietic stem cells takes place in the thymus through the 
processes of positive and negative selection. T cell precursors originate from a 
common lymphoid haematopoietic stem cell in the bone marrow before exiting 
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to the thymus.  Initial proliferation and rearrangement of the TCRβ chain of 
prothymocytes takes place in the subcapsular zone (Petrie and Zuniga-Pflucker, 
2007).  Prothymocytes then migrate into the thymic cortex where they undergo 
the process of positive selection. At this stage thymocytes do not express either 
the CD4 or CD8 co-receptor (double negative). They then upregulate both CD4 
and CD8 to become double positive before undergoing selection. Following 
rearrangement of the α chain to form a mature TCR, thymocytes interact with 
MHC:self antigen complexes, presented by specialised cortical thymic epithelial 
cells (cTEC), to determine their affinity for this molecule (Nitta et al., 2008). CD4 
and CD8 have a role in maintaining a stable interaction between the developing 
thymocytes and MHC molecule; cells that interact with MHC II become CD4+CD8- 
and those that interact with MHC I become CD4-CD8+. Single positive thymocytes, 
that now have a TCR with a sufficiently high affinity, upregulate C-C chemokine 
receptor type 7 (CCR7) and are able to migrate to the thymic medulla to continue 
their maturation (Nitta et al., 2008). Thymocytes with low affinity TCR undergo 
apoptosis and are cleared by macrophages, therefore they are deleted from the 
peripheral T cell repertoire (Surh and Sprent, 1994). In the medulla the process 
of negative selection identifies and eliminates TCR that have high affinity for self-
antigen and therefore the potential to be autoreactive in the periphery. This is an 
important step in establishing central tolerance. This process is mediated by 
medullary thymic epithelial cells (mTEC) expressing autoimmune regulator 
(AIRE) and involves the presentation of a huge array of tissue-specific antigens. 
As well as direct presentation of tissue restricted antigens (TRA) to thymocytes, 
mTEC can transfer antigen to DC which is cross presented to mediate deletion of 
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potentially self-reactive T cells (Kyewski and Klein, 2006).  Again, cells that fail 
this selection are deleted through apoptosis and the remaining mature T cells 
enter the periphery. Absence of AIRE results in self-reactive thymocytes escaping 
this negative selection and exiting into the periphery resulting in autoimmunity 
(Mathis and Benoist, 2009).  
 
1.5 Antigen Recognition by T cells 
The ability of the immune system to control and eliminate infecting pathogens 
relies on the recognition and destruction of infected cells. Viruses and bacteria 
exploit host cells for proliferation and in an attempt to evade the immune 
system. T cells bring about the recognition and destruction of these cells. To 
enable T cells to detect and target infected cells they must recognise both foreign 
antigen and a self-molecule. Therefore recognition of antigen by the TCR 
requires it to be presented on MHC I or MHC II molecules. MHC I is expressed 
ubiquitously while MHC II expression is mainly restricted to DC, macrophages 
and B cells, known as professional APC. MHC I molecules present intracellular 
antigens to CD8+ T cells. Antigens are degraded by the proteasome to produce 
peptides that are translocated to the endoplasmic reticulum (ER). Here the 
foreign peptide is inserted into the peptide binding grove of an MHC I 
heterodimer (Neefjes et al., 2011). Peptide-MHC I complexes are then presented 
at the cell surface (Vyas et al., 2008). This processes targets cells infected with 
viruses or bacteria, or alternatively cells that have undergone transformation, for 
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destruction by the immune system. The process of cross presentation can be 
used to display extracellular antigens on MHC I molecules. This is required to 
eliminate viruses than don’t infect cells or that supress the normal process of 
antigen presentation by DC, and can also be used for tumour antigens (Heath and 
Carbone, 2001).  
MHC II molecules primarily present exogenous antigens that have been 
phagocytosed and processed in the endocytic pathway to CD4+ T cells (Neefjes et 
al., 2011). Exogenous antigens are taken up by the cell into phagosomes and 
processed into peptides by proteolysis. As with MHC I, MHC II molecules are 
assembled in the ER, however they are then transported in lysosomes and fuse 
with the phagosome to form the phagolysosome where peptide loading takes 
place (Vyas et al., 2008).  
 
1.6 TCR signalling  
Upon engagement of the TCR with peptide:MHC complexes a complex signalling 
cascade is initiated to activate effector T cell functions. As the cytoplasmic region 
of the αβTCR is short, accessory molecules are required to transduce 
downstream signalling. This process is mediated by the CD3 complex, a series of 
accessory chains associated with the TCR. To transduce the signal this complex 
contains transmembrance chains CD3γ, CD3δ, CD3ε and the cytoplasmic 
homodimer CD3ζ.  The cytoplasmic regions of the CD3 chains contain 
immunoreceptor tyrosine-based activation motifs (ITAM). Recognition of 
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peptide:MHC complexes by the TCR induces members of the Src family of kinases 
such as Lck and Fyn to phosphorylate tyrosines contained within these motifs 
(van Oers et al., 1996, Lovatt et al., 2006). This recruits ζ chain associated protein 
(ZAP-70) (Chan et al., 1992), which phosphorylates a number of downstream 
molecules such as phospholipase C-gamma 1(PLC-γ1). Subsequently second 
messengers are produced such as inositol triphosphate (IP3) and diacylglycerol 
(DAG), which cause the release of intracellular calcium (Lovatt et al., 2006). This 
calcium flux then activates protein kinase C (PKC) (for IP3) and Ras guanine 
nucleotide releasing protein (Ras-GRP) (for DAG). A mitogen associated protein 
(MAP) kinase phosphorylation cascade is also activated which results in the 
activation of transcription factors that control transcription (Smith-Garvin et al., 
2009). This coordinated activation of multiple pathways leads to the 
transcription of genes that subsequently control lymphocyte proliferation and 
differentiation.  
  
1.7 T cell subsets 
1.7.1 Cytotoxic CD8+ T cells 
CD8+ T cells are cytotoxic and target cells infected with pathogens and tumour 
cells, however they can also be immunosuppressive to prevent tissue injury 
through production of IL-10 (Palmer et al., 2010). CD8+ T cells are activated by 
endogenous antigens presented on MHC I molecules derived from viruses and 
microbes that enter the cytosol (Pamer and Cresswell, 1998). Upon activation 
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CD8+ T cells undergo rapid proliferation to produce an expanded population of 
effector cells that aid in pathogen clearance, most of which will die by apoptosis, 
while some survive to produce long-lived memory cells (Butz and Bevan, 1998). 
CD8+ T cells exhibit a range of effector functions to destroy pathogens including 
cytolysis and the secretion of chemokines, cytokines and microbiocides. Two 
pathways can mediate the cytolysis of infected cells (Berke, 1995). Firstly the 
release of perforins forms pores in the cell membrane through which granzymes 
can penetrate thereby activating the caspase cascade, which leads to apoptosis of 
the infected cell. Alternatively FasL, expressed on the surface of cytotoxic T cells, 
interacts with Fas on the target cell, which also leads to apoptosis.  CD8+ T cells 
can recruit other cells, such as macrophages and neutrophils, to the infected site 
by production of chemokines (Harty et al., 2000). 
 
1.7.2 Helper CD4+ T cells 
Conventionally defined as “helper” cells CD4+ T cells are a heterogeneous 
population also containing regulatory and cytotoxic cells. CD4+ T cells are 
important in the generation of adaptive immune responses to pathogens such as 
intracellular bacteria; they provide help to B cells to produce antibodies and to 
sustain CD8+ T cell responses (Claman et al., 1966). T helper (Th) cell subsets can 
be divided into subsets based upon their function, which is thought to be 
determined, in part, by expression of key lineage defining transcription factors 
(Mosmann et al., 1986) (Figure 1.3). Each subset produces distinct cytokines and  
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Figure 1.3: Differentiation of T helper cell subsets. Following antigen 
recognition CD4+ T cells differentiate into distinct cell lineages dependent upon a 
number of factors including TCR signalling and the cytokine milieu. This process 
of differentiation depends upon the expression of key lineage defining 
transcription factors and signal transducer and activation of transcription 
(STAT) proteins. Each cell lineage produces a distinct combination of cytokines 
to exert effector functions. 
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exerts distinctive effector functions. In response to stimulation through their 
TCR, T cells differentiate depending on the cytokines that are present in the 
environment and the level of TCR stimulation.  In vitro experiments concluded 
the differentiation of Th subsets could be induced by different combinations of 
cytokines (Mosmann and Coffman, 1989), however more recent work has shown 
a dominant role for TCR signalling in regulating differentiation in vivo (van 
Panhuys et al., 2014). Using intravital imaging this study showed that high 
concentrations of antigen, and therefore TCR signalling, could induce a Th1 
response even in the presence of Th2 polarising adjuvant. Furthermore LPS 
adjuvant induced the Th1 cell lineage by increasing the DC:T cell interaction time 
and therefore enhanced signalling through the TCR.  Much focus has been put on 
identifying the lineage defining transcription factors sufficient to induce Th cell 
gene expression programmes. Differentiation of Th1, Th2, Th17, T follicular 
helper (TFH) and induced T regulatory cells (iTreg) was found to be dependent 
on: T-box transcription factor (T-bet), GATA binding protein 3 (GATA3), retinoic 
acid receptor-related orphan nuclear receptor (RORγt), B cell lymphoma-6 (Bcl-
6) and forkhead box p3 (Foxp3) respectively (Zhu et al., 2010). However 
expression of these transcription factors is not absolute; the context in which 
they are expressed is vital in defining the lineage differentiation path the cell will 
embark upon (Oestreich and Weinmann, 2012). The existence of two other cell 
lineages has recently been recognised: Th9 cells which produce interleukin (IL)-
9 (Veldhoen et al., 2008) and Th22 cells, which produce IL-22 and are located in 
the skin (Eyerich et al., 2009).  
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Although lineage defining transcription factors have been used to identify Th cell 
subsets with distinctive functions, more recently it has been recognised that co-
expression of these molecules occurs (Chung et al., 2011, Hegazy et al., 2010). In 
these circumstances other environmental factors may influence the lineage 
pathway that is taken. Epigenetic modifications, micro RNAs, cytokines and 
costimulatory signals may all impact upon the stability of a T cell lineage 
(Bluestone et al., 2009). This plasticity may allow the development of more 
diverse T cell phenotypes. This is currently an area of active research and the 
precise mechanisms by which plasticity occurs will likely be elucidated in the 
future.  
Th1 cells differentiate in the presence of IL-12 produced in large amounts by 
APC upon activation (Hsieh et al., 1993) and interferon (IFN)-γ produced by NK 
cells (Luckheeram et al., 2012) . Th1 effector cells secrete IFN-γ, IL-2 and 
lymphotoxin to eliminate viruses, intracellular pathogens and tumours but left 
uncontrolled they can lead to autoimmunity. T-bet is the master regulator of Th1 
differentiation, functioning to induce genes that promote commitment to this 
pathway but also supressing the development of other lineages (Afkarian et al., 
2002, Lazarevic et al., 2011, Djuretic et al., 2007). Th2 cells differentiate in 
response to IL-4 produced by NK T cells, mast cells and basophils (Wang et al., 
1999). They secrete IL-4, IL-5 and IL-13 which aid in the expulsion of helminths 
(Le Gros et al., 1990). Th2 cells can cause allergic responses through the 
induction of immunoglobulin (Ig) E class switching in B cells. IgE binds to 
receptors on mast cells and basophils, which leads to the secretion of products 
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such as histamine that promote allergic inflammation (Zhu and Paul, 2008). 
More recently Th17 cells were also found to differentiate from naive T cells in 
response to transforming growth factor-beta (TGFβ) and IL-6, producing IL-17A, 
IL-17F and IL-22 to enhance resistance to extracellular bacteria and fungi (Park 
et al., 2005, Harrington et al., 2005). They function through the recruitment of 
neutrophils and direct inflammatory responses. In combination with Th1 cells 
they are a key cause of autoimmunity.  As well as natural T regulatory (nTreg) 
cells, which emerge from the thymus iTreg can differentiate in the periphery 
under the influence of IL-2 and TGF-β (Curotto de Lafaille and Lafaille, 2009). 
Tregs act to modulate the immune response through their suppressive 
mechanisms, production of anti-inflammatory cytokines such as TGF-β and IL-
10, ensuring responses are not mounted against self-tissues.  
 
1.7.2.1 T follicular helper cells 
TFH cells have recently been shown to constitute a cell lineage that differentiates 
under the control of bcl-6 (Johnston et al., 2009, Nurieva et al., 2009, Yu et al., 
2009). They can be identified by high expression of the CXC chemokine receptor 5 
(CXCR5), which facilitates homing to the B cell follicle of lymph nodes (Johnston 
et al., 2009), programmed death-1 (PD-1) and inducible costimulator (ICOS) 
relative to other T cell subsets (Vinuesa et al., 2005b).  The signals required for 
TFH cell differentiation were recently elucidated by Choi et al. (Choi et al., 2011). 
During T cell:DC interaction, signals through ICOS induce expression of Bcl-6, 
which subsequently causes the upregulation of CXCR5. Bcl-6 also prevents 
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differentiation into the Th1 cell lineage through transcriptional repression of 
Blimp-1 (Tunyaplin et al., 2004). Expression of ICOS ligand (ICOSL) by B cells is 
required for the maintenance of TFH cells (Nurieva et al., 2008).  
Co-localisation of B and T cells in the follicle is essential to their function of 
providing help to B cells. Migration to the follicle is controlled by expression of 
the chemokine receptor CXCR5 and ICOS (Xu et al., 2013, Vinuesa and Cyster, 
2011). CXC chemokine ligand 13 (CXCL13), expressed by follicular stromal cells, 
binds CXCR5 to direct movement into the follicle (Vinuesa and Cyster, 2011). 
TFH cells provide help to B cells through molecules such as CD40L, IL-4, IL-21 
and PD-1 (Crotty, 2011). Interaction with B cells at the T-B border initiates the 
formation of germinal centres (GC) by inducing the differentiation of GC B cells 
(Allen et al., 2007). GC are dense structures within B cell follicles consisting of 
TFH cells, GC B cells, follicular dendritic cells (FDC), macrophages and stromal 
cells. In the absence of TFH cells GC form but are aborted suggesting TFH cells 
are required for the maintenance of these structures (de Vinuesa et al., 2000). 
Therefore TFH cells are required for the generation of high affinity plasma cells 
and memory B cells, which are produced by the GC response. The process of 
affinity maturation takes place in the GC to generate B cells with higher affinity 
for antigen (Victora and Nussenzweig, 2012). GC B cells present antigen to TFH 
cells presented on MHC II; TFH cells in turn provide survival and proliferation 
signals to B cells. As TFH cells preferentially provide signals to B cells displaying 
the most antigen they select for the highest affinity B cells. Uncontrolled 
provision of T cell help to B cells results in the production of lower affinity 
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antibodies (Victora et al., 2010); this process is tightly regulated by limiting the 
number of TFH cells thereby promoting competition among B cells. IL-21 
produced by TFH cells can induce IgG and IgA class switch recombination in 
human B cells (Avery et al., 2008).  
There is some debate over whether TFH cells survive long-term in the absence of 
antigen as memory cells. A study tracking endogenous T cells responding to 
Listeria monocytogenes infection concluded that TFH cells do not form memory 
cells as CXCR5hiPD-1hi cells were absent at memory timepoints (Pepper et al., 
2011). However other studies have suggested TFH cells do enter the memory cell 
pool but down-regulate key markers such as PD-1, ICOS and Bcl-6 compared to 
their effector counterparts, while maintaining low levels of CXCR5 expression 
(Kitano et al., 2011, Hale et al., 2013, Hale and Ahmed, 2015). TFH memory cells 
were identified by their CXCR5+Ly6clo phenotype while Th1 memory cells were 
CXCR5-Ly6chi. Analysis of gene expression in CXCR5+Ly6clo cells found that 
common genes involved in TFH cell function such as Il6ra, Pdcd1 (PD-1), Cd200 
and Sh2d1a (SAP) were highly expressed in these cells compared to CXCR5-
Ly6chi memory cells (Hale et al., 2013). This suggests that resting TFH memory 
cells have a less activated phenotype and were also found to recirculate in the 
blood or reside in spleen or lymph nodes (Hale et al., 2013). Discrepancies 
between these studies may be due to different uses of nomenclature and 
infection models. For example Pepper et al. designated CXCR5+ cells as T central 
memory (Tcm) cell precursors while TFH cells were CXCR5+PD-1+ (Pepper et al., 
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2011). More recently it has been suggested that all CXCR5+ cells are TFH cells 
while those that express high levels of PD-1 are GC TFH cells (Crotty, 2011).  
 Unlike TFH cells responding to primary infection, antigen experienced TFH cells 
responding to secondary challenge are not confined to the GC, like B cells and are 
able to freely move between the follicle and neighbouring GC (Suan et al., 2015). 
Interaction with B cells is not required to generate TFH effector cells from 
memory TFH cells unlike in the primary response (Hale et al., 2013). CXCR5+ 
memory cells are able to provide enhanced help to B cells to facilitate rapid 
production of high affinity antibody following antigen encounter (MacLeod et al., 
2011).  
 
1.8 Costimulation 
Following engagement of the TCR with cognate antigen a complex pathway of 
signalling mechanisms is initiated, as described in section 1.5. However the 
recognition of antigen by the TCR is not sufficient to fully activate a T cell, and 
this action alone results in anergy, whereby the cell becomes unresponsive to 
antigenic stimulation, or apoptosis (Harding et al., 1992). The two signal model 
of T cell activation was proposed by Bretscher and Cohn in 1970 (Bretscher and 
Cohn, 1970). They postulated that, as well as a specific signal, a non-specific 
signal was also required to distinguish self from non-self and prevent anergy of 
the responsive cells. This theory was extended by Lafferty and colleagues, who 
found that only haematopoietic cells were capable of activating T cells in vitro 
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(Lafferty et al., 1974). They proposed that APC provide the second signal to 
activate T cells. This second signal, termed costimulation, is dependent on 
environmental factors such as IL-2, which induce expression of costimulatory 
molecules. When a T cell receives both of these signals in concert it becomes fully 
activated and proliferates to carry out effector functions (Figure 1.4). Although 
the two signal model elegantly explains the ability of the immune system to 
modulate it’s functions, it oversimplifies a complex system of interactions. The 
strength of the signal from the TCR influences the activation and differentiation 
of the T cell and is integrated with an array of cell receptor:ligand interactions 
(Viola and Lanzavecchia, 1996). These include other members of the CD28 family 
such as ICOS, PD-1 and cytotoxic T lymphocyte antigen 4 (CTLA4) as well as 
other diverse receptor:ligand families. If the TCR signal is very strong or 
maintained, T cell activation can occur in the absence of a costimulatory signal 
(Bachmann et al., 1996).  
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Figure 1.4: The mechanism of T cell activation. Engagement of peptide:major 
histocompatibility complex (pMHC) expressed on APC and T cell receptor (TCR) 
expressed on T cells, along with CD28 and its ligands CD80 and CD86 results in 
optimal T cell activation. In the absence of costimulation apoptosis or anergy of 
the cell is induced (adapted from Alegre et al., 2001) (Alegre et al., 2001). 
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1.8.1 Immunoglobulin family 
1.8.1.1 CD28 
CD28 was identified in the 1980s as a receptor that enhanced the proliferation of 
T cells (Gmunder and Lesslauer, 1984). It is now the best characterised 
costimulatory receptor and is known to bind two B7 family member ligands 
CD80 (B7.1) and CD86 (B7.2) expressed primarily by APC. CD28 is expressed 
constitutively on the surface of most murine T cells, naive and activated, and on 
80 % of human T cells (Gross et al., 1992). Expression of CD80 and CD86 is 
regulated on APC such as DC, B cells and macrophages; although CD86 mRNA is 
found constitutively at low levels while CD80 mRNA is absent both ligands are 
rapidly upregulated following activation due to inflammatory stimuli (Freeman 
et al., 1993, Hathcock et al., 1994). It is now thought that CD80 and CD86 have 
overlapping functions although this has not always been the case; the higher 
affinity of CD86 and differences in structure suggested they might have distinct 
roles (Lanier et al., 1995, Borriello et al., 1997).  
CD28 encodes a 44 kDa glycoprotein that forms homodimers (Aruffo and Seed, 
1987). Interaction of CD28 with it’s ligands CD80 and CD86 is determined by a 
MYPPPY motif (Harper et al., 1991, Kariv et al., 1996). Following ligand 
engagement CD28 associates with intracellular signalling proteins such as 
phosphatidylinositol 3-kinase (PI3K). These initiate a cascade of interactions 
such as AKT (also known as protein kinase B) activation which exert 
downstream effects on T cell functions (Riha and Rudd, 2010). One pathway that 
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is activated by CD28 signalling, but not TCR signalling alone, is the nuclear 
factor-κB (NF-κB) pathway (Cheng et al., 2011). Effector functions induced by 
signalling through this pathway play a key role in immune responses to infection 
demonstrated by multiple impacts of dysregulation. 
Another CD28 superfamily member, CTLA4, binds the same ligands as CD28 but 
with greater avidity. CTLA4 is not constitutively expressed and is upregulated on 
ligation of the TCR, providing an inhibitory signal to T cell responses (Linsley et 
al., 1992). CTLA4-/- mice suffer from fatal autoimmunity with multi-organ 
lymphocyte infiltration due to over-activation of T cells (Tivol et al., 1995).  
CD28 was found to be highly expressed on thymocytes (Gross et al., 1992), 
although it’s role in thymic development is unknown as mice deficient in CD28 
show normal T cell development (Shahinian et al., 1993). The major role of CD28 
is to provide a costimulatory signal to activate T cells; in effect lowering the 
activation threshold so T cells become responsive to lower levels of antigen 
(Viola and Lanzavecchia, 1996). Binding of TCR in the absence of CD28 ligation 
can cause apoptosis or anergy of the T cell (Harding et al., 1992).  Costimulation 
through CD28 sustains T cells responses by promoting T cell survival. In vitro 
experiments showed that the addition of agonist anti-CD28 monoclonal antibody 
(mAb) to cell cultures enhanced the survival of T cells and this was due to 
increased expression of the anti-apoptotic Bcl-extra large (xL) protein (Boise et 
al., 1995). This results in the production of increased levels of cytokines (such as 
IL-2), proliferation and differentiation (Thompson et al., 1989, Boise et al., 1995). 
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In one study a modest induction of Bcl-2 was observed, another anti-apoptotic 
protein, however this was not as significant as Bcl-xL (Mueller et al., 1996).  
Mice lacking CD28 show immune defects resulting from impaired T cell 
activation (Shahinian et al., 1993). Development of T and B cells in these mice is 
normal, however following stimulation T cells did not produce IL-2. Addition of 
exogenous IL-2 only partially restored proliferation indicating CD28 works 
through a combination of mechanisms. Furthermore basal antibody titres and 
isotype switching were significantly decreased due to diminished T cell help. GC 
formation is abrogated in CD28-/- mice due to a failure of B cell proliferation in 
the follicle (Ferguson et al., 1996).These effects were also observed in the 
absence of CD80 and CD86, yet mice deficient in CD80 or CD86 only were able to 
isotype switch and form GC when immunised with complete Freund’s adjuvant 
(CFA) (Borriello et al., 1997). Therefore costimulation through CD28 enhances 
the survival and function of helper CD4+ T cells which provide signals to B cells 
vital for the formation of GC. Following infection with lymphocytic 
choriomeningitis virus (LCMV) CD8+ T cells proliferated normally indicating that 
not all responses are dependent on CD28 costimulation. Repeated antigenic 
stimulation, such as in chronic viral infection, can bypass the requirement for 
CD28 costimulation (Shahinian et al., 1993, Kundig et al., 1996). 
Until recently it was thought that expansion of memory T cells upon secondary 
challenge was independent of costimulation due to a higher affinity for antigen. 
This idea was based on in vitro studies involving stimulation of cells and the use 
of CD28-/- mice (Croft et al., 1994, London et al., 2000). New in vivo studies have 
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contested this with evidence that both CD4+ and CD8+ memory T cells require 
CD28 costimulation for optimal expansion (Ndejembi et al., 2006, Fuse et al., 
2011). One study found a differential effect of blocking costimulation with 
CTLA4Ig depending on the memory cell subset; it was found that T effector 
memory (Tem) cells were more inhibited than Tcm cells (Ndejembi et al., 2006).  
 
1.8.1.2 ICOS 
ICOS is a costimulatory receptor in the CD28 family, which interacts with ICOSL 
constitutively expressed on B cells, DC, macrophages and is also inducible on 
some non-haematopoietic cells (Hutloff et al., 1999, Yoshinaga et al., 1999, 
Swallow et al., 1999). Although ICOSL shows homology with B7 ligands CD80 
and CD86, ICOS does not bind these ligands (Yoshinaga et al., 1999, Beier et al., 
2000). Unlike CD28, ICOS is not expressed on naive T cells, but is upregulated 
upon activation (Mages et al., 2000, Hutloff et al., 1999). ICOS expression is 
controlled by a combination of signals from the TCR and CD28 (McAdam et al., 
2000). Following activation, signalling through Src kinase Fyn and the MAP 
kinase extracellular signal-related kinase (ERK) control upregulation of ICOS 
(Tan et al., 2006). Fyn causes activation of the phosphatase calcineurin, which 
consequently causes dephosphorylation of nuclear factor of activated T cells, 
cytoplasmic, calcineurin-dependent 2 (NFATc2) and translocation to the nucleus. 
In the nucleus binding of NFATc2 and ERK to the ICOS promoter enhance 
transcription of ICOS. T-bet and GATA3 additionally regulate expression in Th1 
and Th2 cells respectively by binding to the ICOS promoter or a 3’ untranslated 
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region element alongside NFATc2 (Tan et al., 2008). Expression of ICOSL on a 
wide range of cell types including B cells, macrophages and DC indicates the 
effects of ICOS costimulation may be wide ranging (Swallow et al., 1999, 
Yoshinaga et al., 2000). Upon engagement with it’s ligand ICOS signals by 
recruiting PI3K, which activates downstream MAP kinases (Fos et al., 2008, Feito 
et al., 2003). Consequently this causes the activation of AKT which is know to aid 
T cell survival, suggesting ICOS could be involved in this function.  
 ICOS was initially found to have potent costimulatory effects on T cells following 
activation, enhancing proliferation, cytokine production and providing B cell 
help (Hutloff et al., 1999).  However experiments in vivo showed modest effects 
in comparison to CD28 on proliferation and production of IL-2 (McAdam et al., 
2000, McAdam et al., 2001, Tafuri et al., 2001). ICOS was thought to have a role in 
promoting Th2 differentiation as blockade of ICOS during stimulation enhanced 
Th1 differentiation (McAdam et al., 2000). However this is now attributed to the 
role of ICOS interactions in controlling production of IL-4 and IL-13 by effector 
cells (Tafuri et al., 2001, McAdam et al., 2001). Evidence suggests that in contrast 
to CD28, ICOS regulates the production of cytokines such as IL-4 and IL-13 by 
effector cells, rather than the initial proliferation following antigenic stimulation. 
Initial reports from ICOS-/- mice also indicated that ICOS was important in 
providing B cell help; mice showed defects in GC formation and class switching 
to IgA, IgE and some IgG isotypes (Dong et al., 2001, McAdam et al., 2001, Tafuri 
et al., 2001). These defects were also seen in common variable immunodeficient 
(CVID) patients that lack ICOS (Grimbacher et al., 2003).  Further work using 
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adoptive transfers showed that this was as a result of a direct defect in T cell help 
due to the loss of TFH cells (Bossaller et al., 2006, Akiba et al., 2005). TFH cells 
are absent in ICOS-/- mice due to reduced transcription of c-Maf and production 
of IL-21, which is made by TFH cells themselves (Bauquet et al., 2009). ICOS has 
also been implicated in the development of Th17 cells (Park et al., 2005), 
however a subsequent study found that the regulation of IL-21 by ICOS was 
essential only for the maintenance and function of Th17 cells (Bauquet et al., 
2009). ICOS has shown to be protective in several different responses to 
bacteria, parasites and viruses, probably due to provision of B cell help 
(Mittrucker et al., 2002, Greenwald et al., 2002, Bertram et al., 2002). The 
interaction between CD40L on T cells and CD40 on B cells aids B cells maturation 
and survival. Maintained expression of CD40L on T cells, and therefore the 
duration of engagement with CD40, is controlled by ICOS costimulation in 
combination with CD28 (Kaminski et al., 2009).  
Sanroque mice, in which ICOS is constitutively expressed, exhibit increased IL-21 
production, TFH cell and GC formation and develop lupus like autoimmune 
disease (Vinuesa et al., 2005a, Linterman et al., 2009). These mice express a 
mutated form of Roquin, a RING-type ubiquitin ligase family member that 
mediates the post-transcriptional degradation of ICOS mRNA. Normally Roquin 
degrades ICOS mRNA through a micro-RNA dependent process however the 
mutated form of Roquin present in Sanroque mice is unable to perform this 
function (Yu et al., 2009). ICOS has also been implicated in the development of 
autoimmune disease in several animal models. ICOS mRNA and protein were 
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found to be upregulated on T cells following induction of a model of 
experimental allergic encephalomyelitis (EAE) (Rottman et al., 2001). Blockade 
of ICOS after the period of antigen priming resulted in a complete abrogation of 
the disease. Blocking anti-ICOSL mAb administered to mice with Collagen type II 
induced arthritis, a model of human rheumatoid arthritis (RA), ameliorated 
inflammation in synovial joints (Iwai et al., 2002). In a model of airway 
inflammation induced by Schistosoma mansoni eggs lymphocyte infiltration into 
the lungs, and thereby inflammation, was reduced by treatment with ICOS-Ig to 
block ICOS interactions (Tesciuba et al., 2001). As ICOS has been shown to be 
essential for the development of TFH cells and consequently the production of 
high affinity antibody by B cells the most promising targets of ICOS blockade are 
antibody mediated autoimmune diseases. Another study showed in two models 
of autoimmune disease, systemic lupus erythematosus and collagen-induced 
arthritis, that attenuation of the TFH cell response following anti-ICOSL mAb was 
responsible for amelioration of disease (Hu et al., 2009). Given the dominant role 
of ICOS in promoting immune responses and it’s involvement in autoimmune 
diseases it is a promising target for immunotherapy. 
ICOS expression can be detected on some Tregs suggesting there may be a role 
for ICOS in regulating immune responses (Herman et al., 2004). ICOS-/- mice 
show reduced numbers of Foxp3+ Tregs indicating ICOS may be involved in their 
generation or survival (Burmeister et al., 2008).  ICOS was essential for 
establishing mucosal tolerance to EAE attributable to a role in regulating the 
effector function of Treg cells (Miyamoto et al., 2005).  
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1.8.3 Tumour necrosis factor super family (TNFSF) 
The tumour necrosis factor super family (TNFSF) consists of 19 ligands and 30 
receptors (Croft, 2009).  The tumour necrosis factor receptor (TNFR) family are 
characterised by type 1 membrane proteins which contain cysteine rich repeats. 
These receptors can be divided into two groups depending on the presence of a 
70-80 amino acid region in the cytoplasmic domain: death domain (DD) 
containing and non-DD containing (Screaton and Xu, 2000). DD containing 
receptors, such as Fas, usually function to activate the caspase cascades, which 
lead to apoptosis, while non-DD containing receptors enhance proliferation, 
differentiation and survival. I will focus on non-DD containing receptors such as 
CD27, CD30 and OX40, which have been described to have important roles in T 
cell function. TNFR family members function by binding TNF receptor-associated 
factors (TRAF) to initiate signalling pathways such as NF-κB. TNF receptors also 
activate the PI3K and AKT pathways which contribute to T cell activation (So and 
Croft, 2013). TNF ligands, such as CD70 (CD27L), CD30L (CD153) and OX40L 
(CD134L) are type II membrane proteins that bind to TNFR members to exert 
effector functions. However these ligands have also been reported to receive 
signals thereby acting as receptors for cells expressing them, know as reverse 
signalling (Bowman et al., 1994, Stuber et al., 1995, Wiley et al., 1996, Lens et al., 
1999). This bi-directional signalling allows both the cell expressing the receptor 
and the ligand to benefit from signalling induced by receptor:ligand interactions.  
Interactions between TNFR family members and their ligands result in activation 
of multiple signalling pathways that contribute to the activation or suppression 
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of T cell responses. TNFR can signal through the same pathways, for example 
OX40, CD30 and 4-1BB all signal through TRAF 2 (Arch and Thompson, 1998), 
indicating there may be redundancy between receptors. This has been 
demonstrated for some receptors, for example OX40 and CD30 (Gaspal et al., 
2005), however others have shown non-overlapping functions (Dawicki et al., 
2004). 4-1BB and OX40 were found to exert non-redundant effects on CD8+ and 
CD4+ T cells respectively. Additionally some TNFR, such as OX40, are 
constitutively expressed on Tregs, which complicates the analysis of their 
function in vivo (Takeda et al., 2004).  
  
1.8.3.1 CD27 
CD27 is expressed on the majority of CD4+ T cells, naive and memory, NK cells 
and on a small population of B cells (Gravestein et al., 1995, Sugita et al., 1992). 
Although there is constitutive expression on naive T cells, following TCR 
stimulation CD27 is rapidly upregulated (de Jong et al., 1991). It binds the ligand 
CD70, a member of the TNF superfamily that is expressed on activated T and B 
cells (Tesselaar et al., 1997). Expression of CD70 is strictly controlled to ensure 
responses only occur in the presence of antigen. Pro- and anti- inflammatory 
cytokines can also act to increase or decrease CD70 expression respectively 
(Lens et al., 1997). This interaction produces a costimulatory signal that 
enhances effector cell responses to suboptimal stimulation in vitro (Gravestein et 
al., 1995).  Engagement of CD27 with its ligand enables binding to TRAF 2 and 5 
which subsequently initiates signalling through the NF-κB pathway and stress-
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activated protein kinase (SAPK)/ c-Jun N-terminal kinase (JNK) (Akiba et al., 
1998). CD27 does not enhance IL-2 production and cell cycle progression as has 
been shown for the immunoglobulin family member CD28 (Fraser et al., 1991, 
Boonen et al., 1999). Functions ascribed to CD27 are production of tumour 
necrosis factor (TNF) (Hintzen et al., 1995) and enhanced T cell survival 
(Hendriks et al., 2000).  Mice deficient in CD27 exhibit defects in both CD4+ and 
CD8+ effector T cell expansion in response to infection with influenza virus 
(Hendriks et al., 2000). The most profound effects though were seen in memory 
cells, which showed delayed kinetics of response as well as a reduction in 
absolute number following influenza challenge. Constitutive expression of CD70 
in B cells caused increased numbers of CD4+ and CD8+ T cells in secondary 
lymphoid tissue and downregulation of CD27 on these cells (Arens et al., 2001). 
In addition CD70 also drove the differentiation of T cells with effector memory 
phenotype (CD44hiCD62L-). 
 
1.8.3.2 CD30 
CD30, alongside OX40, appears to be important for CD4+ T cell responses. 
Expression of CD30 is found on activated T cells following CD28 costimulation or 
in response to IL-4 (Gilfillan et al., 1998, Toennies et al., 2004). In vitro 
expression of CD30 on CD4+ T cells peaks 1-2 days after stimulation but for CD8+ 
T cells this is delayed until 4-5 days (Bowen et al., 1996).  CD30L is expressed 
primarily by activated CD4+ T cells, some group 3 innate lymphoid cells (ILC3) 
and B cells (Shanebeck et al., 1995, Shimozato et al., 1999, Kim et al., 2003, 
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Cerutti et al., 2000). In vitro, CD30 has been shown to enhance T cell proliferation 
following sub-optimal stimulation with anti-CD3 (Gilfillan et al., 1998). Signals 
through CD30 can either enhance T cell survival or induce apoptosis, depending 
upon the situation. CD30-/- mice have increased numbers of thymocytes due to 
impaired negative selection but the number of T and B cells in the periphery 
were not altered (Amakawa et al., 1996). Following stimulation proliferation of T 
cells was normal, probably due to compensatory mechanisms by other TNFR 
family members, making it difficult to elucidate the role of CD30. However CD30 
has been shown to signal through TRAF 2 and 5 to activate the NF-κB pathway as 
other members of the TNFR family do (Aizawa et al., 1997).  
 
1.8.3.3 OX40 
OX40 was initially identified on rat CD4+ T cells in 1990 (Mallett et al., 1990) 
before being identified in the mouse (Calderhead et al., 1993). Unlike CD28, 
which is constitutively expressed, OX40 is upregulated on CD4+ T cells following 
antigenic stimulation indicating an important role in fine-tuning of T cell 
responses. Expression of OX40 in vitro and in vivo is transient, usually occurring 
within 24 hours of TCR stimulation and peaking at 2- 3 days before being lost 4-5 
days post stimulation (Gramaglia et al., 1998, Rogers et al., 2001, Dawicki et al., 
2004). As OX40 expression is closely linked to TCR stimulation the context in 
which antigen is presented will likely dictate the kinetics of expression; for 
example in chronic viral infections expression can be maintained for 20 days 
(Boettler et al., 2012). Expression of OX40 is dependent on CD28; although not 
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absent in CD28-/- CD4+ T cells OX40 expression is delayed and sub-optimal 
(Rogers et al., 2001, Walker et al., 1999).  
The ligand for OX40, OX40 ligand (OX40L), is highly expressed on APC such as 
DC and to a lower extent on B cells, T cells and some ILC (Chen et al., 1999, Kim 
et al., 2003). Expression of OX40L is transient and is induced by inflammatory 
stimuli such as signals through CD40 and Toll–like receptors (TLR). Interaction 
with OX40L initiates signalling through TRAFS 1, 2, 3 and 5 which activates the 
NF-κB pathway and PI3K/AKT signalling (Song et al., 2004, Song et al., 2008, 
Kawamata et al., 1998). This results in the upregulation of anti-apoptotic 
proteins such as Bcl-2, Bcl-xL and molecules that regulate proliferation, survivin 
and aurora B (Song et al., 2004, Rogers et al., 2001, Song et al., 2007, Song et al., 
2005).  
In vitro experiments have shown that, in contrast to CD28, OX40 is not required 
for initial CD4+ T cell proliferation and production of IL-2 however is required 
later on for survival, clonal expansion and therefore cytokine production (Rogers 
et al., 2001, Gramaglia et al., 1998).  OX40L-/- mice showed impairment in the T 
cell/ DC mediated contact hypersensitivity response, which was due to 
decreased T cell expansion and cytokine production (Chen et al., 1999). T cell 
homing, antibody isotype switching and GC formation were all normal in these 
mice. Early studies in OX40-/- mice showed no differences in susceptibility to 
Leishmania major, Nippostrongylus brasiliensis or Theiler’s murine 
encephalomyelitis virus due to normal T cell and antibody responses (Pippig et 
al., 1999). However since then multiple studies have shown a requirement for 
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OX40 in CD4+ T cell responses in vivo (Gramaglia et al., 2000, Gaspal et al., 2005, 
Kopf et al., 1999). There is known to be redundancy among the TNF family 
members and consistent with this OX40-/-CD30-/- mice show further impairment 
in CD4+ T cell responses (Gaspal et al., 2008, Gaspal et al., 2005). Deficiency of 
both OX40 and CD30, but not CD28 alone, is protective against fatal autoimmune 
disease in mice that lack Treg cells (Gaspal et al., 2011, Singh et al., 2007). This 
highlights the importance of these molecules in driving CD4+ T cell responses.  
Although some studies have shown normal B cell responses in OX40-/- mice, 
others have found a defect in the T cell dependent humoral response. In vitro 
studies showed that activated B cells receive signals through OX40L to 
proliferate and produce antibodies (Stuber et al., 1995).  In the T dependent B 
cell response to 2, 4, 6 trinitro-phenyl-keyhole limpet haemocyanin, blocking 
OX40 decreased the anti-hapten IgG response while IgM titre and GC formation 
were unaffected (Stuber and Strober, 1996).  However multiple in vivo studies 
have shown normal B cell and TFH cell responses in the absence of OX40:OX40L 
interactions (Chen et al., 1999, Pippig et al., 1999, Kopf et al., 1999). Expression 
of OX40 has been reported on TFH cells in some situations, depending on the 
mouse strain and tissue in which they are located (Akiba et al., 2005). Yet normal 
TFH cell and GC formation in the absence of OX40 indicates these processes are 
not reliant on OX40:OX40L interactions (Akiba et al., 2005).  Other studies have 
shown a requirement for OX40 in the upregulation of CXCR5 and migration of T 
cells to the follicle, where they provide help to B cells (Walker et al., 1999, 
Fillatreau and Gray, 2003, Flynn et al., 1998, Brocker et al., 1999). These data 
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indicate the relative contribution of OX40 to TFH cell and B cell responses may 
rely upon the mouse strain and type of immunisation.  
The size of the memory cell compartment is significantly reduced in OX40-/- mice 
indicating a role for OX40 in memory cell responses (Figure 1.5) (Gramaglia et 
al., 2000). CD4+ memory T cells were absent from the lamina propria in CD30-/-
OX40-/- mice but only reduced in either CD30-/- or OX40-/- mice (Withers et al., 
2009).  This suggests combined signals from both CD30 and OX40 are 
responsible for the optimal generation of the CD4+ memory T cell pool. It is 
however difficult to elucidate whether differences in memory cell populations 
derive from defective primary responses or if OX40 is essential for the long-term 
survival of memory cells. To elucidate the exact time in an immune response 
when OX40 is needed more sophisticated methods such as temporal application 
of blocking antibodies or inducible conditional knockout mice are required.   
Reactivation of memory cells is thought to be independent of costimulation but 
recent studies have challenged this idea. Rapid upregulation of OX40 on memory 
cells following stimulation, within 4 hours, indicates there may be a role for 
OX40 in secondary responses (Gramaglia et al., 1998). One study found the recall 
response of TCR transgenic OTII cells was absent in OX40L-/- mice following  
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Figure 1.5: The role of OX40 in the generation of the CD4+ memory T cell 
pool. Signals received during the primary response to antigen impact upon the 
size and function of the memory cell pool. T cells activated in the absence of 
OX40 costimulation show impaired survival and cytokine production during the 
latter stages of the primary response.  This results in a memory cell pool that is 
reduced in size and recall function.  
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challenge with ovalbumin (OVA) and lipopolysaccharide (LPS), despite there 
being no impairment in the primary response (Dawicki et al., 2004). In a mouse 
model of asthma, blocking OX40L mAb following challenge of sensitised animals 
resulted in reduced numbers of Th2 effector memory cells and lung 
inflammation (Salek-Ardakani et al., 2003).  
OX40 has also been implicated in the development of autoimmune diseases. 
OX40 is constitutively expressed on Tregs, which suppress immune responses to 
self-tissues (Takeda et al., 2004). Administration of a blocking OX40L mAb 
decreased the severity of collagen-induced arthritis by decreasing IFN-γ 
production (Yoshioka et al., 2000). In a murine model of asthma OX40-/- mice 
were unable to develop a robust Th2 response and lung inflammation was 
reduced (Jember et al., 2001). These studies highlight the potential of OX40 as a 
therapeutic target.  
A human patient deficient in OX40 has recently been identified and described 
(Byun et al., 2013).  Here functional OX40 deficiency resulted in a reduced 
proportion of CD4+ Tem cells circulating in peripheral blood however CD8+ T 
cells were less impaired. Recall response to previously vaccinated antigens or 
encountered pathogens were significantly impaired; IFN-γ production following 
stimulation for bacillus Calmette-Guerin (BCG), tetanus toxoid and 
cytomegalovirus (CMV) was not above the background level found in healthy 
control patients. This was due to deficiency in the memory cell population and 
not due to a requirement for OX40 upon recall. Although the number of memory 
B cells in peripheral blood was reduced, antibody responses to vaccine remained 
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normal and the proportion of CXCR5+ TFH cells was similar to healthy controls. 
Thus these data indicate OX40 functions in humans are closely aligned to the role 
OX40 plays in murine T cell responses.  
 
1.9 CD4+ T cell memory 
The ability of the adaptive immune system to form long-lived memory cells 
enables antigen-specific protection against secondary pathogenic challenge.  
CD4+ memory T cells are generated after infection with pathogens and provide 
rapid and enhanced protection upon reencounter (Seder and Ahmed, 2003). 
Following antigen recognition naive T cells undergo clonal expansion to form a 
primary effector cell population. The majority of this population die through 
apoptosis but a small number of cells remain and form a long-lived memory cell 
pool (Sprent and Surh, 2002).  
Memory cells are a quiescent population, persisting in greater numbers than 
naive cells of the same specificity, and are long-lived with a half-life of around 40 
days in mice (Pepper et al., 2010). They have the ability to migrate throughout 
the body, through both lymphoid and non-lymphoid tissue, to survey for 
pathogens. Following activation naive T cells upregulate CD44, required for 
survival of Th1 cells through the contraction phase, which remains highly 
expressed on memory cells (Baaten et al., 2010). Memory T cells can be divided 
into subsets based upon expression of key lymphocyte homing molecules and 
function (Sallusto et al., 1999). Tcm cells express CCR7 and CD62L (L-selectin), 
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migrate through lymphoid tissue and proliferate to produce more effector cells 
upon antigenic stimulation as well as secreting IL-2. Tem cells lack lymphocyte 
homing molecules, are thought to migrate through non-lymphoid tissue and 
blood and rapidly produce effector cytokines such as IFN-γ upon stimulation. 
More recently a population of CD8+ tissue resident memory (Trm) cells has been 
identified which are protective at the major sites of pathogen entry such as the 
skin and mucosal surfaces (Gebhardt et al., 2009, Masopust et al., 2010), 
however less is known about this population for CD4+ T cells.  
When investigating T cell memory it is important to consider the different 
phases of the response. Generation, survival and reactivation of memory cells are 
separated temporally and therefore may show different requirements for 
signals.  
 
1.9.1 Generation of CD4+ T cell memory 
An understanding of how memory T cells are generated is key for the design of 
efficacious vaccines. Difficulties have arisen in deciphering the mechanism of 
CD4+ memory T cell development due to the low frequencies of responding CD4+ 
effector T cells compared to CD8+ T cells (Homann et al., 2001). 
It is still to be determined what factors dictate whether or not a T cell enters the 
memory cell pool or dies by apoptosis. Initial ideas proposed that expression of 
IL-7Rα might mark those cells that survive to form memory cells, as IL-7 is a 
survival factor. Arguing against this, ablation of IL-7 signalling did not affect the 
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normal contraction of effector cells and consequent survival of memory cells 
(Tripathi et al., 2007). Other candidates that may dictate this decision include 
TCR signal strength and asymmetric cell division (Williams et al., 2008, Chang et 
al., 2007). Optimal activation and clonal expansion of T cells depends on 
sustained TCR:pMHCII interactions (Celli et al., 2007). The strength and duration 
of TCR stimulation influences the resultant population of effector cells and 
therefore determines the functional properties of the memory cell pool (Gett et 
al., 2003). Although there are no definitive surface markers for identifying cells 
that will enter the memory cell pool, it has been shown that CD4+ memory T cells 
originate from cytokine producing cells that have undergone clonal expansion 
following exposure to antigen (Harrington et al., 2008, Lohning et al., 2008). 
Effector cells expressing IFN-γ in response to LCMV and Listeria monocytogenes 
infection were genetically marked and found to persist in the memory cell 
population.  Another study tracking an endogenous CD4+ T cell population 
responding to Listeria monocytogenes found that two effector cell populations, 
one Tbethi and one T-betlo, both entered the memory cell pool (Pepper et al., 
2010).  These data suggest that some effector T cells survive the contraction 
phase to become memory cells.  
The generation of a functional memory T cell population depends upon a number 
of factors. The size of the naive T cell population and the signals received in the 
primary response both dictate the size and function of the resulting memory cell 
pool. Naive T cell pools can consist of between 20 to 1500 cells in the mouse 
(Moon et al., 2007, Tubo et al., 2013, Jenkins and Moon, 2012, Whitmire et al., 
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2006). Interestingly high precursor frequency can inhibit the formation of 
memory T cells. High numbers of adoptively transferred TCR transgenic T cells 
are not as efficient at forming memory cells as low numbers mimicking an 
endogenous population (Hataye et al., 2006). This is probably due to a decreased 
number of DC interactions through increased competition (Blair and Lefrancois, 
2007). Two-photon imaging revealed that as the number of T cell precursors was 
increased, the interaction time between antigen-specific T cells and DC were 
decreased (Garcia et al., 2007). This resulted in impaired activation and clonal 
expansion.  
A number of key factors, including costimulatory molecules, contribute to the 
optimal activation of CD4+ T cells in the primary response which impacts upon 
the memory cell pool. Signals through CD28 mediate primary proliferation of 
effector CD4+ T cells and production of cytokines such as interleukin 2 (IL-2) 
(Shahinian et al., 1993, Fraser et al., 1992). Deficiency of CD28 results in a 
significantly reduced CD4+ memory T cell population following bacterial 
infection (Pagan et al., 2012). Additionally a host of other receptor:ligand pairs, 
including members of the TNFSF, are also involved in the formation of an 
optimal effector population and functional memory cell pool.  
Cytokines can also play a role in the development of T cell memory. The 
cytokines present within the environment influence the proliferation and 
differentiation of effector cells. Depending on the T cell subset they may also 
affect the survival of effector cells to enter the memory cell pool (Pepper et al., 
2011). 
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1.9.2 Survival of CD4+ T cell memory 
Memory T cells are a quiescent population that persist long-term due to slow 
turnover, unlike naive T cells which rarely divide. They show distinct 
requirements for survival from naive T cells, which likely reflects their raised 
state of activation, ready to rapidly respond to pathogens (Tough and Sprent, 
1994).   
The mechanisms regulating the survival of CD4+ memory T cells have been 
difficult to elucidate. Low cell frequency in vivo makes the study of these cells 
challenging. Additionally many factors involved in the optimal primary 
expansion of effector cells impact upon the memory cell population. Therefore 
the study of memory cells in genetically deficient mice does not distinguish 
between effects during priming and long-term survival of memory cells. TCR 
transgenic cells have been used to circumvent this problem and increase the 
frequency of antigen-specific cells to a level detectable by flow cytometry 
(Harrington et al., 2008).  However problems have arisen with this method as 
clonal competition at high precursor frequency can be detrimental to memory 
cell generation and survival (Marzo et al., 2005, Blair and Lefrancois, 2007, 
Hataye et al., 2006).   
Initial studies focused on the use of CD44 and CD62L to identify memory cells 
based on the expression of surface markers. Naive mice contain a population of 
memory phenotype cells, thought to be due to responses to environmental 
antigens. However the unknown origin of these memory phenotype cells 
confounded conclusions drawn from them. Recent studies have shown that 
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memory phenotype cells are a heterogeneous population consisting of a rapidly 
dividing population and a quiescent long-lived population similar to antigen-
specific memory cells (Purton et al., 2007). Studies then transitioned to following 
antigen-specific cells that have undergone clonal expansion in response to a 
known antigen. TCR transgenic T cells were often used to circumvent problems 
associated with low cell frequency, however as described above such 
experiments have their own caveats.  
Initial studies with memory phenotype cells indicated that persistence of low 
levels of antigen and therefore TCR:MHCII interactions were key to the long-
term survival of memory cells (Gray and Matzinger, 1991). However the survival 
of CD4+ memory T cells in MHC II-/- mice was not impaired, suggesting TCR 
signals may not be required (Swain et al., 1999). These experiments were 
performed using CD4+ effector T cells activated in vitro and transferred into T 
cell deficient hosts. Therefore a lack of competition from host T cells for non-
antigen specific signals may mask a requirement for TCR signalling. Purton et al. 
showed that the survival of antigen-specific CD4+ memory T cells was 
independent of TCR signalling (Purton et al., 2007). They demonstrated that 
discrepancies between studies might be due to the heterogeneous nature of 
memory phenotype cells; this population was found to consist primarily of a 
subset of rapidly diving cells that required MHC II interactions for survival. 
Antigen-specific cells responding to LCMV were slowly proliferating and their 
survival was independent of MHC II. Distinct requirements for memory 
phenotype and antigen-specific memory cells mean these populations cannot be 
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used interchangeably to elucidate the mechanisms regulating CD4+ memory T 
cell survival.  
Experiments with CD8+ T cells were the first to show a requirement for cytokines 
for memory cells. Type I IFN induced the proliferation of CD8+ memory T cells in 
vivo (Tough et al., 1996). Other cytokines that have been shown to exhibit similar 
effects are IL-12, IL-15, IL-18 and IFN-γ (Zhang et al., 1998, Tough et al., 2001).  
The survival and homeostatic proliferation of CD8+ memory T cells have now 
been shown to rely on both IL-15 and IL-7 (Schluns and Lefrancois, 2003). 
However data indicated that CD4+ memory T cell survival was independent of 
these cytokines; memory phenotype cells are not reduced in IL-15-/- mice 
(Kennedy et al., 2000) and persistence of memory cells in common γ chain -/- 
mice is normal (Lantz et al., 2000). However multiple studies have since shown a 
dominant role for IL-7; blockade of IL-7 using mAb decreased the number of 
surviving CD4+ memory phenotype cells (Seddon et al., 2003). Studies using 
antigen-specific memory cells have corroborated this finding. IL-7 was found to 
enhance the survival of OTII memory cells in vitro and caused them to upregulate 
the survival factor Bcl-2 (Kondrack et al., 2003). Impaired survival was also 
observed in vivo using IL-7-/- mice or by mAb mediated blockade of IL-7. 
Experiments by Purton et al. showed the number of TCR transgenic memory cells 
recovered from IL-7-/- hosts was five fold less than wild-type (WT) mice (Purton 
et al., 2007). These findings were confirmed with endogenous polyclonal CD4+ 
memory T cells responding to LCMV. They also found that IL-15 was required for 
both homeostatic proliferation and survival. IL-15 and IL-7 both contributed to 
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driving homeostatic proliferation in non-lymphopenic hosts.  The presence of 
normal numbers of memory phenotype cells previously observed in IL-15-/- mice 
is thought to be due to habituation to an environment deficient in IL-15. (Purton 
et al., 2007).  
The role of costimulation in memory T cell survival is not fully understood. One 
possibility is that the survival of memory cells is enhanced by continuous or 
periodic interactions with costimulatory molecules. Alternatively the effects 
exerted during the priming and contraction phases may enhance the survival of 
effector cells that go on to form the memory cell pool. Absence of CD28 does not 
alter the long-term survival of memory cells (Pagan et al., 2012). Members of the 
TNFSF may enhance the survival of memory cells thorough promotion of anti-
apoptotic proteins such as Bcl-2. CD27- memory cells were found to survive 
poorly following adoptive transfer compared to CD27+ counterparts (Pepper et 
al., 2010). OX40 and CD30 have also been implicated in the long-term survival of 
memory T cells. CD4+ memory T cells in the lamina propria were reduced in the 
absence of these molecules despite normal priming (Withers et al., 2009). This 
appeared to be independent of Bcl-2 or Bcl-xL as CD30-/-OX40-/- cells expressed 
comparable levels to WT cells. However, evidence for the periodic provision of 
costimulatory signals is lacking, as many studies have been unable to separate 
the requirement for costimulation for survival through the contraction phase 
from long-term persistence. Given the differences in costimulatory requirements 
in different types of primary response, this may be reflected in different 
requirements for the survival of CD4+ memory T cells  
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1.10 T cell migration 
The migration of lymphocytes around the body is key to immunosurveillance. 
Active circulation increases the chance of antigen-specific T cells, which exist at 
low frequency, of coming into contact with cognate antigen.  The migration of T 
cells is controlled by a number of surface molecules such as chemokine 
receptors, selectins and integrins and is dependent upon activation state. Naive T 
cells express CCR7 and CD62L, which allow them to recirculate through lymph 
nodes (Forster et al., 1999, Bradley et al., 1994). Up-regulation of molecules such 
as CXCR3 and CCR9 allow effector cells to enter inflamed tissues at peripheral 
sites where they carry out effector functions to eliminate threats (Groom and 
Luster, 2011, Papadakis et al., 2000). Following clearance of antigen memory 
cells either retain expression of non-lymphoid homing molecules or re-express 
lymphoid homing molecules such as CD62L.  Naive T cells are thought only to be 
able to enter lymph nodes from blood through high endothelial venules (HEV) 
(von Andrian and Mackay, 2000) or from another lymph node connected in a 
chain (Braun et al., 2011). Antigen-experienced cells however are able to enter 
lymph nodes through HEV or afferent lymphatics from peripheral tissues 
(Mackay et al., 1990). The superior migratory properties of memory cells and 
their increased presence in both lymphoid and non-lymphoid tissues enable 
enhanced responses to secondary infections.  
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1.10.1 Migration into lymph nodes 
Expression of chemokines by stromal cells within the lymph node and 
chemokine receptors on T cells act to control the migration of T cells into lymph 
nodes. C-C chemokine ligand (CCL) 19 and CCL21 are expressed by fibroblastic 
reticula cells (FRCs), which form the T cell zone of the lymph node (Luther et al., 
2000). DC associate closely with this structure therefore T cells expressing the 
receptor for these chemokines, CCR7, migrate towards DC. This migration 
facilitates T cell:DC interaction and thereby T cell activation (Friedman et al., 
2006). Naive T cells enter lymph nodes through a process dependent on CCR7 
and CD62L. T cells in the blood have to tether to the endothelium as blood flow 
exerts shear forces on lymphocytes. CD62L expressed by T cells binds to it’s 
ligand peripheral node addressin (PNAd) expressed by HEV (Berg et al., 1991, 
Streeter et al., 1988). This interaction allows T cells to roll on endothelial cells. 
Endothelial cells of HEV express CCL21 which is bound by CCR7 on T cells (Stein 
et al., 2000). This causes the activation of integrins such as lymphocyte function-
associated antigen-1 (LFA-1) to enable entry through HEV. Once inside T cells 
remains for between 6-18 hours while they search for cognate antigen before 
leaving via the efferent lymphatics (Tomura et al., 2008, Grigorova et al., 2010).  
Upon initiation of an immune response exit of T cells from the lymph node is 
inhibited and entry of cells into the lymph node is increased (Hall and Morris, 
1965, Cahill et al., 1976). Entry of effector and memory T cells into the lymph 
node is also increased. Inflammatory signals activate stromal cells, which induce 
expression of chemokines and adhesion molecules on HEV (Guarda et al., 2007, 
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Martin-Fontecha et al., 2008). Once activated, effector cells express a range of 
chemokine receptors and adhesion molecules that enable their migration into 
inflamed tissues. For example migration to mucosal tissues requires expression 
of the integrin α4β7, which binds to mucosal addressin cell adhesion moelcule-1 
(MAdCAM-1) expressed on endothelium (Hamann et al., 1994, Gorfu et al., 2009). 
Exit from lymph nodes is mediated by sphingosine-1-phosphate receptor 1 
(S1P1) (Cyster and Schwab, 2012). S1pr1-/- T cells are able to enter lymph nodes 
through HEVS but are unable to exit highlighting that different molecules 
regulate these processes (Matloubian et al., 2004). Although CCR7 is required for 
entry into lymph nodes it is not required for exit, in fact it facilitates retention 
(Pham et al., 2008). However CCR7 is required for exit from non-lymphoid 
tissues since entry into the draining lymphatics is CCR7 dependent (Bromley et 
al., 2005, Debes et al., 2005).   
A striking feature of T cells is that they preferentially home to the site where 
they were activated. For example T cells responding to antigen in the mLN, 
which drain the intestine, upregulate α4β7 and CCR9 facilitating homing back to 
this site (Campbell and Butcher, 2002, Mora et al., 2003, Zabel et al., 1999). This 
ability is imprinted on T cells by the surface molecules expressed by the DC 
during priming.  
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1.10.2 Memory T cell migration 
As described in section 1.8, memory cells can be sub-divided into subsets based 
upon their migratory capacity. Tcm cells express CCR7 and CD62L and are able 
to traffic through secondary lymphoid tissue (Reinhardt et al., 2001). Tem cells 
lack these molecules and therefore are preferentially found in non-lymphoid 
tissues (Masopust et al., 2001). Trm cells express unique cell surface markers 
that facilitate their homing to peripheral tissues. These cells permanently reside 
here even after clearance of the pathogen ready to respond to reinfection at 
these sites (Gebhardt et al., 2009, Masopust et al., 2010). Trm cell populations 
have been described in many tissues for CD8+ but are less well studied for CD4+ 
T cells. It is possible that trafficking of CD4+ memory cells from peripheral 
tissues varies from CD8+ memory T cells. In the steady state a large number of 
CD4+ memory T cells were found to traffic to draining lymph nodes from the skin 
(Tomura et al., 2010). Yet a population of CD4+ T cells was observed to persist in 
the lungs of mice for several months following infection and express higher 
levels of CD69 and CD11a compared to recirculating memory cells (Hogan et al., 
2001, Teijaro et al., 2011). These cells were found to preferentially migrate back 
to the lungs when adoptively transferred into naive recipients (Teijaro et al., 
2011).  
CD4+ memory T cells are found in the afferent lymph draining skin, unlike naive 
T cells which can only enter through HEV from the blood or from other lymph 
nodes (Mackay et al., 1990, Yawalkar et al., 2000). This indicates that CD4+ 
memory T cells can utilise additional mechanisms to gain entry to lymph nodes 
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that naive T cells cannot exploit. This is supported by studies in CCR7-/- mice in 
which lymph nodes contain reduced numbers of naive T cells but a significant 
population of memory T cells (Forster et al., 1999). A recent study found that 
expression of CCR7 was dispensable for the entry of Tcm cells into lymph nodes 
(Vander Lugt et al., 2013). Using mixed bone marrow chimeras to mitigate the 
effects on lymphoid architecture found in CCR7-/- mice, they showed that 
expression of CCR7 on Tcm cells did not infer any advantage in homing to lymph 
nodes.  
 
1.11 Tracking antigen-specific CD4+ T cells in vivo 
 There are currently no specific surface markers for identifying antigen-specific 
CD4+ T cells responding to infection in vivo. This has made it difficult to track a 
polyclonal CD4+ T cell response from expansion through to the memory cell 
phase.  Low frequency of naive and memory CD4+ T cells means they have been 
below the level of detection for flow cytometry. Previously in vitro methods have 
been used to isolate total CD4+ T cell populations and study their responses 
(Boise et al., 1995). Methods using peptide loaded on cultured APC can over-ride 
antigen processing and presentation by MHC II. These methods do not reflect the 
TCR stimulus that would be present in a physiological response and therefore 
the requirement for costimulation may be reduced or abrogated completely. 
Additionally in vitro studies cannot reflect the complex microenvironments or 
replicate the effects of inflammation that naturally occur in vivo.  
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A number of methods have been developed which enable antigen-specific T cells 
to be followed from activation through proliferation, contraction and memory 
phases of the response. One of these methods uses immunisation with pigeon 
cytochrome c peptide 81-104 in mice expressing H-2 I-Ek. Around 70% of CD4+ T 
cells that respond to this have a characteristic TCR enabling a population of 
antigen-specific cells to be tracked (McHeyzer-Williams and Davis, 1995). TCR 
transgenic T cells have been widely used to elucidate the characteristics of T cell 
response in vivo and have greatly enhanced our understanding of this area (Pape 
et al., 1997). However problems have arisen with the use of this method. The 
transfer of large numbers of TCR transgenic T cells into mice has been used to 
enhance detection, however this elevated frequency is also a disadvantage. 
Increasing the size of the precursor pool can upset the fine balance of signals and 
interactions that take place during an immune response. Unphysiological 
numbers of TCR transgenic T cells have shown poor conversion to memory cell 
populations due to increased clonal competition (Hataye et al., 2006). Limiting 
numbers of mature DC mean that T cells must compete with each other for 
ligation, therefore T cell:DC interaction times are shortened and T cells are sub-
optimally activated (Celli et al., 2007).  
The use of TCR transgenic T cells has been refined to limit these problems and 
reflect a physiological response. Transferring low numbers of T cells, between 
103-104, mimics more closely the size of an endogenous polyclonal T cell pool as 
only around 10 % of transferred cells will survive (Hataye et al., 2006, Blattman 
et al., 2002). Adoptive transfer of low numbers of TCR transgenic SM1 CD4+ T 
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cells provides a population that can be tracked in allogeneic hosts (McSorley et 
al., 2002, Hataye et al., 2006).   
More recently MHC tetramers have been developed to track peptide specific T 
cells. This method has been successful for CD8+ T cells but has proved more 
technically challenging for CD4+ T cells, where the TCR shows low affinity for 
peptide:MHC complexes. However recent refinements in tetramer design and 
staining techniques have increased the use of MHC II tetramers to track antigen-
specific CD4+ T cells (Landais et al., 2009). 
 
1.12 Aims 
The role of costimulatory molecules in CD4+ T cells responses has been widely 
investigated however conflicting reports have arisen, likely due to differences in 
methodology. It has become clear that studies tracking endogenous polyclonal 
populations of antigen-specific CD4+ T cells are now required to clarify these 
roles. The study of CD4+ memory T cells in particular has been confounded by 
low cell frequency which necessitated the analysis of larger ‘memory phenotype’ 
populations. Memory T cell subsets have conventionally been defined by surface 
receptors that dictate their ability to home to secondary lymphoid tissue. 
However the recent discovery of Trm cells suggests that memory cell 
populations may be more heterogeneous than originally thought. We therefore 
sought to clarify the role of costimulatory receptors in CD4+ T cell responses and 
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investigate the migratory capacity of CD4+ memory T cells by addressing the 
following aims: 
 Clarify the role of costimulatory receptors OX40, ICOS and CD28 in the 
generation and long-term survival of CD4+ memory T cells 
 Explore the therapeutic potential of agents that block or stimulate 
signalling through costimulatory pathways 
 Investigate the location of memory cell subsets and if their migratory 
capabilities are intrinsically tied to their expression of key surface 
molecules  
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 Mice 
All of the animals used throughout this study were used in accordance with 
Home Office regulations at the
 WT mice were purchased from external suppliers (Harlan or 
Charles River) or bred in house. Details of mice used are listed in Table 2.1. 
Mice used were between 6-12 weeks of age and were sacrificed by cervical 
dislocation of the neck or a rising concentration of CO2.  All mice used were on a 
C57BL/6 background.  
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Table 2.1 Mouse strains used in study 
Mouse Strain CD45 
isotype 
Phenotype Source 
C57BL/6 CD45.2 WT or externally 
sourced from Harlan or 
Charles River 
B6.SJL-
Ptprca Pepcb/BoyJ 
 
CD45.1 Congenic C57BL/6 WT 
CTLA4Ig  
transgenic 
CD45.2 Limited signalling through 
CD28 due to circulating 
CTLA4Ig fusion protein 
P. J. Lane,  
Cd30-/- Ox40-/- CD45.2 Deficient in TNF family 
members CD30 and OX40 
resulting in impaired survival 
of CD4+ T cells in a primary 
response 
Novel cross by P. J. Lane, 
B6.129S4-
Cd80tm1ShrCd86tm2ShrIJ 
CD45.2 Deficient in CD80 and CD86 
costimulatory ligands 
resulting in failure to generate 
optimal CD4+ T cell responses 
The Jackson Laboratory  
B6129P2-
Icosltm1MakIJ 
CD45.2 Deficient in costimulatory 
ligand ICOSL which results in 
impaired T cell dependent B 
cell responses 
 
The Jackson Laboratory 
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2.2 Medium and Reagents 
All media were prepared in advance and stored at 4 °C except for the stock 
solutions for Haemolytic Gelatin Gey’s Solution which were stored at room 
temperature. 
 
 
Kaede CD45.2 All cells express the 
photoconvertible fluorescent 
Kaede protein that changes 
from green to red upon 
exposure to violet light. 
J. Brewer, University of 
Glasgow 
Kaede Ccr7-/- CD45.2 Express the photoconvertible 
Kaede protein in all cells. 
CCR7 deficient, which impairs 
migration of lymphocytes in 
response to CCL19 and CCL21. 
Novel cross at
 
Rag1-Cre Tbx21 
fl/fl Rosa26-tdRFP 
CD45.2 Cells expressing RAG (T and B 
cells) are deficient in T-bet 
resulting in impaired IFN- 
production and express red 
fluorescent protein.   
S. Reiner courtesy of M. 
Veldhoen, Babraham 
Institute, Cambridge 
Rag2-/- SM1  CD45.1 
CD45.2 
Deficient in B and T cells with 
TCR transgenic SM1 CD4+ T 
cells 
S. McSorely, University of 
California  
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Table 2.2 Preparation of RPMI with EDTA 
 
Table 2.3 Preparation of Culture Medium 
 
 
 
 
 
 
 
 
 
 
Medium and Additives Volume Final Concentration 
RPMI-1640 (1x) + L-
Glutamine 
500 ml - 
0.5 M  
Ethylenediaminetetraacetic 
acid (EDTA) 
2.5 ml 2.5 mM 
Medium and Additives Final Concentration 
RPMI-1640 (1x) + L-
Glutamine 
- 
Penicillin and Streptomycin 1 % 
L-Glutamine  2 mM 
  Heat-inactivated foetal 
bovine serum (FBS) 
10 % 
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Table 2.4 Preparation of Staining Buffer 
 
Table 2.5 Preparation of Immunofluorescence Staining Solution 
 
2.2.1 Haemolytic Gelatin Gey’s Solution 
Solutions were made up to 1 L in distilled water and autoclaved. Components of 
the solutions are listed in Table 2.6. For the working solution 10 ml of Solution A, 
2.5 ml of Solution B, 2.5 ml of Solution C and 35 ml of distilled H2O were mixed.  
For red blood cell lysis 5 ml of working solution was used per sample.  
Medium and Additives Volume Final Concentration 
Dulbecco’s Phosphate 
Buffered Saline +CaCl2 +MgCl2 
500 ml - 
Heat-inactivated foetal bovine 
serum (FBS) 
10 ml 2 % 
0.5 M 
Ethylenediaminetetraacetic 
acid (EDTA) 
2.5 ml 2.5 mM 
Medium and Additives Volume Final Concentration 
Phosphate buffered 
saline 
20 ml - 
Bovine serum albumin 
(BSA) 
0.2 g 1 % 
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Table 2.6 Haemolytic Gelatin Gey’s Solution components 
 
2.3 Dissection of Mouse Tissue 
Spleen, lymph nodes or lung were dissected from adult mice and placed in RPMI 
with EDTA. Tissues were cleaned using forceps under a dissection microscope to 
remove fat. Lungs were perfused with Dulbecco’s Phosphate Buffered Saline 
prior to dissection to wash out lymphocytes in circulation. At days 2 and 3 post 
Solution Additive Quantity 
A NH4Cl 35 g 
KCl 1.85 g 
Na2HPO4.12H2O 1.5 g 
KH2PO4 0.119 g  
Glucose 5.0 g 
Gelatin 25 g 
1% Phenol red 1.5 ml 
B MgCl2.6H2O 4.2 g 
MgSO4.7H2O 1.4 g 
CaCl2 3.4 g 
C NaHCO5 22.5 g 
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immunisation lymph nodes were teased apart using forceps to enhance 
detection. 
 
2.4 Cell Isolation 
Spleen and lymph node tissues were crushed through a 70 μm Falcon cell 
strainer and washed with RPMI with EDTA to obtain a single cell suspension and 
centrifuged to form a pellet. Red blood cells lysis was carried out by 
resuspending the pellet in 5 ml Haemolytic Gelatin Gey’s solution for 5 minutes 
on ice. The lysis was stopped by addition of 10 ml RPMI with EDTA before 
centrifugation. Typical centrifugation conditions were 6 minutes, 4 °C, 394 rcf, 
unless stated.  
Following perfusion lung tissue was chopped into small pieces using scissors and 
suspended in 2 ml of culture medium in a falcon tube. 10 μl DNAse (10 mg/ml- 
Roche Life Sciences) and 500 μl Liberase TM Research Grade (42.4 μg/ml-Roche 
Life Sciences) were added to 3.5 ml culture medium, 3 ml of this mixture was 
added to the lung tissue and it was then incubated for 40 minutes at 37 °C in a 
shaking incubator (250 rpm). Tissues were then crushed through a 70 μm Falcon 
cell strainer and washed with culture medium before being centrifuged. Red 
blood cell lysis was carried out in 3 ml Haemolytic Gelatin Gey’s solution for 5 
minutes on ice. Addition of 10 ml culture medium was used to stop the lysis 
before centrifugation.  
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2.5 Cell separation by MACS cell enrichment 
For identification of rare 2W1S:I-Ab or SM1-specific cell populations, samples 
were enriched using the Miltenyi MACS enrichment method at day 2, day 3, day 4 
and day 28 onwards as described previously (Moon et al., 2007). For 
identification of endogenous 2W1S:I-Ab -specific cell populations, samples were 
stained with 10 μg/ml APC conjugated 2W1S:I-Ab MHC II tetramer, consisting of 
four biotinylated peptide:I-Ab MHC molecules, for 1 hour in the dark in a room 
temperature water bath; cells were agitated periodically. MHC II tetramers were 
obtained from National Institute Health (NIH) Tetramer facility or generated by 
the Protein Expression Facility, University of Birmingham after the kind 
provision of 2W1S:I-Ab producing S2 cells by Dr. Marc Jenkins. For identification 
of TCR transgenic SM1-specific cell populations, samples were stained with anti-
CD45.1 PE or anti-CD45.2 PE, depending upon host allotype, and anti-CD16/32 
both at a concentration of 1:50 for 30 minutes on ice. The samples were then 
incubated with 25 μl magnetic anti-PE or anti-APC beads (Miltenyi Biotec) for 15 
minutes at 4 °C. Cell suspensions were washed with 10 ml staining buffer and 
centrifuged. To enrich, cells were filtered through a 70 μm cell strainer and 
passed through an LS column (Miltenyi Biotec) mounted on a magnet, previously 
primed with 3 ml staining buffer, and washed 3 times with 3 ml staining buffer. 
To elute the enriched fraction columns were removed from the magnet and 5 ml 
staining buffer was pushed through. Enriched and run through fractions were 
incubated with the same cocktail of surface antibodies to enable calculation of 
cell frequencies. 
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2.6 Cell Culture 
For analysis of OX40 expression on 2W1S:I-Ab+ CD4+ memory T cells, spleen and 
lymph node cells were cultured overnight at 37 °C with or without IL-7.  Cells 
were prepared as described in section 2.4 and resuspended in culture medium. 
10 million cells in 1 ml of culture media were incubated overnight in a 6 well 
plate at 37 °C alone or in addition to 100 ng IL-7. The following day enrichment 
for 2W1S:I-Ab+ CD4+ memory T cells was performed as described in section 2.5 
and cells were analysed for expression of OX40. 
 
2.7 Flow Cytometry 
2.7.1 Antibodies and Immunolabeling 
Primary antibodies used for flow cytometry are listed in Table 2.7. Prior to use 
antibodies were titrated for optimal concentrations. The amount of cells stained 
was dependent upon the frequency of the population of interest; for low 
frequencies the whole of the enriched fraction or tissue was stained, for higher 
frequencies 10-15 % of the tissue was stained.  
For the identification of TFH cells an anti-CXCR5 antibody was included alone or 
alongside MHC II tetramer for 1 hour in a room temperature water bath.  
For in vivo peptide restimulation experiments 10 μg/mL brefeldin A (Sigma) was 
added at this stage to prevent secretion of cytokines and enhance signal 
detection.  
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Lung tissue were stained with LIVE/DEAD fixable near-IR dead cell stain kit (Life 
Technologies) for 20 minutes at 4 °C prior to surface staining. This was to aid in 
the exclusion of dead cells, which were increased due to the additional digestion 
step at 37 °C. Anti-CD45.2 antibody was also included to aid in the identification 
of lymphocytes 
All cell surface staining was done in a 96 well U bottomed plate to enable 
pelleting of cells. Plates were centrifuged for 2 minutes, 4 °C, 394 rcf. The 
supernatant was flicked off and cell pellets were resuspended in 50 μl of the 
desired antibody cocktail. All antibody cocktails were made in staining buffer. 
Cells were incubated on ice for 30 minutes. Detection of CCR7 expression was 
performed at 37 °C for 30 minutes. A single colour control for each fluorochrome 
was used to set compensation parameters on the flow cytometer. Isotype 
controls were used where necessary to delineate negative populations; these are 
listed in Table 2.8. Cell pellets were washed twice with 150 μl staining buffer. 
Samples were resuspended in approximately 250 μl staining buffer and 
transferred into polystyrene fluorescence-activated cell sorting (FACS) tubes 
(Becton) for analysis on the flow cytometer.  
 
2.7.2 Intracellular Immunolabeling 
Following surface staining some samples were stained for intracellular 
transcription factors using the Foxp3/ Transcription factor staining buffer set 
(eBioscience) following the manufacturers instructions. Surface stains were fixed 
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and cells were permeabilised in 100 μl of fixation/permeabilisation solution 
made to a 1:3 ratio of fixative concentrate to diluent. Samples were incubated for 
30 minutes on ice before being washed 3 times with 150 μl 10 % 
permeabilisation buffer, prepared with distilled water. Cells were then incubated 
with antibodies against the desired transcription factors for 30 minutes on ice 
with 50 μl antibody cocktail made up in 10 % permeabilisation buffer. 150 μl of 
10 % permeabilisation buffer was used to wash twice before flow cytometric 
analysis.  
Intracellular cytokine production was analysed in experiments where an in vivo 
peptide restimulation had been performed. 10 μg/ml brefeldin A was used in all 
staining performed at room temperature or 37 °C to prevent secretion of 
cytokines. Following surface staining cells were fixed and permeabilised with 
Cytofix/Cytoperm Plus (BD Biosciences) following manufacturer’s instructions. 
Cells were then incubated with anti-IL-2 and anti-IFN-γ directly conjugated 
antibodies in 10 % permeabilisation buffer for 30 minutes on ice. Cells were 
washed twice with 10 % permeabilisation buffer before flow cytometric analysis.  
 
2.7.3 Flow Cytometry Analysis 
Samples were acquired using either the LSR II or LSR Fortessa X-20 using FACS 
diva software (BD Biosciences). Single colour controls were acquired to set 
compensation parameters to accommodate bleed over of fluorochromes into 
other channels prior to acquisition of experimental samples. Forward and side 
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scatter gates were set to exclude non-viable cells and debris. The number of 
events acquired was dependent upon the frequency of the population of interest; 
due to the low frequency of antigen-specific CD4+ T cells this was usually 
between 2-5 million events per sample. Analysis of data was performed using 
FlowJo software (Miltenyi Biotec). Addition of 10 000 Spherotech Accucount 
blank particles was used to calculate cell frequencies. 
 
Table 2.7 Primary antibodies used for flow cytometry 
Specificity 
(clone) 
Conjugate Dilution Manufacturer 
Anti-B220  
(RA3-6B2) 
efluor 450 
FITC 
1:200 
1:400 
eBioscience 
eBioscience 
Anti-CCR7 
(4B12) 
PE 
Brilliant Violet 650 
1:100 
1:100 
eBioscience 
BD Biosciences 
Anti-CD3  
(17A2) 
Alexa fluor 700 1:200 eBioscience 
Anti-CD4  
(RM4-5) 
V500 
Brilliant violet 510 
1:300 
1:300 
BD Biosciences 
Biolegend 
Anti-CD8  
(53-6.7) 
APC efluor 780 
Brilliant Violet 711 
1:200 
1:200 
eBioscience 
BD Biosciences 
Anti-CD11b  
(M1170) 
efluor 450 
FITC 
1:200 
1:400 
eBioscience 
eBioscience 
Anti-CD11c  
(N418) 
efluor 450 
FITC 
1:200 
1:400 
eBioscience 
eBioscience 
Anti-CD25  APC 1:100 eBioscience 
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(PC61) 
Anti-CD27  
(LG.7F9) 
PerCP-efluor 710 1:200 eBioscience 
Anti-CD44  
(1M7) 
APC-efluor 780 
Brilliant violet 785 
1:200 
1:200 
eBioscience 
BD Biosciences 
Anti-CD45.1  
(A20) 
FITC 
PerCP-Cy5.5 
PE 
1:200 
1:200 
1:200 
eBioscience 
eBioscience 
eBioscience 
Anti-CD45.2  
(104) 
FITC 
PerCP-Cy5.5 
PE 
1:300 
1:200 
1:500 
eBioscience 
eBioscience 
eBioscience 
Anti-CD62L   
(MCL-14) 
PE 
PE Cy7 
APC 
1:500 
1:200 
1:200 
eBioscience 
eBioscience 
eBioscience 
Anti-CD69  
(HI.2F3) 
PE Cy7 1:100 eBioscience 
Anti-CXCR5  
(2G8) 
Biotin 
PE Cy7 
PE 
1:50 
1:50 
1:50 
BD Biosciences 
BD Biosciences 
BD Biosciences 
Anti-
CD16/CD32 
(2.4G2) 
n/a 1:50 BD Biosciences 
Anti-FOXP3  
(FJK-16s) 
FITC 1:100 eBioscience 
Anti-ICOS  
(15F9) 
PerCP-efluor 710 
Alexa fluor 647 
1:100 
1:100 
eBioscience 
Biolegend 
Anti-OX40  APC 1:10 eBioscience 
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(OX-86) Brilliant violet 421 1:10 Biolegend  
Anti-PD-1  
(RMPI-30) 
PE Cy7 
Brilliant violet 421 
1:100 
1:100 
Biolegend 
Biolegend 
Anti-IL-2  
(JES6-5H4) 
Alexa fluor 488 1:100 eBioscience 
Anti-IFN-γ  
(XMG1.2) 
PE Cy7 1:200 eBioscience 
Anti-T-bet  
(4B10) 
eFluor 660 1:25 eBioscience 
 
Table 2.8 Isotype controls used for primary antibodies in flow 
cytometry 
Antibody Isotype control Clone  Manufacturer 
Anti-OX40 APC  Rat IgG1 APC eBRG1 eBioscience 
Anti-CXCR5 PE 
Cy7 
Rat IgG2a PE Cy7 eBR2a eBioscience 
Anti-ICOS 
PerCP 710 
Syrian Hamster IgG  
PerCP 710 
n/a eBioscience 
Anti-ICOS 647 Hamster IgG APC eBio299Arm eBioscience 
Anti-CCR7 PE 
Anti-CCR7 
Brilliant violet 
650 
Rat IgG2a κ PE 
Rat IgG2a κ 
Brilliant violet 650 
eBM2a 
RTK2758 
eBioscience 
Biolegend 
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2.8 Immunohistology 
2.8.1 Sectioning and fixation of tissue 
Tissues from experimental mice were frozen on dry ice and stored at -80 °C. 
Lymph nodes were frozen in Optimal Cutting Temperature (OCT) compound due 
to their small size. 6 μm sections were cut and mounted onto 4 spot slides 
(Hendley-Essex) and dried for 1 hour at room temperature. Slides were fixed in 
acetone (J.T. Baker) for 20 minutes at 4 °C then air-dried for 30 minutes. Slides 
were stored face to face in grip seal polythene bags at -20 °C.  
 
2.8.2 Immunolabeling of frozen tissue sections 
Slides were air-dried for 30 minutes at room temperature prior to 
commencement of immunolabeling then hydrated in PBS for 5 minutes. Primary 
antibodies used for immunofluorescent staining are listed in Table 2.9 and 
secondary through to quinternary reagents are listed in Table 2.10. All 
antibodies and reagents were diluted in Immunofluorescence staining solution 
containing 1 % bovine serum albumin (BSA) in PBS. Slides were blocked for 10 
minutes with 75 μl 10 % horse serum in staining solution. Excess blocking 
solution was aspirated from slides before addition of 75 μl primary antibodies 
for 1 hour in a humidified chamber. Slides were washed in PBS for 10 minutes 
between staining steps. Secondary antibodies were cross adsorbed in 10 % 
mouse serum before incubation for 30 minutes, then diluted further to the 
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required concentration before incubation. Tertiary, quaternary and quinternary 
antibodies and reagents were prepared and incubated as for secondary 
antibodies.  If required, slides were immersed in 50 μg/mL DAPI (4',6-diamidino-
2-phenylindole) in PBS solution for 20 seconds to stain nuclei, then washed 3 
times in PBS. Coverslips were mounted with ProLong Gold antifade reagent 
(Invitrogen) and sealed with clear nail varnish. Slides were allowed to air dry 
overnight before analysis or storage at -20 °C. 
 
2.8.3 Confocal analysis of immunofluorescent stained 
tissue sections 
Confocal analysis was completed using an LSM 510 Meta confocal microscope 
(Zeiss) and analysed using LSM software (Zeiss) except for tile scans which were 
taken using an LSM 780 ZEN confocal microscope (Zeiss) and analysed using 
ZEN lite (Zeiss). Four channels were used which were each scanned separately, 
with no overlap in detection between each channel. Alexa 555 conjugated 
antibodies were excited with a 561 nm helium laser, FITC/Alexa fluor 488 
conjugated antibodies were excited with a 488 nm argon laser, Alexa fluor 647 
conjugated antibodies were excited with a 633 nm helium laser and DAPI were 
excited by a 405 nm diode laser.  
For quantitation of TCR transgenic SM1 CD4+ T cells Zeiss LSM image browser 
(version 4.2.0.121) was used to draw around the T zone and B cell follicle. The 
number of SM1 CD4+ T cells, identified by CD45 isotype staining, located in these 
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areas was counted. To enumerate the number of SM1 CD4+ T cells located at the 
B/T interface the border between the T zone and B cell follicle was drawn. An 
area 20 μm either side of this line was allocated as the B/T interface and any 
SM1 CD4+ T cells lying within this were included in the count. Percentage of SM1 
CD4+ T cells in these areas was then calculated. 
 
Table 2.9 Primary antibodies used for immunofluorescent 
staining 
Specificity 
(clone) 
Conjugate Host/Isotype Manufacturer Dilution 
Anti-B220 
(RA3-682) 
Biotin Rat IgG2a, κ eBioscience 1:200 
Anti-Bcl-6 
(K112-91) 
Alexa fluor 488 Mouse IgG1, κ BD Biosciences 1:25 
Anti-CD3 
(eBio500A2) 
Biotin Armenian 
Hamster IgG 
eBioscience 1:100 
Purified anti-
CD4 (GK 1.5) 
Conjugated to 
Alexa fluor 647 
in house 
Rat IgG2b, κ eBioscience 1:150 
Anti-CD45.1 
(A20) 
FITC 
 
Mouse IgG2a, 
κ 
eBioscience 
 
1:200 
 
Anti-IgG2a FITC Goat Southern 
Biotech 
1:100 
 
Table 2.10 Secondary, tertiary, quaternary and quinternary 
reagents used for immunofluorescent staining 
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Specificity (clone) Host/Isotype Manufacturer Dilution 
Anti-Alexa Fluor 488 Rabbit Invitrogen 1:200 
 Anti-FITC Alexa fluor 
488 (polyclonal) 
Rabbit Invitrogen 1:200 
Anti-rabbit IgG Alexa 
fluor 488  
Donkey Invitrogen 1:200 
Anti-rabbit FITC Goat Southern 
Biotech 
1:100 
Streptavidin Alexa 
fluor 555 
- Invitrogen 1:500 
 
 
2.9 Immunisation and infection 
2.9.1 Growth of Listeria monocytogenes for infection 
Attenuated Listeria monocytogenes expressing peptide were used to infect mice 
so that a population of antigen-specific CD4+ T cells could be tracked from a 
primary response through to the memory phase. This infection route involves 
the uptake and processing of peptide by APC, which then display peptide 
fragments via their MHC II molecules. As described previously (Pepper et al., 
2010), 107 actA-deficient Listeria monocytogenes expressing the recombinant 
protein chicken OVA fused to either 2W1S52-68 (Rees et al., 1999, Ertelt et al., 
2009) (EAWGALANWAVDSA (Lm-2W1S)- kind gift from Professor Marc Jenkins) 
or FliC427-441 (McSorley et al., 2000, Johanns et al., 2011) (VQNRFNSAITNLGN- 
(Lm-FliC) kind gift from Sing Sing Way) peptides were injected intravenously 
(i.v.) in the tail vein. Bacteria were grown on chloramphenicol selective Luria 
Bertani (LB) agar at 37 °C overnight. LB agar plates were made by dissolving 
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17.5 g LB broth with agar (Lennox) powder (Sigma-Aldrich) in distilled water 
and shaking to dissolve. The mixture was autoclaved and cooled to around 50 °C, 
determined by being able to comfortably touch the bottle for 10 seconds. 
Chloramphenicol was then added to a final concentration of 20 μg/ml. 25 ml of 
LB agar was poured into large petri dishes and left to set before being stored at 4 
°C.  A single colony was subcultured in 10 ml LB broth supplemented with 20 
μg/ml chloramphenicol overnight at 37 °C in a shaking incubator. Bacteria were 
diluted 1/10, 1/20, 1/50 in LB broth with 20 μg/ml chloramphenicol and grown 
until optical density (OD)600=0.1 to ensure bacteria were used when in the log 
growth phase. Optical density measurements were taken on a 
spectrophotometer (Jenway 6405) calibrated against a blank containing LB 
medium only. 1 ml aliquots of bacteria were washed twice with PBS and 
centrifuged at 300 rcf for 10 minutes at room temperature to remove dead 
bacteria. Optical density measurements were taken again post washing to 
calculate the correct number of bacteria for injection. Bacteria were diluted in 
sterile PBS so each mouse received 107 in 200 μl i.v. infection with Lm-FliC was 
carried out 24 hours post adoptive transfer of TCR transgenic SM1 CD4+ T cells, 
as described in section 2.10.  
 
2.9.2 Peptide and protein immunisation 
For in vivo restimulation experiments mice that had previously been infected 
with Lm-2W1S or Lm-FliC were given 2W1S or FliC peptide and LPS to assess 
cytokine production and therefore identify cells based on their function. On day 
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28 post infection mice were injected with 100 μg peptide and 2.5 μg LPS i.v. in 
the tail vein. Mice were sacrificed 4 hours later and tissues were harvested for 
analysis.  
Aluminium precipitated (alum ppt) peptide or protein was used to elicit a strong 
Th2 response (Grun and Maurer, 1989). 500 μg 2W1S peptide in 25 μl dimethyl 
sulfoxide (DMSO) was mixed with 125 μl sterile PBS and 150 μl 10 % aluminium 
sulphate before addition of 7 μl 10 M NaOH and mixed. Alternatively 125 μl of 1 
mg/mL OVA protein conjugated to Alexa fluor 647 (Life Technologies) was 
substituted for 2W1S peptide and the amount of sterile PBS was adjusted 
accordingly to 25 μl. This was incubated in the dark at room temperature for 30 
minutes before washing 3 times with 500 μl sterile PBS. Samples were 
centrifuged at 400 rcf for 5 minutes at room temperate. 5 μg or 20 μg of alum ppt 
peptide or protein was then injected into the paw pad of the mouse in 10 μl or 20 
μl sterile PBS.  
 
2.10 Cell Transfer 
 The TCR transgenic SM1 CD4+ T population was used as an alternative way to 
track antigen-specific CD4+ T cells. This model system allowed the generation of 
CD4+ memory T cells in WT mice, which were then transferred into genetically 
deficient hosts to assess specific effects on memory cell survival rather than 
formation. Spleen and peripheral lymph nodes were harvested from TCR 
transgenic Rag-/- SM1 mice and prepared as described in section 2.4. Briefly, 
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tissues were cleaned of excess fat, crushed through a 70 μm cell strainer and red 
blood cell lysed with Haemolytic Gelatin Gey’s solution under sterile conditions. 
CD45.1+ and CD45.2+ allotype was confirmed by the staining technique described 
in section 2.7.1. The frequency of CD45.1+ and CD45.2+ TCR transgenic SM1 CD4+ 
T cells among total cells was calculated by flow cytometry using forward and 
side scatter to gate on live cells. Mice were injected i.v. with 104 TCR transgenic 
SM1 CD4+ T cells suspended in 200 μl sterile PBS in the tail vein. Consistent with 
previous studies (Hataye et al., 2006) we have shown that approximately 90 % of 
transferred cells do not survive (see Chapter 4, Figure 4.3 B), so this transfer was 
expected to form a naive population of around 1000 SM1 CD4+ T cells.  
For transfer of WT memory cells into genetically deficient hosts, TCR transgenic 
SM1 CD4+ T cells were prepared from spleen and lymph nodes as described 
above from WT mice which had received 10 000 TCR transgenic SM1 CD4+ T 
cells and been immunised with Lm-FliC 28 days previously. Typically SM1 CD4+ 
memory T cells were harvested from 4 donor mice. Cells were enriched as 
described in section 2.5 by MACS cell enrichment. Samples were then pooled and 
a small aliquot, around 2 % of the sample, was removed and stained to check for 
the presence and frequency of TCR transgenic SM1 CD4+ memory T cells, using 
expression of CD45.1, CD45.2 and CD44. Again the frequency of TCR transgenic 
SM1 CD4+ T cells among live cells was determined using forward and side scatter 
gates. SM1 CD4+ memory T cells were then transferred into donors by i.v. 
injection in the tail vein. Typically there were twice as many recipients as 
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donors, therefore ensuring a physiological number of cells were transferred, 
usually between 20,000-40,000 cells.  
 
2.11 Antibody Injection 
Temporal blockade of costimulatory pathways was achieved using mAb to 
circumvent the problems associated with impaired CD4+ T cell formation in 
genetically deficient mice and to model therapeutic administration of these 
substances. Blocking mAb against mouse OX40L (clone RM134L) and CD30L 
(clone RM153) were provided by Hideo Yagita (Akiba et al., 2000). Control rat 
IgG was purchased from Sigma-Aldrich. Mice were injected intraperitoneally 
(i.p.) with 0.25 mg anti-OX40L or control rat IgG. To assess memory cell survival 
mice were injected twice weekly for 4 weeks at 28 days post infection (dpi). To 
assess the effect of blocking OX40L on primary responses, mice were injected 1 
and 3 dpi. To enhance signalling through OX40:OX40L mice were injected i.p. 
with 100 μg agonistic anti-OX40 mAb (clone OX86) 1 dpi or on the day of 
secondary challenge for memory experiments. Anti-OX40 mAb was also given 
the day following secondary challenge when stated to assess the time period in 
which it could be effective.  
Blocking anti-ICOS and isotype control mAb were provided by MedImmune 
(Yusuf et al., 2014). Mice were injected i.p. with 0.25 mg anti-ICOS or isotype 
control mAb. Mice were injected 0 and 3 dpi for primary responses, 0 and 4 dpi 
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for memory responses and 1 day pre and post secondary challenge. To assess 
memory cell survival mice were injected twice weekly for 4 weeks from 28 dpi. 
 
2.12 Photoconversion surgery 
To investigate the migration of antigen-specific CD4+ T cells we used 
photoconvertible Kaede mice. These mice are engineered to express the green 
fluorescent Kaede protein cloned from the stony coral Trachyphyllia geoffroyi 
(Ando et al., 2002) in every cell under the control of a CAG promoter (Tomura et 
al., 2008). When exposed to violet light in the spectrum 350-400 nm a peptide 
cleavage occurs and the formation of a double bond causes the Kaede protein to 
become red fluorescent in an irreversible reaction (Mizuno et al., 2003). Once 
converted the Kaede red protein exhibits a long half-life in vivo although after 
multiple cell divisions it can be difficult to detect due to dilution with newly 
synthesised Kaede green protein (Tomura et al., 2008). To monitor the migration 
of antigen-specific cells from a site of local immunisation we developed a surgical 
method to expose the brachial lymph node to violet light and irreversibly label 
the cells within (Figure 2.1). The brachial lymph node was chosen due to our 
ability to target this lymph node with local paw pad immunisation and the ease 
with which it can be exposed to violet light compared with other lymph nodes. 
Mice undergoing surgery were 8-12 weeks of age and were weighed prior to the 
procedure. 2 mg/kg pre-operative Burprenorphine (Tamgesic, Animal Care UK) 
was administered sub-cutaneously (s.c.) 1 hour prior to surgery for analgesia. 
 
 
 
 
79 
Mice were anaesthetised within a chamber containing 4 % Isofluorane (May and 
Barker, Dagenham UK) carried with oxygen. Once mice were anaesthetised and 
breathing rate had slowed they were transferred to a face mask with 2 % 
Isofluorane. Throughout the procedure mice were kept on a 37 °C heat pad and 
breathing patterns were monitored to ensure a sufficient depth of anaesthesia. 
Pedal withdrawal reflex was checked prior to the first incision and at intervals 
throughout. Mice were shaved in the armpit region and located on their back 
with the left arm held above the head with micropore surgical tape to expose the 
area above the brachial lymph node. The area was cleaned using Hibitane 
disinfectant (Bioglan) and sterile gauze. An incision approximately 0.5-1 cm in 
length was made above the site of the brachial lymph node. Once located the 
brachial lymph node was exposed to 365 nm violet light (Campells) for 3 
minutes. The incision was then closed with coated vicryl 13 mm round bodied 
sutures (Ethicon).  Mice were given 500 μl saline s.c. in the back to replace fluids 
and placed in a warm chamber at 24 °C to recover and monitored at regular 
intervals by  staff. Mice were sacrificed 24 hours post surgery. In 
experiments to assess the migration of 2W1S:I-Ab+ CD4+ T cells mice were 
immunised s.c. in the left paw pad with 5 μg alum ppt 2W1S peptide 8, 21 or 42 
days previous to photoconversion surgery.  
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Figure 2.1: Surgery to expose the brachial lymph node to violet light. (A) 
The mouse is anaesthetised and positioned so the shaved armpit area is exposed. 
(B) An incision is made around 0.5-1 cm to expose the brachial lymph node. (C) 
The lymph node is exposed to violet light for 3 minutes before incision is closed 
with suture.  
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2.13 Statistical Analysis 
Data were analysed using GraphPad Prism (version 6.0e). Non parametric Mann-
Whitney test was used to determine significance which was set at p≤0.05. 
Kruskal-Wallis non-parametric one-way ANOVA was used to compare multiple 
groups with post hoc Dunn’s test where stated. Median values were calculated 
and used in all analyses except where stated.  
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CHAPTER 3: THE ROLE OF OX40 IN PRIMARY AND 
MEMORY CD4+ T CELL RESPONSES 
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3.1 Introduction 
Much progress has been made in elucidating the mechanisms of CD4+ T cell 
responses through the use of TCR transgenic T cells, however new physiological 
methods to track endogenous polyclonal populations are now required to refine 
and validate these findings. Combining MHC II tetramers and magnetic bead 
enrichment has successfully been used to track an endogenous population of 
antigen-specific CD4+ T cells responding to infection with Listeria monocytogenes 
(Pepper et al., 2010, Pepper et al., 2011). This method allows an antigen-specific 
population to be tracked from infection, through priming and into the memory 
cell phase. Tracking an antigen-specific population in this way also means that 
memory cells can be defined by time and reduces the reliance of defining these 
populations on surface markers such as CD44 and CD62L. Despite these obvious 
advantages the use of MHC II tetramers has some limitations; due to their 
binding of the TCR they cannot be used to isolate cells for downstream 
applications as this may affect the activation state of the cell.  Additionally, 
labelling cells with fluorescent MHC II tetramers can be problematic and 
incubation time and temperatures must be adjusted accordingly.  
Although an essential function for OX40 has been shown in the formation of 
robust primary CD4+ T cell responses, the role of this receptor for memory cell 
populations is less clear. Clearly signals received during the primary response, 
including through OX40, impact upon the resultant memory cell population. Tem 
cells were reduced in OX40-/- mice while Tcm cell number was normal, indicating 
a differential requirement for OX40 signals by CD4+ memory T cell subsets 
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(Soroosh et al., 2007). However whether periodic signalling through this 
receptor is required for the long-term persistence of CD4+ memory T cells once 
formed is unknown. Expression of OX40 has been reported on memory 
phenotype (CD44hiCD62L-) CD4+ T cells and TCR transgenic memory cells, 
indicating a possible role for OX40 in memory cell responses, yet studies tracking 
endogenous polyclonal populations are lacking (Gaspal et al., 2005). Addition of 
IL-7 to cell cultures induced CD4+ T cells to upregulate OX40. As IL-7 is known to 
promote the persistence of memory cells (Kondrack et al., 2003, Purton et al., 
2007), this may provide a mechanism by which CD4+ memory T cells receive 
survival signals through OX40 independent of TCR:MHC II interactions. CD4+ 
memory T cells were found to be reduced in the lamina propria of CD30-/-OX40-/- 
mice, while priming appeared normal suggesting that OX40 is important for the 
survival of CD4+ memory T cells (Withers et al., 2009). It was found that the 
number of antigen-specific CD4+ memory T cells was reduced in RORγt-/- mice, 
which lack group 3 ILC (Withers et al., 2012). ILC3 constitutively express OX40L, 
therefore it was proposed they might provide periodic signals to CD4+ memory T 
cells through OX40 to enable their long-term persistence.  
It has also been suggested that OX40 is important for the generation of TFH cells, 
which maintain GC and high affinity antibody production. OX40 expression has 
been shown on TFH cells, but appears to be highly variable depending upon the 
tissue and mouse strain (Akiba et al., 2005). OX40 was found to be essential for 
the upregulation of CXCR5 and therefore the movement of T cells towards the 
follicle, where they are located to provide survival and proliferation signals to B 
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cells (Walker et al., 1999, Fillatreau and Gray, 2003, Flynn et al., 1998). However 
several recent studies, one using antigen-specific T cells, have shown that GC 
formation and antibody production is normal in the absence of OX40 (Akiba et 
al., 2005, Kopf et al., 1999, Pippig et al., 1999, Chen et al., 1999). Furthermore a 
recent studied showed that administration of an OX40 agonist mAb was 
detrimental to the formation of TFH cells and GC, due to the diversion of cells 
towards the Th1 lineage, in response to LCMV infection (Boettler et al., 2013).  
The role of OX40 in augmenting CD4+ T cell responses highlighted it’s potential 
for use as a therapeutic to either promote immune responses to infection or 
tumour cells. Anti-OX40 mAb has undergone phase I clinical trials to test the 
efficacy against cancer (Curti et al., 2013). More recently combination of OX40 
with other immunotherapies is being considered as the best way to target 
tumour cells.  As expression of OX40 can be rapid and transient, depending upon 
the context of the antigen, the timing of administration of mAb is vital to the 
clinical outcome.  
In this chapter the aim was to determine the specific points at which OX40 
signals are required by an endogenous, polyclonal CD4+ T cell population. We 
have tracked an endogenous CD4+ T cell population responding to infection with 
Lm-2W1S. Using blocking anti-0X40L mAb to study memory cell persistence, we 
were able to study CD4+ memory T cells primed within a normal environment. 
Additionally as anti-OX40 mAb has shown promise as a therapeutic we dissected 
the effect of over-provision of OX40 signalling on both primary effector and 
memory CD4+ T cell populations.  
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3.2 Results 
3.2.1 Utilising Infection with Listeria monocytogenes to 
track an antigen-specific CD4+ T cell response 
Previously many studies that have investigated antigen-specific T cell responses 
have used TCR transgenic cells to achieve this (Rogers et al., 2001, Gaspal et al., 
2005). Much progress has been made in defining T cell responses using this 
approach, for example the pivotal finding that antigen-specific CD4+ T cells are 
reliant upon CD28 for optimal proliferation (Lucas et al., 1995). However the 
limitations of using TCR transgenic T cells mean that more physiological 
methods are now required to fully elucidate the mechanisms of CD4+ T cell 
responses in vivo. TCR transgenic T cell populations are monoclonal and 
therefore do not have the clonal variation in responses that would be seen for an 
endogenous T cell pool.  They are often transferred in abnormally large numbers, 
between 105 and 107 cells, thousands of times greater than a naive endogenous T 
cell pool, to enable ease of detection (Kearney et al., 1994). It has been shown 
that around 10 % of transferred cells survive within the host 24 hours after 
transfer and this has been termed the “park rate” (Hataye et al., 2006, Blattman 
et al., 2002). As the size of the effector cell population is linked to that of the 
precursor population (Moon et al., 2007), this results in intraclonal competition 
due to the presence of large numbers of identical T cells (Badovinac et al., 2007, 
Ford et al., 2007, Hataye et al., 2006, Foulds and Shen, 2006).  
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TCR transgenic T cells have been useful to advance the study of memory cells, as 
using surface markers such as CD44 and CD62L to distinguish them has 
associated caveats. Confusion over the survival requirements for memory cells 
has been caused by the use of memory phenotype cells, which have since been 
shown to have different survival requirements to antigen-specific T cells (Lenz et 
al., 2004, Purton et al., 2007). Memory phenotype cells can arise spontaneously, 
as opposed to antigen-specific memory cells, which form in response to 
immunisation with antigen. They consist of a heterogeneous population; some of 
which resemble antigen-specific cells and a small subset that undergo rapid 
homeostatic proliferation (Purton et al., 2007, Lenz et al., 2004). This 
proliferation is driven by TCR interaction, unlike antigen-specific memory cells, 
which are more reliant on cytokines IL-7 and IL-15 for their survival (Lenz et al., 
2004, Kondrack et al., 2003, Purton et al., 2007). Although TCR transgenic T cells 
have been useful in the analysis of primary responses, studies have shown poor 
conversion to memory cells with large cell number transfers (Hataye et al., 
2006), probably due to increased competition for dendritic cell interactions. 
Furthermore T cell differentiation has also been shown to be unphysiological in 
this situation resulting in a bias towards Tcm phenotype cells (Badovinac et al., 
2007, Ford et al., 2007, Marzo et al., 2005). 
Therefore we utilised a method optimised by the Jenkins laboratory to track a 
population of antigen-specific CD4+ T cells from the primary through to the 
memory response using MHC II tetramers. The immunogenic peptide 2W1S 
(Rees et al., 1999) was chosen as the precursor frequency of CD4+ T cells that 
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recognise this peptide is larger than for other populations that can be studied 
with MHC II tetramers (Moon et al., 2007). The number of cells responding to 
this peptide will therefore be larger making it less technically challenging. A 
vaccine strain of Listeria monocytogenes was engineered to secrete a fusion 
protein containing a region of OVA and the 2W1S peptide under the control of 
the hly promoter (Ertelt et al., 2009). This strain has been attenuated by a 
mutation in the actA gene (Portnoy et al., 2002), preventing cell-to-cell 
movement and therefore producing a mild acute infection that is rapidly cleared 
by the mouse. Following infection, 2W1S peptide is produced by antigen 
processing and presented on MHC II molecules.  CD4+ T cells with TCR specific 
for 2W1S were identified by staining spleen and lymph node cells with PE or APC 
labelled 2W1S:I-Ab MHC II tetramers. Cells were stained with antibodies specific 
for CD3 to identify T cells and a dump channel of non-T cell specific markers 
(B220, CD11b and CD11c) were used to exclude cells that may be binding 
tetramer non-specifically or phagocytic cells. Staining for co-receptors CD8 and 
CD4 and the activation marker CD44 were also used to positively identify 
activated 2W1S:I-Ab+ CD4+ T cells following infection (Figure 3.1 A). Uninfected 
mice contained a small population of around 100 CD3+CD4+ cells that bound 
2W1S:I-Ab tetramer; the majority of these were CD44lo, which is consistent with 
a naive phenotype (Figure 3.1 B). A tetramer binding population was not 
detected in CD8+ T cells (Figure 3.1 B). This was also the case when CD4+ T cells 
were stained with class II-associated invariant peptide (CLIP) control tetramer 
(Figure 3.1 C). This irrelevant peptide is used as a negative control tetramer to 
rule out non-specific staining. Following infection with Lm-2W1S, the naive  
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Figure 3.1: Infection with Lm-2W1S forms a population of antigen-specific CD4+ 
T cells that can be tracked using MHC class II tetramers. (A) Gating strategy for 
the identification of 2W1S:I-Ab+ CD4+ T cells; gated on lymphocytes, CD3+B220-
CD11b-CD11c-, CD4+CD8-, CD44hi2W1S:I-Ab+. (B) CD4+ (left) or CD8+ (right) T cells 
identified as in (A) from an uninfected WT mouse with gates showing 2W1S:I-Ab+ cells. 
(C) CD4+ T cells identified as in (A) from a WT mouse 7 dpi mouse stained with CLIP 
control tetramer. (D) CD4+ T cells from day 3 (left) and day 7 (right) post infection with 
Lm-2W1S with gating showing 2W1S:I-Ab+ CD4+ T cells. (E) Time course showing 
number of 2W1S:I-Ab+ CD4+ T cells following infection with Lm-2W1S (n= 4-13 mice for 
each data point).  
 
(A,B and D) Plots are representative of ≥5 mice from 2 independent experiments. (C) 
Plot is representative of 3 mice from 2 independent experiments. (E) Graph shows 
pooled data from ≥2 independent experiments. Data points represent mean and error 
bars show SEM. 
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population expands rapidly through cell proliferation. We investigated the 
kinetics of this response by analysing spleen and lymph node cells following i.v. 
infection. At day 3 post infection it was necessary to pool cells from 3 mice to 
provide a large enough population for phenotyping; there was then an 
exponential proliferation of cells between day 3 and day 7 when a median of 
around 70 000 2W1S:I-Ab+ CD4+ T cells can be found in the spleen alone (Figure 
3.1 D and E). We extended this analysis to look at the memory phase of the 
response; following the initial proliferation after infection there is a drastic 
contraction of the population until day 20, which then slowly declines over the 
following year (Pepper et al., 2011). A time course looking at day 0, day 3, day 4, 
day 5, day 7, day 28 and day 80 showed a similar pattern of expansion and 
contraction as has previously been reported (Figure 3.1 E), with a quiescent 
population of memory cells surviving at 80 dpi. Unusually there were more 
2W1S:I-Ab+ CD4+ memory T cells recovered at day 80 compared to day 28 post 
infection (Figure 3.1 E). This is likely an artefact resulting from fixation at day 28 
to stain for intracellular cytokines, a protocol which results in cell loss. 
We chose to use day 28 for all analyses of memory cells to ensure the response 
had entered the quiescent memory phase. At this timepoint a population of 
2W1S:I-Ab binding cells were identified using the magnetic enrichment method 
described previously (Moon et al., 2007). Following staining with fluorescent 
tetramers, 2W1S:I-Ab+ CD4+ T cells were enriched as described in Section 2.5. 
The 2W1S:I-Ab+ CD4+ T cells bound to the column were eluted and then stained 
with surface markers as described above. To identify memory cell subsets based 
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on their function we performed an in vivo restimulation with 2W1S peptide and 
LPS, which induces cytokine production (Pepper et al., 2011). Infection with Lm-
2W1S produces both a population of IL-2+ Tcm cells and IL-2+IFN-γ+ Tem cells at 
28 dpi following restimulation with peptide (Figure 3.2 A), consistent with 
previous studies (Pepper et al., 2011). The Tcm cell population was around 3 fold 
larger than the Tem cell population (Figure 3.2 B and C). 
 
3.2.2 Expression of OX40 on 2W1S:I-Ab+ CD4+ T cells is 
transient and heterogeneous 
The role of OX40 in primary CD4+ T cells responses has been extensively studied, 
however much of this data has not been shown for endogenous, polyclonal T cell 
populations. In addition studies tracking memory cell responses in OX40-/- 
and/or CD30-/- mice have not taken into account the effect of impaired priming 
in these mice (Gaspal et al., 2005). OX40 is induced upon TCR activation however 
the pattern of expression varies depending upon the model studied; expression 
can be detected anywhere from 2 to 20 days post activation depending on 
whether it is an acute or chronic response (Boettler et al., 2013, Gramaglia et al., 
1998). Knowledge of the timing of OX40 expression is essential to therapeutic 
interventions that target this receptor and are therefore only effective within a 
short window of time.  
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Figure 3.2: Infection with Lm-2W1S forms a population of antigen-specific 
CD4+ memory T cells. WT mice were infected with Lm-2W1S and analysed 28 dpi. 
Mice were restimulated in vivo with 2W1S peptide and LPS and analysed for 
cytokine secretion after 4 hours. (A) Gating to identify 2W1S:I-Ab+ CD4+ memory T 
cells based on functional secretion of IL-2 and IFN-γ post in vivo restimulation. (B) 
Number of 2W1S:I-Ab+ CD4+ Tcm and Tem cells 28 dpi with Lm-2W1S. (C) 
Percentage of 2W1S:I-Ab+ CD4+ Tcm and Tem cells 28 dpi with Lm-2W1S.   
  
 
(A) Plots are representative of ≥5 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 3 independent 
experiments. Bars show mean and error bars show SEM. (C) Graph shows pooled 
data from 3 independent experiments. Bars show median.   
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To investigate the role of OX40 in CD4+ T cell responses we first determined the 
kinetics of expression on the endogenous 2W1S:I-Ab+ CD4+ T cell population. 
Total CD4+ Treg cells were used as a positive control as a proportion of this 
population constitutively express OX40 (Figure 3.3 A). At 2 dpi there was a small 
number of 2W1S:I-Ab+ CD4+ T cells, which meant that it was necessary to pool 
cells from 2 mice. Among the 2W1S:I-Ab+ CD4+ T cells present at this time, there 
was no detectable OX40 expression (Figure 3.3 A). 
 OX40 expression was only detected at 3 dpi however still less than 50 % of 
2W1S:I-Ab+ CD4+ T cells expressed OX40; by 4 dpi almost all OX40 expression 
was absent and there was no detectable expression at 7 dpi (Figure 3.3 A and B). 
These data are in contrast to that published for TCR transgenic cells where OX40 
expression is uniform amongst the population (Boettler et al., 2013, Boettler et 
al., 2012, Rogers et al., 2001). As TCR transgenic T cells are monoclonal they do 
not show the natural variation in response that would be present in a polyclonal 
endogenous population due to the presence of clones of different affinities 
(Ertelt et al., 2011). High levels of TCR stimulation have been shown to be 
important for expression of OX40 (Verdeil et al., 2006), suggesting that only 
2W1S:I-Ab+ CD4+ T cells with high affinity TCR express OX40. T cells receiving 
different levels of TCR stimulation may differentially express costimulatory 
receptors and progress down different differentiation pathways. This highlights 
the requirement for studies assessing endogenous polyclonal populations.  
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Figure 3.3: Expression of OX40 on endogenous 2W1S:I-Ab+ CD4+ T cells is 
transient and heterogeneous in response to infection with Lm-2W1S. WT mice 
were infected with Lm-2W1S and analysed at various timepoints as indicated. (A) 
Expression of OX40 on 2W1S:I-Ab+ CD4+ T cells at day 2, day 3, day 4, day 7 and 
day 28 post infection with Lm-2W1S, 4 hours post peptide restimulation and 4 days 
post-secondary challenge, and on Foxp3+ CD4+ Treg cells which were used as a 
positive control for OX40 staining. (B) Percentage of 2W1S:I-Ab+ CD4+ T cells 
expressing OX40 at day 3, day 4 and day 7 post infection. (C) WT mice were 
infected with Lm-2W1S and 28 dpi spleen and lymph node cells were harvested and 
cultured overnight alone or with IL-7. Samples were then enriched for 2W1S:I-Ab+ 
CD4+ T cells and stained for OX40. Gated on CD4+ T cells.  
 
(A) Plots are representative of ≥5 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 2 independent 
experiments. Bars show median. (C) Plots are representative of 5 mice from 1 
experiment. Values on plots are percentages. 
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2W1S:I-Ab+ CD4+ memory T cells, at 28 dpi, did not express OX40 directly ex vivo 
(Figure 3.3 A), however these cells could rapidly upregulate OX40 when 
restimulated in vivo with 2W1S peptide and LPS. Four hours following peptide 
restimulation the vast majority of 2W1S:I-Ab+ CD4+ T cells expressed OX40 
indicating a rapid inducement of OX40 expression upon TCR stimulation and a 
less restricted expression pattern than in a primary response (Figure 3.3 A). 
Again OX40 expression was not maintained for a long period; 4 days post 
secondary challenge with Lm-2W1S all 2W1S:I-Ab+ CD4+ T cells were OX40- 
(Figure 3.3 A). These data are in line with that previously published showing 
OX40 is not expressed on the majority of CD4+ memory T cells but rather is 
linked to antigenic stimulation, however some studies have found low levels of 
OX40 on memory cells, so it is likely context dependent (Croft, 2010, Salek-
Ardakani et al., 2003). Addition of IL-7 to in vitro cultures has been shown to 
upregulate OX40 expression on CD4+ memory T cells (Gaspal et al., 2005). To test 
if this was also true for 2W1S:I-Ab+ CD4+ memory T cells, WT mice were infected 
with Lm-2W1S to form a memory cell population. Spleen and lymph node cells 
were harvested 28 dpi and cultured overnight with IL-7.  Addition of IL-7 caused 
around 70 % of 2W1S:I-Ab+ CD4+ memory T cells to express OX40 (Figure 3.3 C). 
This shows that memory cells receiving IL-7 signals in vivo may express OX40, 
however does not explain why expression cannot be detected on these cells 
directly ex vivo.  
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3.2.3 OX40 is primarily expressed on 2W1S:I-Ab+ CD4+ T 
cells with an effector phenotype following infection 
 Effector cells responding to Lm-2W1S can be divided into 3 populations based 
on their expression of CXCR5 and PD-1 (Pepper et al., 2011); CXCR5-PD-1-T-bet+ 
Teff cells, CXCR5+PD-1-Bcl-6+ cells that give rise to central memory cells and 
CXCR5+PD-1+Bcl-6+ TFH cells. These 3 populations could be identified in WT 
mice 7 dpi with Lm-2W1S by expression of the chemokine receptor CXCR5 and 
CD28 family member PD-1 (Figure 3.4 A). It has previously been shown that 
these populations present at day 7 go on to form distinct memory cell 
populations from Teff and T central memory precursors (Pepper et al., 2011).  In 
contrast to previous studies using TCR transgenic T cells we found that 
expression of OX40 was heterogeneous among the responding 2W1S:I-Ab+ CD4+ 
T cell population, indicating a certain subset may specifically benefit from OX40 
signals. As OX40 was only expressed early in the primary response, 3 dpi, then 
rapidly lost we analysed effector and TFH cell markers at this timepoint to 
determine if OX40 is preferentially expressed on one subset.  
On day 3 post infection there are very few 2W1S:I-Ab+ CD4+ T cells present in the 
spleen and lymph nodes, as the population has not yet undergone exponential 
expansion. Therefore it was necessary to pool samples from 3 mice following 
magnetic enrichment to ensure there were enough cells to correctly identify 
expression levels. We sought to investigate if OX40 was specifically expressed by 
the previously identified CXCR5- Teff cells or CXCR5+PD-1+ TFH cells or if there 
was no bias in the expression pattern. T-bet is the key lineage defining 
 
 
 
 
97 
transcription factor expressed by Th1 effector cells (Szabo et al., 2000), however 
at 3 dpi 2W1S:I-Ab+ CD4+ T cells uniformly express T-bet therefore it cannot be 
used to differentiate Teff cells from TFH cells (Figure 3.4 B). The IL-2 receptor 
CD25 is expressed on CXCR5- Teff cells but not on CXCR5+ Tcm precursors or TFH 
cells (Pepper et al., 2011). CD25 was found to be required for the development of 
CXCR5- Teff cells; CXCR5- cells developed at 1/10 the rate of WT in the absence of 
CD25 but Tcm precursors and TFH cells developed normally (Pepper et al., 
2011). CD25 can therefore be used to identify Teff cells at 3 dpi, the timepoint at 
which OX40 expression is present. CD25 is expressed on around half of 2W1S:I-
Ab+ CD4+ T cells at 3 dpi identifying a population of Teff cells (Figure 3.4 B). TFH 
cells can be identified by a lineage defining transcription factor Bcl-6, however it 
is not expressed on 2W1S:I-Ab+ CD4+ T cells as early as 3 dpi therefore cannot be 
used to identify TFH cells when OX40 expression is present (Figure 3.4 B). 
CXCR5 is also used as a key marker to identify TFH cells (Ansel et al., 1999). 3 dpi 
with Lm-2W1S around 80% of 2W1S:I-Ab+ CD4+ T cells were CXCR5+ (Figure 3.4 
B), meaning it is not a useful marker to distinguish Teff cells from TFH cells at 
this point. Therefore we could identify Teff cells based upon their expression of 
CD25. CD25 and OX40 are co-expressed on 2W1S:I-Ab+ CD4+ T cells (Figure 3.4 
C). The majority of cells expressing OX40 at 3 dpi are CD25+ and conversely the 
majority of OX40+ cells are CD25+ (Figure 3.4 D and E). This indicated that they 
are committed at an early stage to the effector cell lineage, not the TFH cell 
lineage. This was surprising as OX40 has previously been implicated in the 
development and survival of TFH cells (Gaspal et al., 2005). 
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Figure 3.4: Expression of T-bet, CD25, Bcl-6 and CXCR5 on 2W1S:I-Ab+ CD4+ T 
cells. WT mice were infected with Lm-2W1S and analysed at the specified 
timepoints. On day 3 post infection samples were enriched and 3 mice were pooled 
due to low cell number. (A) 2W1S:I-Ab+ CD4+ T cells can be split into subsets 7 dpi 
based on expression of CXCR5 and PD-1; CXCR5- Teff cells (red), CXCR5+ T 
central memory precursors (green) and CXCR5+PD-1+ TFH cells (blue). (B) 
Expression of T-bet, CD25, Bcl-6 and CXCR5 on 2W1S:I-Ab+ CD4+ T cells 3 dpi. (C) 
Co-expression of OX40 and CD25 on Teff cells 3 dpi. (D) Percentage of OX40- and 
OX40+ cells expressing CD25 and (E) Percentage of CD25- and CD25+ cells 
expressing OX40 3 dpi. (F)  Expression of OX40 and Bcl-6 on 2W1S:I-Ab+ CD4+ T 
cells 4 dpi. (G) Percentage of Bcl-6- and Bcl-6+ cells expressing OX40 at 4 dpi.  
 
(A-C and F) Plots are representative of of ≥4 mice from ≥2 independent 
experiments. Values on plots are percentages. (B) Grey shaded areas on 
histograms represent relevant isotype control and values show percentage of 
positive cells. (D, E and G) Graphs show pooled data from 2 independent 
experiments. Bars show median.   
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 Studies have shown a defect in the migration of CXCR5+ CD4+ T cells into the B 
cell follicle in the absence of OX40, implying a detrimental effect on TFH cells, 
which may complete their differentiation in the B cell follicle (Walker et al., 1999, 
Fillatreau and Gray, 2003, Crotty, 2011). However more recent work has shown 
normal TFH cell differentiation and GC development in OX40-/- mice, OX40L-/- 
mice and using blocking anti-OX40L mAb (Kopf et al., 1999, Akiba et al., 2005, 
Ekkens et al., 2003). Bcl-6 expression could be detected at 4 dpi however by this 
point the majority of 2W1S:I-Ab+ CD4+ T cells were OX40-. However a small 
percentage of Bcl-6+ cells were OX40+ indicating that OX40 is not exclusively 
expressed by Teff cells in the primary response (Figure 3.4 F and G).  
 
3.2.4 Peptide restimulation rapidly induces OX40 
expression on 2W1S:I-Ab+ CD4+ T cells 
To investigate the kinetics of OX40 expression following TCR stimulation we 
used 2W1S peptide and LPS to stimulate mice that had previously been infected 
with Lm-2W1S. Restimulation at 7 dpi caused the majority of 2W1S:I-Ab+ CD4+ T 
cells to upregulate OX40 (Figure 3.5 A). This included not only CXCR5- Teff cells, 
but also a large proportion of CXCR5+ Tcm precursor cells and TFH cells (Figure 
3.5 B). This indicated that OX40 is more broadly expressed following 
restimulation and not mainly restricted to Teff cells as seen at day 3 post 
infection.  
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Figure 3.5: Upon re-encounter of antigen, OX40 is more broadly expressed on 
2W1S:I-Ab+ CD4+ T cells. WT mice were infected with Lm-2W1S then restimulated 
28 dpi in vivo with 2W1S peptide and LPS. Tissues were harvested 4 hours post 
restimulation for analysis of OX40 expression. (A) Expression of OX40 on 2W1S:I-
Ab+ CD4+ T cells following restimulation with 2W1S peptide 7 dpi. (B) Percentage of 
T cell subsets expressing OX40 following restimulation with 2W1S peptide 7 dpi. 
Shown are 2W1S:I-Ab+ CD4+ T cells that are Teff cells, T central memory precursor 
cells and TFH cells. (C) Expression of OX40 on 2W1S:I-Ab+ CD4+ T cells following 
restimulation with 2W1S peptide 28 dpi. (D) Percentage of 2W1S:I-Ab+ CD4+ T cells 
expressing OX40 28 dpi directly ex vivo (no peptide) and following restimulation with 
2W1S peptide.  
 
(A and C) Plots are representative of 6 mice from 2 independent experiments. 
Values on plots are percentages. (B and D) Graphs show pooled data from 2 
independent experiments. Bars show median.   
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OX40 was not detected on 2W1S:I-Ab+ CD4+ memory T cells directly ex vivo 
(Figure 3.5 A), however following restimulation around 80% of 2W1S:I-Ab+ CD4+ 
T cells are OX40+ (Figure 3.5 C and D).  
 
3.2.5 Blocking OX40 signalling does not impair memory 
cell survival, however does affect expansion upon 
secondary challenge 
Previous work in our laboratory has shown impaired survival of CD4+ memory T 
cells in mice that lack group 3 ILC. This was postulated to be due to a deficiency 
in signalling through OX40, as ILC3 constitutively express OX40L (Withers et al., 
2012). Although the majority of CD4+ T cells do not express OX40, surface 
expression can be upregulated following incubation with IL-7 (Gaspal et al., 
2005), so this was a possible mechanism by which OX40 may provide survival 
signals.  To test this hypothesis we used blocking anti-OX40L mAb to temporally 
control signalling though the OX40:OX40L pathway. This approach was used to 
circumvent the caveats associated with using OX40-/- mice where primary T cell 
survival is impaired and therefore defects in the precursor population impact 
upon the memory cell pool.  As there is redundancy in the OX40 signalling 
pathway we combined this with blockade of CD30L (Gaspal et al., 2005).  We 
infected mice with Lm-2W1S and rested for 28 days to form a population of 
endogenous 2W1S:I-Ab+ CD4+ T cells that could be tracked. Once the memory cell 
population had formed mice were given blocking anti-OX40L, blocking anti-
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CD30L, a combination of both blocking mAb or control IgG mAb twice weekly for 
4 weeks (Figure 3.6 A). Although the half-life of the 2W1S:I-Ab+ CD4+ memory T 
cell population is 40 days (Pepper et al., 2010), if OX40 signals play a key role in 
the survival of memory cells we would expect to see a reduction in their number 
after a 4 week period of antibody treatment. Blocking anti-OX40L mAb did not 
cause a significant reduction in the number of 2W1S:I-Ab+ CD4+ memory T cells 
recovered (Figure 3.6 B; median for control: 6794, anti-OX40L: 4509). 
Combination of OX40L and CD30L blockade however caused a modest, but 
statistically significant reduction in the number of 2W1S:I-Ab+ CD4+ memory T 
cells (Figure 3.6 B; median for control: 6794, anti-OX40L & CD30L: 2505).  
We then investigated whether providing additional signalling through the 
OX40:OX40L pathway using agonistic anti-OX40 mAb could enhance memory 
cell survival. Agonistic OX40 mAb have the potential for use in the clinic to 
enhance CD4+ T cell responses; for example they are currently being trialled in 
models of cancer (Weinberg et al., 2000, Curti et al., 2013). They have also been 
considered for use as adjuvants in vaccination due to their efficacy in enhancing 
the immune response in several different viral and fungal models (Munks et al., 
2004, Humphreys et al., 2003). However the number of 2W1S:I-Ab+ CD4+ 
memory T cells recovered from mice receiving anti-OX40 mAb for 4 weeks was 
not significantly greater than from mice that received control IgG mAb (Figure 
3.6 C; median for control: 5673, anti-OX40: 5211).   
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Figure 3.6: Blocking OX40L mAb impairs expansion of memory cells upon 
challenge but not memory cell survival. WT mice were infected with Lm-2W1S 
and at 28 dpi blocking anti-OX40L, blocking anti-CD30L, combined blocking anti-
OX40L and anti-CD30L or control IgG mAb were administered twice weekly for 4 
weeks. 2W1S:I-Ab+ CD4+ memory T cells were then enumerated from spleen and 
lymph nodes. (A) Schematic showing the immunisation protocol. (B) Number of 
2W1S:I-Ab+ CD4+ memory T cells recovered following mAb treatment. 
 
WT mice were infected with Lm-2W1S and at 28 dpi agonistic anti-OX40 or control 
IgG mAb were administered twice weekly for 4 weeks. 2W1S-I-Ab+ CD4+ memory T 
cells were then enumerated from spleen and lymph nodes. (C) Number of 2W1S:I-
Ab+ CD4+ memory T cells recovered following mAb treatment. 
 
WT mice were infected with Lm-2W1S and at 28 dpi challenged again with 
Lm-2W1S. Blocking anti-OX40L, blocking anti-CD30L, combined blocking anti-
OX40L and anti-CD30L or control IgG mAb were administered 1 day pre and post 
secondary challenge and spleen and lymph nodes were analysed 4 days post 
secondary challenge. (D) Number of of 2W1S:I-Ab+ CD4+ memory T cells recovered 
following secondary challenge. (E) Number of 2W1S:I-Ab+ CD4+ Tem, Tcm and TFH 
from mice receiving blocking anti-OX40L or control IgG mAb following challenge. (F) 
Flow cytometry plots showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ 
T cells following secondary challenge.  
 
 
(B and D) Graphs show pooled data from 2 independent experiments except for 
blocking anti-CD30L and blocking anti-OX40L & CD30L which are from 1 
experiment. Bars show median. (C and E) Data are from 1 experiment. Bars show 
median. (F) Plots are representative of 4 mice from 1 experiment. Mann-Whitney 
test: *p<0.05, **p<0.01, ns= non-significant. 
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These data suggest that in the response to Lm-2W1S the survival of CD4+ 
memory T cells was independent of OX40, however a modest effect on survival 
was seen when CD30L was also blocked. 2W1S:I-Ab+ CD4+ memory T cells did 
not constitutively express the OX40 costimulatory receptor suggesting signals 
through OX40 are an unlikely survival mechanism. However 2W1S:I-Ab+ CD4+ 
memory T cells were able to rapidly upregulate OX40 following restimulation 
with 2W1S peptide. This led to the question of whether manipulating OX40 
signals at this timepoint could affect the re-expansion of memory cells. The rapid 
expansion of memory cells following antigenic stimulation is one of their 
defining characteristics. Previous work has shown an important role for OX40 in 
the memory recall response in an asthma model (Salek-Ardakani et al., 2003). 
We examined whether there is a requirement for OX40 costimulatory signals 
upon secondary challenge. Mice were challenged with Lm-2W1S at day 28 post 
infection and spleen and lymph node tissues were analysed 4 days post 
secondary challenge. Blocking anti-OX40L, blocking anti-CD30L or control IgG 
mAbs were administered 1 day pre and post secondary challenge due to the 
rapid and transient expression of OX40 on 2W1S:I-Ab+ CD4+ T cells.  In contrast 
to their survival, OX40 was required for the optimal expansion of 2W1S:I-Ab+ 
CD4+ T cells following secondary challenge, however combined blockade of 
CD30L did not cause an additive effect (Figure 3.6 D; median for control: 338 
051, anti-OX40L: 219533, anti-OX40L & CD30L: 209 632). Furthermore when 
2W1S:I-Ab+ CD4+ T cells were broken down into subsets, Tem, Tcm and TFH cells, 
this effect was specifically seen on the Tem cell subset (Figure 3.6 E and F).  
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3.2.6 Ligation of OX40 upon secondary challenge 
enhances Tem cell expansion 
Since blocking OX40 signalling caused a reduction in the expansion of memory 
cells post secondary challenge we investigated whether ligation of OX40 could 
enhance expansion. As before WT mice were infected with Lm-2W1S and 
challenged again 28 dpi. Agonistic anti-OX40 or control mAb were administered 
on the day of secondary challenge. Enumeration of 2W1S:I-Ab+ CD4+ memory T 
cells from spleen and lymph nodes showed a significant increase in number 
(approximately 6.4 fold) from mice treated with anti-OX40 mAb (Figure 3.7 B). 
Interestingly the phenotype of the expanded antigen-specific pool was biased in 
favour of CXCR5- Tem cells (Figure 3.7 A) with a significant increase in both their 
proportion and absolute number (Figure 3.7 C). This was accompanied by a 
decrease in the proportion of TFH cells however the absolute number was not 
significantly affected, indicating that agonistic anti-OX40 mAb have specific 
effects on CXCR5- cells (Figure 3.7 D). 
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Figure 3.7: Ligation of OX40 upon challenge enhances Tem cell expansion. WT 
mice were infected with Lm-2W1S and at 28 dpi challenged with Lm-2W1S. Agonistic 
anti-OX40 or control IgG mAb were administered on the day of secondary challenge. 
2W1S:I-Ab+ CD4+ T cells were enumerated from spleen and lymph nodes 3 days 
later. (A) Flow cytometry plots showing expression of CXCR5 and PD-1 on 2W1S:I-
Ab+ CD4+ T cells. (B) Number of of 2W1S:I-Ab+ CD4+ memory T cells. (C) Percentage 
(left) and number (right) of  Tem cells. (D) Percentage (left) and number (right) of TFH 
cells.   
 
(A) Plots are representative of >5 mice from 2 independent experiments. (B-D) 
Graphs show pooled data from 2 independent experiments. Bars show median. 
Mann-Whitney test: ***p<0.001, ****p<0.0001 ns= non-significant.  
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The expression of OX40 in this response is rapid and transient therefore we 
investigated whether the timing of administration of the mAb had a bearing on 
the response; an important point to consider when implementing their use 
therapeutically. WT mice were infected with Lm-2W1S and challenged on day 28 
as before, however administration of anti-OX40 or control mAb was delayed 
until the following day. Despite a modest increase in number in mice receiving 
anti-OX40 mAb this difference was not significant indicating mAb must be given 
at the point of secondary challenge for the greatest effect, given the rapid loss of 
OX40 expression (Figure 3.8 A and B).  
Ligation of OX40 upon secondary challenge biased the resulting population 
towards Tem cells and reduced the proportion of TFH cells. As TFH cells are 
essential for the maintenance of GC we cut spleen sections from mice post 
secondary challenge to identify what affect this would have. Sections were 
stained for Bcl-6 (the transcription factor expressed by GC B cells and TFH cells), 
CD3 and CD4 and counter-stained with the nuclear marker DAPI. Tile scans were 
taken of whole spleen sections to accurately assess the number and size of GC. 
GC were identified as dense clusters of Bcl-6+ cells within the B cell follicle which 
was identified by absence of CD3+ and CD4+ stained cells. GC were identified in 
both mice receiving control and anti-OX40 mAb however in the latter there were 
considerably fewer present and they were reduced in size (Figure 3.9 A). This 
difference was quantified by drawing around the GC in each spleen section and 
calculating their area; the total GC area was then divided by area of the spleen 
section to account for any differences in spleen size.   
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Figure 3.8: Timing of anti-OX40 mAb administration impacts response. WT 
mice were infected with Lm-2W1S and at 28 dpi challenged with Lm-2W1S. 
Agonistic anti-OX40 or control IgG mAb were administered 1 day post secondary 
challenge. 2W1S-specific memory cells were enumerated from spleen and lymph 
nodes. (A) Flow cytometry plots showing the population of CD44hi 2W1S:I-Ab+ CD4+ 
T cells following secondary challenge from control and anti-OX40 treated mice. (B) 
Number of of 2W1S:I-Ab+ CD4+ memory T cells recovered secondary challenge from 
control and anti-OX40 treated mice. 
 
(A) Plots are representative of 8 mice from 2 independent experiments. (B) Graphs 
shows pooled data from 2 independent experiments. Bars show median. Mann-
Whitney test: ns= non-significant.  
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Figure 3.9: Ligation of OX40 upon challenge decreases the area and total 
number of GC. Mice were infected with Lm-2W1S and at 28 dpi challenged again 
with Lm-2W1S. Agonistic anti-OX40 or control IgG mAb were administered on the 
day of secondary challenge. (A) Spleen sections were cut and stained for 
expression of Bcl-6 (green), CD3 (blue) and CD4 (red) and counterstained with 
DAPI to identify GC by dense clusters of Bcl-6+ cells. “GC” denotes germinal centre 
outlined by white dashed line; “T” denotes T cell zone and “F” denotes B cell follicle. 
(B) GC area from control and anti-OX40 treated mice was calculated by drawing 
around Bcl-6+ areas on Zen lite and dividing by total splenic area to adjust for 
differences in spleen size. (C) Total number of GC per section were counted and 
divided by total splenic area to adjust for differences in spleen size. 
  
(A) Confocal images are representative of 5 mice from 1 experiment. Magnification 
25x. Scale bar represents 100 µm. (B and C) Graphs show data from 1 independent 
experiment. Bars show median. Mann-Whitney test: *p<0.05, *p<0.01. 
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The total area (Figure 3.9 B) and number (Figure 3.9 C) of GC were both 
significantly reduced in mice that received anti-OX40 mAb compared to control 
mice. This effect was seen despite there being a reduction only in the proportion 
of TFH cells but not in the absolute number (Figure 3.7 D). This may be due to 
alterations in the fine balance of T cell subsets and spreading of CD4+ T cells into 
the B cell follicle impacting upon the response.  
 
3.2.7 Manipulation of OX40 signalling shapes the 
primary response to Lm-2W1S 
Agonistic anti-OX40 mAb have previously been shown to increase the numbers 
of TCR transgenic T cells following primary immunisation (Gramaglia et al., 
1998, Williams et al., 2007). Studies using OX40-/- mice have shown a defect in 
the primary expansion of CD4+ T cells due to poor survival late in the primary 
response (Gramaglia et al., 2000, Murata et al., 2000). Some studies have inferred 
a role for OX40 in the generation of TFH cells however this is from the study of 
total, not antigen-specific, CXCR5+ T helper cells and therefore does not separate 
effects on T cell survival from TFH cell differentiation (Walker et al., 1999, 
Fillatreau and Gray, 2003). Since provision of agonistic anti-OX40 mAb at 
challenge specifically benefitted the CXCR5- Teff cell population, we manipulated 
OX40 signalling in the primary response to determine which subsets are reliant 
on this pathway. WT mice were infected with Lm-2W1S and received either 
agonistic anti-OX40, blocking anti-OX40L or control mAb and were analysed 7 
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dpi to determine the effect on proliferation of antigen-specific CD4+ T cells in a 
primary response. Data using the Lm-2W1S model was consistent with previous 
studies; provision of agonistic anti-OX40 mAb 1 dpi resulted in a 5.5-fold 
increase in the number of 2W1S:I-Ab+ CD4+ T cells at 7 dpi (Figure 3.10 B; 
median for control 53 972, anti-OX40 316 688). Ligation of OX40 using anti-
OX40 mAb specifically expanded the CXCR5- Teff cell subset as seen in response 
to secondary challenge (Figure 3.10 A). This increase was observed in both the 
proportion (Figure 3.10 D) and absolute number (Figure 3.10 E) of Teff cells 
among the 2W1S:I-Ab+ population. Interestingly the TFH cell subset was 
completely abrogated (Figure 3.10 A), despite reports that OX40 may be 
important for the generation of TFH cells (Gaspal et al., 2005).  Both the 
proportion and absolute number of TFH cells were significantly decreased 
following anti-OX40 treatment (Figure 3.10 F and G). Blocking anti-OX40L mAb 
recapitulated data shown for OX40-/- mice; the number of 2W1S:I-Ab+ CD4+ T 
cells was 2-fold lower than mice receiving control mAb (Figure 3.10 C). Blockade 
of OX40L caused a significant decrease in the number and proportion of Teff 
cells, consistent with a role for OX40 in survival of CD4+ T cells, but there was no 
significant effect on TFH cells (Figure 3.10 D-G). 
T-bet is the key transcription factor that directs lineage commitment to the Th1 
response. As we observed a bias towards expansion of Teff cells with ligation of 
OX40 we analysed intracellular expression of T-bet in mice that received anti-
OX40, anti-OX40L or control mAb.  
 
 
 
 
114  
100 101 102 103 104
100
101
102
103
104
0.2 
7.4 
90 
100 101 102 103 104
100
101
102
103
104
1.2
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
6.7 
32 
58 
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
10 
52 
33 
A 
CXCR5 
P
D
-1
 
CD44 
2W
1S
:I-
A
b 
control 
anti-OX40 
anti-OX40L 
B 
C 
ns 
**** *** 
ns 
**** 
**** 
D E 
F G 
*** 
** 
**** 
** 
%
 T
ef
f 
N
um
be
r o
f T
ef
f 
 
 
 
 
115 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Manipulation of signalling through OX40 shapes the 2W1S:I-Ab+ 
CD4+ T cell response to Lm-2W1S. WT mice were infected with Lm-2W1S and 
taken 7 dpi. Mice received either agonistic anti-OX40 or control IgG mAb 1 dpi, or 
blocking anti-OX40L or control IgG mAb 1 and 3 dpi. (A) Flow cytometry plots 
showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells 7 dpi from 
mice receiving control IgG, agonistic anti-OX40 or blocking anti-OX40L mAb. (B) 
Number of 2W1S:I-Ab+ CD4+ T cells 7 dpi from mice receiving control IgG or 
agonistic anti-OX40 mAb. (C) Number of 2W1S:I-Ab+ CD4+ T cells 7 dpi from mice 
receiving control IgG or blocking anti-OX40L mAb. (D) Percentage of Teff cells 
among 2W1S:I-Ab+ CD4+ T cells 7 dpi from mice receiving control IgG, agonistic anti-
OX40 or blocking anti-OX40L mAb. (E) Number of Teff 2W1S:I-Ab+ CD4+ T cells cells 
7 dpi from mice receiving control IgG, agonistic anti-OX40 or blocking anti-OX40L 
mAb. (F) Percentage of TFH cells among 2W1S:I-Ab+ CD4+ T cells 7 dpi from mice 
receiving control IgG, agonistic anti-OX40 or blocking anti-OX40L mAb. (G) Number 
of TFH cells 7 dpi from mice receiving control IgG, agonistic anti-OX40 or blocking 
anti-OX40L mAb. 
 
(A) Plots are representative of ≥7 mice from ≥2 independent experiments. (B-G) 
Graphs show pooled data from 2 independent experiments. Bars show median. 
Mann-Whitney test: **p<0.01, ***p<0.001, ****p<0.0001, ns= non-significant. 
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Within the 2W1S:I-Ab+ CD4+ T cell population expression of T-bet was primarily 
by CXCR5- Teff cells (Figure 3.11 A).  Ligation of OX40 resulted in the vast 
majority (99%) of 2W1S:I-Ab+ CD4+ T cells expressing T-bet at 7 dpi, confirming 
that the CXCR5- Teff population are specifically expanded. Conversely blocking 
OX40 caused a reduction in the percentage of cells expressing T-bet (Figure 3.11 
B).  
 
3.2.8 Intrinsic expression of T-bet is not required for the 
enhanced expansion of Teff cells in response to OX40 
ligation 
As we observed an increase in the number of 2W1S:I-Ab+ CD4+ T cells expressing 
T-bet when mice were treated with agonistic anti-OX40 mAb we investigated 
whether endogenous expression of T-bet was required for expansion of Teff cells 
responding to OX40. To this end mice with a selective deletion of the gene 
encoding T-bet in cells that express RAG1 (B and T cells) were utilised. WT and 
Rag1-Cre Tbx21 fl/fl Rosa26-tdRFP were immunised with Lm-2W1S, given 
control or anti-OX40 mAb at 1 dpi and analysed at 7 dpi. As seen in WT mice 
provision of agonistic anti-OX40 mAb in Rag1-Cre Tbx21 fl/fl Rosa26-tdRFP 
mice resulted in significantly more 2W1S:I-Ab+ CD4+ T cells 7 dpi (Figure 3.12 B), 
due to the specific expansion of Teff cells (Figure 3.12 A and D). Again this was 
accompanied by the complete loss of TFH cells (Figure 3.12 A and C).  
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Figure 3.11: Ligation of OX40 increases the proportion of T-bet+ 2W1S:I-Ab+ 
CD4+ T cells. WT mice were infected with Lm-2W1S and taken 7 dpi. Mice received 
either agonistic anti-OX40 or control IgG mAb 1 dpi, or blocking anti-OX40L mAb or 
control IgG 1 and 3 dpi. (A) Flow cytometry plots showing expression of CXCR5 and 
T-bet on 2W1S:I-Ab+ CD4+ T cells. Values show percentage of Tbet+CXCR5- cells. 
(B) Percentage of 2W1S:I-Ab+ CD4+ T cells expressing T-bet. 
 
(A) Plots are representative of ≥ 6 mice from 2 independent experiments. (B) Graph 
shows pooled data from 2 independent experiments. Bars show median. Mann-
Whitney test: **p<0.01, ***p<0.001.   
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Figure 3.12: Intrinsic expression of T-bet is not required for the enhanced Teff 
cell response to agonistic anti-OX40 mAb. WT and Rag1-Cre Tbx21 fl/fl Rosa26-
tdRFP (Tbx21 fl/fl) mice were infected with Lm-2W1S and taken 7 dpi. Mice 
received either agonistic anti-OX40 or control IgG mAb 1 dpi. (A) Flow cytometry 
plots showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells from 
Tbx21 fl/fl mice receiving agonistic anti-OX40 or control IgG mAb. (B) Number of 
2W1S:I-Ab+ CD4+ T cells from Tbx21 fl/fl mice receiving agonistic anti-OX40 mAb or 
control IgG. (C) Percentage of TFH cells among 2W1S:I-Ab+ CD4+ T cells from 
Tbx21 fl/fl mice receiving agonistic anti-OX40 or control IgG mAb. (D) Percentage of 
2W1S:I-Ab+ CD4+ Teff and T central memory precursor cells from mice receiving 
agonistic anti-OX40 or control IgG mAb. (E) Histograms of expression of T-bet on 
WT and Tbx21 fl/fl mice receiving agonistic anti-OX40 or control IgG mAb. Values 
on plots are percentages of T-bet+ cells. 
 
(A and E) Plots are representative of ≥ 5 mice from 2 independent experiments. (B-
D) Graphs show pooled data from 2 independent experiments. Bars show median. 
Mann-Whitney test: *p≤0.05     
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Staining for expression of T-bet confirmed its absence in Rag1-Cre Tbx21 fl/fl 
Rosa26-tdRFP mice and that ligation of OX40 did not induce T-bet expression 
(Figure 3.12 E), demonstrating that the effects of agonistic anti-OX40 mAb on T 
cell phenotype do not require T-bet expression. This finding is consistent with 
experiments with non-antigen specific CD4+ T cells where T-bet was not 
required for proliferation and acquisition of effector function in response to 
OX40 costimulation (Williams et al., 2007). 
 
3.2.9 Agonistic anti-OX40 mAb impairs GC formation 
TFH cells are essential for the maintenance of GC; although they can form 
spontaneously in the absence of T cell help they are quickly lost (de Vinuesa et 
al., 2000). To assess the effect of a complete loss of TFH cells following treatment 
with agonistic anti-OX40 mAb spleen sections were taken at 7 dpi and stained for 
Bcl-6. GC B cells can be identified by nuclear expression of Bcl-6 and TFH cells by 
co-expression of Bcl-6, CD3 and CD4. There was a complete absence of GC 
structures in mice that received agonistic anti-OX40 mAb and CD4+ T cells had 
spread from the T cell zone into the B cell follicle (Figure 3.13 A). Class switching, 
the process of rearrangement to change one antibody isotype to another, occurs 
in the GC (Liu et al., 1996). Infection with Lm-2W1S generates a Th1 response, 
conventionally marked by switching to the IgG2a antibody isotype (Toellner et 
al., 1998).  Spleen sections were analysed for expression of IgG2a to determine if 
antibody switching had taken place.  
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Figure 3.13: GC are absent in mice treated with agonistic anti-OX40 mAb. WT 
mice were infected with Lm-2W1S and taken 7 dpi. Mice received either agonistic 
anti-OX40 or control IgG mAb 1 dpi. (A) Spleen sections were cut and stained for 
expression of Bcl-6 (green), CD3 (blue) and CD4 (red) and counterstained with 
DAPI to identify GC by dense clusters of Bcl-6+ cells. Scale bar represents 100 µm. 
“GC” denotes germinal centre outlined by white dashed line; “T” denotes T cell zone 
and “F” denotes B cell follicle. (B) Spleen sections were cut and stained for 
expression of IgG2a (green) and B220 (red) and counterstained with DAPI. 
 
Confocal images are representative of 5 mice from 1 experiment (A) or 2 mice (B). 
Magnification 25x, scale bar represents 100 µm.  
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IgG2a was found to be present in both control and anti-OX40 treated mice 
indicating that some antibody switching had occurred in the absence of the GC 
(Figure 3.13 B). However, this is consistent with previous data indicating that GC 
are not required for initial antibody switching but are necessary for generation 
of high affinity antibody (MacLennan et al., 2003).  
 
3.2.10 OX40 is not required for the generation of 
2W1S:I-Ab+ CD4+ TFH cells 
 OX40 has previously been implicated in the generation of TFH cells however 
these studies looked at total CXCR5+ T helper cells, not antigen-specific cells, 
which makes it difficult to dissect impacts on survival from TFH cell 
differentiation (Fillatreau and Gray, 2003, Walker et al., 1999). Previously it has 
been shown that GC cannot be maintained in CD30-/-OX40-/- mice (Gaspal et al., 
2005). This was attributed to a deficient T cell population in the B cell follicle and 
therefore a lack of cognate help for B cells. On 2W1S:I-Ab+ CD4+ T cells OX40 is 
expressed at 3 dpi, a time when TFH cells could not yet be identified due to a lack 
of Bcl-6 and PD-1 expression.  To further investigate whether OX40 signals were 
required for the formation of TFH cells in the response to Lm-2W1S, mice 
deficient in both OX40 and CD30 were used, since there may be redundancy in 
these signalling pathways (Gaspal et al., 2005). WT and CD30-/-/OX40-/- mice 
were immunised with Lm-2W1S and the number and phenotype of 2W1S:I-Ab+ 
CD4+T cells were analysed at 7 dpi. There was an overall decrease in the number 
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of 2W1S:I-Ab+ CD4+ T cells (Figure 3.14 B) resulting from a significantly reduced 
number and proportion of Teff cells (Figure 3.14 C and D). This finding is 
consistent with decreased survival of effector cells, however the generation of 
TFH cells was not impaired (Figure 3.14 A, E and F) indicating that the 
generation of these cells did not require OX40 or CD30 signals.  
 
3.2.11 Agonistic anti-OX40 mAb does not deplete OX40+ 
cells 
The agonistic anti-OX40 mAb has been used extensively in previous studies and 
clinical trials to augment CD4+ T cell responses (Weinberg et al., 2000, Curti et 
al., 2013). However, some mAb can target cells for deletion through antibody 
dependent cell mediated cytotoxicity. To test if the effects we saw with mAb 
treatment were due to depletion of OX40+ cells WT mice were infected with Lm-
2W1S and given either anti-OX40 mAb or control 1 dpi. We then analysed the 
total number of Foxp3+ CD4+ Treg cells and 2W1S:I-Ab+ CD4+ Treg cells in the 
spleen, as it is known that the majority of these cells constitutively express OX40 
(Takeda et al., 2004). Treg cells were identified by intracellular expression of the 
lineage defining transcription factor Foxp3 and analysed for expression of OX40 
(Figure 3.15 A). Over 70 % of both total and 2W1S:I-Ab+ CD4+ Treg cells 
expressed OX40 (Figure 3.15 B). The 2W1S:I-Ab+ CD4+ T cell pool consists of 
around 10 % Treg cells, although it has previously been shown that infection 
with Lm-2W1S poorly expands this Foxp3+ population (Ertelt et al., 2009).  
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Figure 3.14: OX40 signals are not required for the generation of 2W1S:I-Ab+ 
CD4+ TFH cells. WT and CD30-/-/OX40-/- mice were infected with Lm-2W1S and 
taken 7 dpi. (A) Flow cytometry plots showing expression of CXCR5 and PD-1 on 
2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ T cells. (C) Number of 
2W1S:I-Ab+ CD4+ Teff cells. (D) Percentage of Teff cells among 2W1S:I-Ab+ CD4+  T 
cells. (E) Number of 2W1S:I-Ab+ CD4+ TFH cells. (F) Percentage of TFH cells 
among 2W1S:I-Ab+ CD4+ T cells.  
 
(A) Plots are representative of 5 mice from 2 independent experiments. (B-F) 
Graphs show pooled data from 2 independent experiments, representative of 3 
independent experiments. Bars show median. Mann-Whitney test: *p≤0.05, ns= 
non-significant. 
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Figure 3.15: Agonistic anti-OX40 mAb do not deplete OX40+ cells. WT mice 
were infected with Lm-2W1S and taken 7 dpi. Mice received either agonistic anti-
OX40 or control IgG mAb 1 dpi. Spleen cells were fixed and stained for intracellular 
Foxp3 to identify Treg cells. (A) Flow cytometry plots of expression of Foxp3 and 
OX40 on CD4+ T cells (left) and 2W1SI-Ab+ CD4+ T cells (right). (B) Percentage of 
total and 2W1SI-Ab+ CD4+ Treg expressing OX40. (C) Number of Foxp3+ CD4+ Treg 
cells from mice receiving agonistic anti-OX40 or control IgG mAb. (D) Number of 
Foxp3+ 2W1SI-Ab+ CD4+ Treg cells from mice receiving agonistic anti-OX40 or 
control IgG mAb.  
 
(A) Plots are representative of 7 mice from 2 independent experiments. (B-D) 
Graphs show pooled data from 2 independent experiments. Bars show median. 
Mann-Whitney test: ns= non-significant. 
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A very small population of these cells expressing OX40 are present following 
infection with Lm-2W1S (Figure 3.15 A). The number of both total CD4+ Treg 
cells and 2W1S:I-Ab+ Treg cells were not significantly different between control 
and treated mice (Figure 3.15 C and D). This indicates that anti-OX40 mAb is not 
acting upon OX40+ cells to cause their depletion.   
 
3.2.12 The primary response to anti-OX40 mAb depends 
upon timing of antibody administration  
Expression of OX40 on 2W1S:I-Ab+ CD4+ T cells was restricted to a brief window 
of time. However as a proportion of Treg cells constitutively express OX40 it 
remained possible that anti-OX40 mAb indirectly affected the 2W1S response by 
affecting 2W1S:I-Ab- Treg cells. Therefore we administered anti-OX40 mAb 4 dpi, 
after 2W1S:I-Ab+ CD4+ T cells have lost expression of OX40, to assess whether the 
effects we previously observed are lost, thereby supporting a direct role for anti-
OX40 mAb. Mice receiving anti-OX40 mAb 4 dpi showed a similar phenotype of 
CXCR5 and PD-1 expression to control mice (Figure 3.16 A). The number of 
2W1S:I-Ab+ CD4+ T cells recovered was significantly increased however this 
difference was less than 2-fold, so was not as dramatic as when mAb was 
administered 1 dpi (Figure 3.16 B; median for control 46 097, anti-OX40 59 423).  
Both the number and proportion of Teff and TFH cells were not significantly 
different in anti-OX40 treated mice compared to controls indicating the mAb is 
not effective when administered 4 dpi (Figure 3.16 C-F).   
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Figure 3.16: OX40 ligation only affects Teff cell expansion and phenotype when 
administered during the early stages of the primary response. WT mice were 
infected with Lm-2W1S and taken 7 dpi. Mice received either agonistic anti-OX40 or 
control IgG mAb 4 dpi. (A) Flow cytometry plots showing expression of CXCR5 and 
PD-1 on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ T cells. (C) 
Number of 2W1S:I-Ab+ CD4+ Teff cells. (D) Number of 2W1S:I-Ab+ CD4+ TFH cells. 
(E) Percentage of Teff cells among 2W1S:I-Ab+ CD4+ T cells. (F) Percentage of TFH 
cells among 2W1S:I-Ab+ CD4+ T cells.  
 
(A) Plots are representative of 8 mice from 2 independent experiments. (B-F) Graphs 
show pooled data from 2 independent experiments. Bars show median. Mann-
Whitney test: ns= non-significant 
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3.2.13 Ligation of OX40 post infection biases the 
memory cell pool towards Tem cells 
As ligation of OX40 post infection had specific effects on the effector cell 
population we wanted to investigate if there would be a similar impact upon the 
resulting memory cell population. In the primary response, anti-OX40 mAb 
caused the vast expansion of Teff cells and the abrogation of TFH cells (Figure 
3.10). Previous studies have found that increased numbers of effector cells 
following priming resulted in an enlarged memory cell population (Evans et al., 
2001, Gramaglia et al., 2000) and this attribute may be useful for exploiting in 
vaccine development. To investigate this idea WT mice were immunised with 
Lm-2W1S as before and treated with control or agonistic anti-OX40 mAb at 1 
dpi. Mice were left for 28 days to form 2W1S:I-Ab+ CD4+ memory T cells and were 
then restimulated in vivo with 2W1S peptide and LPS before being sacrificed 4 
hours later. This method has been shown to rapidly and synchronously stimulate 
2W1S:I-Ab+ CD4+ T cells to produce cytokines (Pepper et al., 2011). 2W1S:I-Ab+ 
CD4+ memory T cells were then enriched through columns and analysed for 
secretion of cytokines. Tem and Tcm cell populations can then be functionally 
defined by their production of IFN-γ and IL-2 or IL-2 only respectively, as 
infection with Lm-2W1S elicits a Th1 biased response (Pepper et al., 2011). Both 
of these populations could be identified by cytokine secretion following 
restimulation with 2W1S peptide (Figure 3.17 A). The size of the 2W1S:I-Ab+ 
CD4+ Tcm cell population was around 4 fold larger than the Tem cell population 
(Figure 3.17 B; median for Tcm 563, Tem 125).  
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Figure 3.17: Ligation of OX40 post infection alters the phenotype, but does not 
increase the size of the memory cell pool. WT mice were infected with Lm-2W1S 
and restimulated 28 dpi in vivo with 2W1S peptide and LPS. Mice received either 
agonistic anti-OX40 or control IgG mAb 1 dpi. Spleen and lymph nodes were 
harvested 4 hours post restimulation for analysis. (A) Flow cytometry plots showing 
expression of IL-2 and IFN-γ on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ 
CD4+ T cells that are Tem (IL-2+ IFN-γ+- left) and Tcm (IL-2+ IFN-γ-- right) cells. (C) 
Percentage of 2W1S:I-Ab+ CD4+ T cells that are Tem (IL-2+ IFN-γ+- left) and Tcm 
(IL-2+ IFN-γ-- right) cells. (D) Total number of 2W1S:I-Ab+ CD4+ T cells.  
 
(A) Plots are representative of 12 mice from 3 independent experiments. (B and D) 
Graphs show pooled data from 2 independent experiments. Bars show median. (C) 
Graph shows pooled data from 3 independent experiments. Bars show median. 
Mann-Whitney test: *p≤0.05, ****p≤0.0001, ns= non-significant. 
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Treatment with agonistic anti-OX40 mAb resulted in a significant increase in the 
number of Tem cells and a corresponding decrease in Tcm cells (Figure 3.17 B). 
This difference was more pronounced when looking at the proportion of cells 
that were Tem or Tcm (Figure 3.17 C). Although the memory cell population had 
been skewed towards cells with an effector memory phenotype there was not an 
overall increase in the total number of memory cells, in contrast to previous 
findings (Figure 3.17 D) (Weinberg et al., 1998, Maxwell et al., 2000, Gramaglia et 
al., 2000). The 2W1S:I-Ab+ CD4+ T cell population must therefore have undergone 
substantial contraction given the large expansion of cells in the primary 
response.  
 
3.2.14 Expression of OX40 depends upon the route of 
immunisation  
Lm-2W1S is an attenuated strain of intracellular bacteria and is therefore 
cleared from the mouse by innate and adaptive immune mechanisms in a short 
period of time. Infection with bacteria elicits a Th1 response characterised by 
CD4+ T helper cells which produce IFN-γ and IL-2 which consequently activate 
macrophages that initiate cell mediated and phagocyte dependent responses. 
However Th2 responses to gastrointestinal nematodes are characterised by cells 
producing IL-4, IL-5 and IL-13 and robust antibody production (Mosmann et al., 
1986). The expression of OX40 in response to Lm-2W1S is rapid and transient 
therefore we investigated if the response to ligation of OX40 would be the same 
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when the route of infection was varied. Aluminium precipitation of antigen is a 
common method used to elicit a robust Th2 biased response (Grun and Maurer, 
1989, Brewer et al., 1999), yet the intricacies of antigen delivery in this system 
are not fully understood. It has been suggested that aluminium precipitation 
provides a depot from which antigen is released in a controlled manner (Glenny 
et al., 1931), however this mode of action has been questioned by more recent 
work (Hutchison et al., 2012). Studies do show that aluminium precipitation 
elicits a prolonged, robust response compared to peptide alone (Glenny et al., 
1931, Ghimire et al., 2012). We used this method as a comparison to the acute 
bacterial infection elicited by Lm-2W1S. WT mice were immunised i.p. with 100 
μg 2W1S peptide precipitated in aluminium sulphate and taken 7 dpi. In contrast 
to infection with Lm-2W1S, expression of OX40 was not detected on 2W1S:I-Ab+ 
CD4+ T cells until day 4 and was maintained at day 9 post immunisation (Figure 
3.18 A). Unlike following infection with Lm-2W1S, OX40 was more broadly 
expressed on T cells subsets with Teff, Tcm precursors and TFH cells all showing 
some expression at 9 dpi (Figure 3.18 B).   
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Figure 3.18: OX40 expression is dependent on the route of immunisation. WT 
mice were immunised with 100 µg alum ppt 2W1S peptide i.p. and analysed at 3, 4 
and 9 dpi. (A) Flow cytometry plots showing expression of OX40 on 2W1S:I-Ab+ 
CD4+ T cells. (B) Percentage of Teff, Tcm, TFH and total 2W1S:I-Ab+ CD4+ T cells 
expressing OX40 at 9 dpi. 
 
(A) Plots are representative of 3 (day 3) or 4 (day 4) mice from 1 experiment or 7 
mice (day 9)  from 2 independent experiments. (B) Graph shows pooled data from 2 
independent experiments. Bars show median.  
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To investigate the effect of ligating OX40 in this system WT mice were 
immunised with alum ppt 2W1S and given anti-OX40 or control IgG mAb 1 dpi 
and analysed at 9 dpi as the kinetics of this response are slower.  Despite this, 
and different timing of OX40 expression ligation of OX40 still caused a significant 
increase in the number of 2W1S:I-Ab+ CD4+ T cells (Figure 3.19 B). The same 
effect was seen as in the Lm-2W1S response whereby Teff cells were increased 
in proportion and number (Figure 3.19 A and C). However although TFH cells 
were significantly reduced in proportion their number was not altered (Figure 
3.19 D). This could be due to the broader expression of OX40 affecting the 
expansion of other cell types apart from Teff cells.  
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Figure 3.19: Anti-OX40 still causes Teff cell expansion with alum ppt peptide 
immunisation. WT mice were immunised with 100 µg alum ppt 2W1S peptide i.p 
and taken 9 dpi. Mice received either agonistic anti-OX40 or control IgG mAb 1 dpi. 
(A) Flow cytometry plots showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ 
CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ T cells. (C) Percentage (left) and 
number (right) of Teff cells among 2W1S:I-Ab+ CD4+ T cells. (D) Percentage (left) and 
number (right) of TFH cells among 2W1S:I-Ab+ CD4+ T cells.  
 
(A) Plots are representative of 7 mice from 2 independent experiments. (B-D) 
Graphs show pooled data from 2 independent experiments. Bars show median. 
Mann-Whitney test: ***p≤0.001, ns= non-significant. 
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3.3 Discussion 
Using a model to track an endogenous population of antigen-specific CD4+ T cells 
I have shown that signals through OX40 specifically benefit the Teff cell 
population. Following infection with Lm-2W1S OX40 expression is transient and 
expressed primarily on cells with the Teff phenotype. Ligation of OX40 at this 
point specifically expands the Teff cell population and biases the memory cell 
pool towards Tem cells, while TFH cell and GC formation is abrogated. Upon 
secondary challenge OX40 is more widely expressed, however ligation of OX40 
again specifically expanded Tem cells. Once formed, OX40 was dispensable for 
the long-term persistence of the memory cell population. Despite reports that 
OX40 may be required for the optimal formation of TFH cells (Gaspal et al., 2005, 
Walker et al., 1999, Fillatreau and Gray, 2003), CD30-/-/OX40-/- mice did not 
show any impairment in this population.   
Although the use of TCR transgenic T cells has greatly enhanced our 
understanding of CD4+ T cell responses and enabled the study of antigen-specific 
memory cells, there is a now need for more refined physiological methods. 
Problems associated with the injection of large numbers of TCR transgenic T 
cells have recently come to light, particularly with regard to the study of memory 
T cell populations. Clonal competition, poor conversion to memory cells and un-
physiological differentiation have been observed meaning there is now a 
requirement to study endogenous CD4+ T cell populations. Previously this has 
been challenging due to low precursor frequency, however the refinement of 
MHC II tetramers has now made this approach feasible. Infection with Lm-2W1S 
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can be used as a model to track an endogenous, polyclonal antigen-specific 
population of CD4+ T cells through from the primary to the memory response.  
This method was highly reproducible; a small naive population could be detected 
that rapidly expanded following i.v. infection, then contracted to form a stable 
memory cell pool. Restimulation with 2W1S peptide and LPS enabled the 
identification of Tcm and Tem cell subsets defined functionally by the production 
of cytokines, as has been show previously (Pepper et al., 2011).  
Expression of OX40 on 2W1S:I-Ab+ CD4+ T cells was not unlike that previously 
reported from in vitro experiments and for TCR transgenic T cells, being very 
tightly linked to antigen exposure (Gramaglia et al., 1998, Rogers et al., 2001, 
Dawicki et al., 2004). OX40 was detected early at 3 dpi but was rapidly lost and 
was absent by day 7, around the peak of this response. The brief expression of 
OX40 on 2W1S:I-Ab+ CD4+ T cells was likely due to the acute nature of the 
infection, with attenuated bacteria being rapidly cleared. Chronic infections such 
as lymphocytic choriomeningitis virus (LCMV) can maintain OX40 expression for 
up to 20 days (Boettler et al., 2012). Injection with alum ppt 2W1S peptide 
resulted in the expression of OX40 on 2W1S:I-Ab+ CD4+ T cells at 9 dpi. Use of 
aluminium precipitation as an adjuvant has been shown to elicit prolonged 
immune responses (Kool et al., 2008) and therefore the kinetics of OX40 
expression may reflect a chronic infection rather than attenuated Lm-2W1S. This 
demonstrates that the expression of OX40 is very context dependent and should 
be considered when trying to target this receptor therapeutically.  
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At the only timepoint when OX40 was detected in the primary response, around 
40% of 2W1S:I-Ab+ CD4+ T cells expressed the costimulatory receptor. This 
observation was notably distinct to previous studies with TCR transgenic T cells 
where OX40 expression was uniform among the population (Boettler et al., 2013, 
Boettler et al., 2012, Rogers et al., 2001). This is perhaps due to the polyclonal 
nature of the endogenous 2W1S:I-Ab+ population compared to TCR transgenic T 
cells, which are monoclonal. T cells with higher affinity TCR may receive 
additional signals due to an increased interaction time with APC that may affect 
the expression of costimulatory receptors downstream. High levels of TCR 
stimulation were shown to be important for expression of OX40 (Verdeil et al., 
2006), therefore cells with low affinity TCR that do not receive sufficient 
signalling will not express OX40.  However TCR transgenic T cell populations are 
monoclonal and therefore will receive identical signalling through the TCR 
resulting in uniform downstream responses such as expression of OX40. Such 
observations reinforce the need to study endogenous, polyclonal T cell 
populations.  
Heterogeneous expression of OX40 suggested cells might receive different 
signals, dependent upon expression of costimulatory receptors, and differentiate 
into distinct T cells subsets. Common markers of Th1 and TFH cells such as T-
bet, CXCR5 and Bcl-6 were not useful in identifying these populations at the early 
timepoint when OX40 was present as they were either expressed on the majority 
of cells or not present at this time. However, co-expression of OX40 with CD25, a 
marker of Th1 effector cells (Pepper et al., 2011), indicated that OX40 may be 
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important specifically for Teff cells and not Tcm precursors or TFH cells. 
Consistent with this finding, ligation of OX40 post Lm-2W1S infection using 
agonistic anti-OX40 mAb specifically expanded CXCR5- Teff cells but abrogated 
TFH cell generation. This resulted in a complete lack of GC structures in the 
spleen of treated mice. A recent study on LCMV found a similar effect; injection of 
anti-OX40 abrogated development of LCMV-specific TFH cells. This was 
attributed to expression of the transcriptional repressor Blimp-1 in the majority 
of effector cells, driven by enhanced IL-2 production, which subsequently 
antagonises Bcl-6 and therefore prevented TFH cell development (Boettler et al., 
2013). This resulted in a significant decrease in antibody titre due to impaired 
GC responses. This effect was observed in the response to both acute and chronic 
infections. However in the response to Lm-2W1S, cells expressing OX40 were 
already committed to the Teff phenotype at an early stage, evidenced by co-
expression with CD25 3 dpi, indicating these cells benefited from antibody 
ligation of OX40 at this time. It is possible that OX40 promotes the proliferation 
and survival of the 2W1S:I-Ab+ CD4+ Teff cell population rather than impairing 
TFH cell formation and their loss is due to out-competition in this niche. 
Alternatively extensive proliferation of Teff cells may lead to high levels of IFN-γ, 
as seen in CD70 transgenic mice, which may deplete TFH cells (Arens et al., 
2001). Constitutive expression of CD27 on B cells led to an increase in peripheral 
effector T cells and progressive reduction in B cell number due to IFN-γ. Another 
study also found that when anti-OX40 and blocking anti-PD-L1 mAb were 
administered simultaneously during P.yoelii Malaria infection, excessive 
production of IFN-γ by Teff cells resulted in a reduction in TFH cells that led to 
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increased parasite burden (Zander et al., 2015). Therefore although IFN-γ is 
required to control parasitaemia, in excess it acts to disrupt TFH cell 
differentiation or survival leading to impaired GC responses. Agonistic anti-OX40 
mAb have already been trialled to enhance immune responses to tumour models 
in phase 1 clinical trials and are being considered to enhance vaccine responses 
(Croft, 2010, Weinberg et al., 2011). These data suggest caution should be 
employed when considering the use of anti-OX40 mAb in the clinic, especially 
when a robust humoral response is desired.  
We observed that ligation of OX40 post infection caused the majority of 2W1S:I-
Ab+ CD4+ T cells to express T-bet, the key transcription factor regulating Th1 cell 
differentiation. Mice where T-bet was selectively removed from cells expressing 
RAG were used to investigate if the selective expansion of effector cells and loss 
of TFH cells was dependent on expression of this transcription factor. 
Administration of agonistic anti-OX40 mAb in these mice had the same effect as 
in WT mice indicating this mechanism is not dependent on intrinsic expression 
of T-bet, consistent with a previous study showing T-bet is not required for 
effector cell cytokine production in response to OX40 (Williams et al., 2007). In 
this study signalling through the IL-2 receptor was required for T cells to 
produce IFN-γ in response to antigen and OX40 costimulation, however 
expression of T-bet and IL-12 receptor were dispensable.  
Studies have previously implicated OX40 in the generation and maintenance of 
TFH cells and GC. In CD30-/-/OX40-/- mice secondary antibody responses were 
impaired due to a lack of T helper cells in the follicle and GC were not maintained 
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at 14 dpi (Gaspal et al., 2005). Compromised OX40 function has also been shown 
to impair development of CXCR5+ CD4+ T cells and their migration into the B cell 
follicle (Walker et al., 1999, Fillatreau and Gray, 2003). Here we found that 
generation of TFH cells 7 days post infection with Lm-2W1S in CD30-/-/ OX40-/- 
mice was normal as has been seen in another antigen-specific study (Akiba et al., 
2005). Furthermore, blockade of OX40 signalling using mAb resulted in a 
decreased Teff population but did not affect the generation of TFH cells. This 
does not rule out a role for OX40 in the maintenance of TFH cells however in this 
model TFH cells lack OX40 expression at 7 dpi, therefore do not interact with 
OX40L at the time when they are located in the GC. There was however a 2 fold 
reduction in the number of Teff cells, consistent with previous reports showing a 
role for OX40 in survival of CD4+ T cells (Rogers et al., 2001). Ligation of OX40 
did not enhance the number of TFH cells, but conversely abrogated their 
development. Previous studies have shown that OX40 is important for control of 
LCMV and generation of high affinity antibody (Boettler et al., 2012, Gaspal et al., 
2005). This requirement may depend on the context in which the antigen is 
delivered, as LCMV can be chronic this may induce prolonged expression of OX40 
on a wider range of T cell subsets. Other studies have shown normal GC centre 
development, antibody production and control of infection with L. major, N. 
brasiliensis and murine encephalomyelitis virus in the absence of OX40 signalling 
(Kopf et al., 1999, Chen et al., 1999, Pippig et al., 1999). Therefore it is likely that 
the role of OX40 in TFH cell generation and survival is highly dependent upon 
the context in which antigen is delivered, which dictates expression of OX40 and 
OX40L.  
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Expression of OX40 was absent on 2W1S:I-Ab+ CD4+ T memory cells directly ex 
vivo as has been reported for other memory cell populations (Croft, 2010). 
Addition of IL-7 in culture has been used to induce expression of OX40 on 
memory cells (Gaspal et al., 2005) and was successful in upregulating OX40 
expression on 2W1S:I-Ab+ CD4+ memory T cells. IL-7 has been implicated in the 
long term survival of memory T cells once formed indicating that memory cells 
receive signals from IL-7 in a physiological setting (Kondrack et al., 2003, Purton 
et al., 2007). This raises the possibility that signalling through IL-7 upregulates 
OX40 expression on CD4+ memory T cells therefore enhancing survival through 
an antigen independent mechanism. However this is hard to reconcile with the 
fact that OX40 expression is not detected on 2W1S:I-Ab+ CD4+ T cells directly ex 
vivo. RORγt-/- mice, which lack ILC3, were shown to have a defect in survival of 
CD4+ memory T cells (Withers et al., 2012). This was attributed to the lack of 
provision of OX40L by lymphoid tissue inducer (LTi) cells. Blockade of OX40L 
once memory cells had formed did not inhibit their survival however a modest 
reduction was seen when this was combined with CD30L blockade. CD30 is 
technically challenging to stain on CD4+ T cells and the lack of OX40 expression 
on 2W1S:I-Ab+ CD4+ memory T cells make a direct interaction between memory 
cells and LTi an unlikely mechanism regulating their survival. Furthermore 
provision of OX40 signals through anti-OX40 mAb did not enhance the survival 
of 2W1S:I-Ab+ CD4+ memory T cells. OX40 expression can be rapidly induced 
within 4 hours of peptide restimulation indicating it may play an important role 
in secondary effector T cell responses. This also demonstrates that the absence 
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of OX40 on 2W1S:I-Ab+ CD4+ memory T cells is not due to the method of 
preparation ex vivo.  
Although OX40 expression on 2W1S:I-Ab+ CD4+ T cells was restricted to a brief 
period, they rapidly re-express the receptor upon TCR engagement. Four hours 
post restimulation with 2W1S peptide, at either 7 or 28 dpi, the majority of 
2W1S:I-Ab+ CD4+ T cells were OX40+. At this time OX40 was more broadly 
expressed across T cell subsets indicating a less restricted pattern of expression 
in secondary compared to primary responses. Again expression of OX40 was 
rapidly lost; by day 4 post secondary challenge there was no detectable 
expression. We temporally manipulated provision of OX40 signals at the point of 
challenge using mAb; due to the short window of OX40 expression timing of 
antibody administration was important. When agonistic anti-OX40 mAb were 
given on the day of secondary challenge, they specifically expanded 2W1S:I-Ab+ 
CD4+ Tem cells. However the number of 2W1S:I-Ab+ CD4+ T cells was only 
modestly increased when administration of mAb was delayed until the day after 
secondary challenge, indicating OX40 is required early after antigen exposure. 
The specific expansion of Tem cells was associated with a reduction in the 
percentage of TFH cells, however the total number remained the same in control 
and treated mice. Confocal analysis of spleen sections revealed a significant 
reduction in the number and area of GC in the mice receiving anti-OX40 mAb. As 
the total number of TFH cells was not altered this suggests there may be 
increased competition due to a specific expansion of Tem cells in anti-OX40 
treated mice, inhibiting GC formation. Conversely blocking OX40 interactions 
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after secondary challenge using mAb resulted in a specific decrease in Tem but 
there was no significant difference in TFH cell number. Addition of blocking 
CD30L mAb did not further impair the expansion of Tem. These data are 
consistent with previous studies showing OX40 is required for accumulation of 
CD4+ memory T cells and induction of lung inflammation following secondary 
antigen exposure (Salek-Ardakani et al., 2003).  
Administration of agonistic anti-OX40 mAb immediately following infection with 
Lm-2W1S resulted in a memory cell population that was biased towards Tem 
cells. This is consistent with OX40 being important for the survival of Teff cells, 
some of which survive to form the memory cell pool. Surprisingly, despite the 
vast increase in cell number observed at day 7 following anti-OX40 mAb 
treatment, the number of 2W1S:I-Ab+ CD4+ memory T cells recovered 28 dpi was 
not significantly altered. This is in contrast to other studies that have shown 
administration of anti-OX40 mAb enhances the accumulation of CD4+ memory T 
cells (Gramaglia et al., 2000, Maxwell et al., 2000). These studies used adoptive 
transfers of TCR transgenic T cells, which may show different survival 
requirements to the endogenous 2W1S:I-Ab+ CD4+ memory cell population. 
Additionally one of these studies used immunisation with CFA, which is highly 
immunogenic and likely elicits a different response to infection with attenuated 
Lm-2W1S. The large population contraction we observed may be due to poor 
conversion to memory cells when there are abnormally high numbers of T cells, 
as seen when non-physiological numbers of TCR transgenic cells are used 
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(Hataye et al., 2006). This is thought to be due to increased competition among T 
cell clones for DC interactions (Blair and Lefrancois, 2007). 
Overall these data show that OX40 expression by an endogenous, polyclonal 
antigen-specific population of CD4+ T cells is very tightly regulated temporally 
and not uniformly expressed amongst responding cells in a primary response. 
Upon re-encounter of antigen OX40 is rapidly and more broadly expressed, 
indicating a role in secondary responses. Restriction of OX40 signalling through 
administration of blocking mAb or in genetically deficient mice specifically 
impaired the Teff or Tem cell population. Overprovision of OX40 signalling 
specifically expanded Teff cells in the primary response or Tem cells following 
secondary challenge, while being detrimental to the TFH cell population, 
however the overall size of the memory cell pool was not altered. It will be 
important to consider these implications when applying the use of OX40 agonists 
in the clinic or for vaccine design. While it may be desirable to enhance CD4+ T 
cells responses in this way, if high affinity antibody responses are required other 
options may need to be considered. 
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CHAPTER 4: THE ROLE OF COSTIMULATORY 
RECEPTORS ICOS AND CD28 IN CD4+ T CELL 
RESPONSES 
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4.1 Introduction 
4.1.1 Therapeutic Interventions 
Targeting costimulatory pathways for therapeutic benefit has been considered 
since the discovery of the two signal model for T cell activation. Targeting this 
second signal allowed T cell responses to be manipulated without knowing the 
exact nature of the antigen, which is often the case in transplantation or 
autoimmune disease. Controlling the effector T cell response is essential in 
preventing graft rejection and controlling autoimmune diseases such as systemic 
lupus erythematosus, RA and type 1 diabetes. As T cell help is vital for optimal B 
cell responses and production of high affinity antibody, this method can also 
target B cell mediated disease. A number of different costimulatory molecules 
have been considered as therapeutic targets, such as CD40, but the interaction of 
CD28 with its B7 ligands has become the focus of attention. Clinical treatment 
with a human form of CTLA4Ig known as Abatacept has been trialled in 
autoimmune diseases such as RA and psoriasis with some degree of success 
(Ruderman and Pope, 2005, Abrams et al., 1999). Abatacept was approved for 
the treatment of RA in 2005 following trials showing amelioration of RA 
symptoms when combined with the existing treatment methotrexate (Kremer et 
al., 2003). However trials of abatacept in type 1 diabetes (Orban et al., 2014, 
Orban et al., 2011), allergen-induced airway inflammation (Parulekar et al., 
2013) and ulcerative colitis (Sandborn et al., 2012) have not been as successful. 
This suggests that T cell mediated autoimmune diseases show varying responses 
to abatacept and highlights the need for additional therapeutic pathways. A 
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modified form of CTLA4Ig has been developed, Belatacept, with decreased 
dissociation rates from CD80 and CD86. In non-human primates this mutated 
form has been shown to be significantly more effective than abatacept in 
preventing graft rejection (Larsen et al., 2005).  
ICOS has also been exploited as a therapeutic target to control activated T cells 
as, unlike CD28, ICOS is not expressed on naive T cells but is rapidly upregulated 
following antigen recognition (Hutloff et al., 1999, Mages et al., 2000).  This is 
advantageous as memory cells cause pathogenesis in T cell mediated 
autoimmune diseases. Blocking ICOS signalling has proven effective in limiting 
ongoing CD4+ T cell responses in some murine models of disease. Blockade of 
ICOS signals, using ICOS-Ig, following development of EAE symptoms 
ameliorated disease; this was thought to be due to decreased IL-10 and IFN-γ 
production by T cells that mediate pathology (Sporici et al., 2001). However 
timing of administration was found to be vital to the clinical outcome; blocking 
anti-ICOS mAb given during the priming phase increased disease severity due to 
increased IFN-γ production (Rottman et al., 2001). ICOS blockade prevented the 
development of autoimmune diabetes in non-obese diabetic (NOD) mice and 
prolonged allograft survival but was unable to reverse diabetes after onset 
(Ansari et al., 2008).  
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4.1.2 The role of ICOS in CD4+ memory T cell responses 
Although ICOS has a well-documented role in the formation of TFH cells in the 
primary response, the requirement of CD4+ memory T cells for costimulation 
through this receptor is less clear. Initial reports identifying ICOS expression on 
previously activated CD44hi T cells indicated that this receptor might be 
important in memory cell responses (Yoshinaga et al., 1999). ICOSL fusion 
protein administered during secondary challenge resulted in an augmented 
hypersensitivity response, superior to when administered during the primary 
response, supporting the idea that ICOS costimulates memory T cells. In 
agreement with this, another study also found that contact hypersensitivity was 
enhanced following challenge when ICOSL-Ig was injected and was more 
effective than CD86-Ig (Guo et al., 2001). More recently Mahajan and colleagues 
found that the reactivation of an endogenous, polyclonal CD4+ memory T cell 
population was impaired in ICOS-/- mice (Mahajan et al., 2007). This was despite 
normal priming, generation of memory and survival at 10 weeks post infection.  
There have been conflicting reports for the requirement of ICOS signalling by 
Tcm and Tem cells. Several studies have indicated that ICOS is required for the 
formation of the Tem cell population. Expression of ICOS was found to be highest 
on Tem phenotype cells, defined by expression of CD44 and absence of CD62L, 
while Tcm phenotype cells showed only intermediate ICOS expression 
(Burmeister et al., 2008). Although there was no overall difference in the total 
number of CD4+ memory T cells in ICOS-/- mice, CD44hiCD62Llo Tem phenotype 
cells were significantly reduced.  In addition the initial priming of TCR transgenic 
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OTII cells was not affected by the absence of ICOS signalling but the expansion of 
effector cells 5 dpi was reduced by half compared to WT mice (Burmeister et al., 
2008). They concluded that this impaired survival is the cause of the observed 
reduction in Tem cells. Another study tracking antigen-specific cells found very 
similar results. The total number of influenza-specific memory cells was not 
reduced in ICOS-/- mice however there was a significant defect in Tem cells 
attributable to enhanced rate of decline following resolution of infection (Moore 
et al., 2011). However ICOS signalling has also been implicated in the 
development and survival of Tcm cells. An endogenous CD4+ T cell population 
responding to infection with Listeria monocytogenes was analysed in mixed bone 
marrow chimeras reconstituted with an equal mixture of WT and ICOS-/- cells 
(Pepper et al., 2011). The generation of Tcm cell precursors was significantly 
impaired in the absence of ICOS and this population declined more quickly than 
in WT mice. Two human patients with ICOS deficiency were described to have 
decreased CD4+ memory T cell populations in peripheral blood; this resulted 
from a decrease in both Tcm and Tem cells (Takahashi et al., 2009). Production 
of Th1, Th2 and Th17 cytokines were all impaired upon in vitro stimulation.  
We sought to clarify the requirement for ICOS and CD28 signals in the 
generation, survival and reactivation of memory cells. We have tracked an 
endogenous, polyclonal CD4+ memory T cell population and used TCR transgenic 
SM1 CD4+ T cells to analyse the survival of CD4+ memory T cells generated in WT 
mice. A combination of genetically deficient mice and blocking mAb were used to 
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temporally assess the impact of loss of costimulatory signals on CD4+ T cell 
responses.  
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4.2 Results 
4.2.1 CTLA4Ig mice as a model of limited costimulation 
through CD28 
Therapeutic targeting of T cell responses has shown some clinical success, where 
key costimulatory molecules are blocked to limit T cell activation and 
proliferation. As CD28 is a potent costimulatory molecule involved in the 
proliferation and differentiation of T cells it is an attractive therapeutic target. 
Injection of CTLA4Ig has been used to abrogate signalling through the CD28 
pathway (Linsley and Nadler, 2009). Here we aimed to establish a mouse model 
in which constitutive expression of CTLA4Ig could be used to investigate the 
impact of limited costimulation on CD4+ T cells responses. CTLA4Ig mice 
produce a fusion protein consisting of the extracellular domain of CTLA4 and the 
Fc region of human IgG1, which competitively binds to the ligands of the CD28 
receptor, CD80 and CD86 (Lane et al., 1994). CTLA4 binds to these ligands with 
around 20-100 fold greater affinity than CD28 and therefore dramatically 
reduces the number of available ligands, restricting signalling through the CD28 
pathway (Linsley et al., 1994). The CTLA4Ig fusion protein is present at 10-30 
μg/ml in the serum therefore is maintained at a therapeutically relevant level; 
i.v. abatacept therapy is administered at 3-10 mg/kg periodically (Lane et al., 
1994, Keating, 2013).  This mouse model is analogous to abatacept therapy, 
which has been trialled for use in autoimmune diseases such as RA and psoriasis 
with some degree of success (Ruderman and Pope, 2005, Abrams et al., 1999).  
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Signalling through the CD28 pathway is well characterised and is required for 
the optimal expansion of CD4+ T cells following TCR stimulation (Shahinian et al., 
1993, Viola and Lanzavecchia, 1996). We sought to test the efficacy of CTLA4Ig in 
this mouse model using infection with Lm-2W1S to track the expansion of an 
endogenous polyclonal CD4+ T cell population. CD80-/-CD86-/- mice were 
included as a control as these mice lack both of the ligands to which CD28 binds, 
thus establishing the baseline for no signalling through CD28. In these mice 
signalling through CD28 is abrogated and therefore T cell proliferation is 
severely stunted (Chang et al., 1999).  WT, CTLA4Ig and CD80-/-CD86-/- mice 
were infected with Lm-2W1S and the number of 2W1S:I-Ab+ CD4+ T cells were 
enumerated from the spleen 7 dpi. As expected CD80-/-CD86-/- mice showed a 
significant impairment in the expansion of 2W1S:I-Ab+ CD4+ T cells, which were 
almost 20 fold reduced compared to WT mice (Figure 4.1 A; median for WT: 48 
659, CD80-/-CD86-/-: 2328).  There was also a significant reduction in the number 
of 2W1S:I-Ab+ CD4+ T cells in CTLA4Ig mice (Figure 4.1 A; median for CTLA4Ig: 
16495). The 2.5-fold reduction in number of 2W1S:I-Ab+ CD4+ T cells observed 
indicates that constitutive production of CTLA4Ig fusion protein affects the 
optimal expansion of CD4+ T cells, however blockade of CD28 appears to be 
incomplete.  
We also tracked the TCR transgenic SM1 CD4+ T cell response to Lm-FliC. An 
advantage of this method is that CD4+ T cells are adoptively transferred into 
hosts, since endogenous CD4+ T cells in CTLA4Ig mice may be subject to 
developmental defects in the thymus due to the absence of CD28 signalling.  
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Figure 4.1: CTLA4Ig mice can be used as a model of limited CD28 
costimulation. (A) WT, CTLA4Ig and CD80-/-CD86-/- mice were infected with 
Lm-2W1S and spleen was analysed for the number of 2W1S:I-Ab+ CD4+ T cells 7 
dpi. (B) WT mice received 10 000 SM1 CD4+ T cells i.v. and the following day 
spleen and lymph nodes were analysed. Number of SM1 CD4+ T cells surviving is 
shown, defined as the “park rate”. (C) WT and CTLA4Ig mice were injected with 10 
000 SM1 CD4+ T cells and infected with Lm-FliC the following day. Spleen was 
analysed for the number of SM1 CD4+ T cells 7 dpi. (D) Number of Foxp3+ CD4+ 
Treg cells from the spleen of WT, CTLA4Ig and CD80-/-CD86-/- mice.  
 
(A and D) Graph shows pooled data from ≥2 independent experiments. (B) Graph 
shows data from 1 independent experiment. (C) Graph shows pooled data from 2 
independent experiments. Bars show median. Mann-Whitney test: ***p<0.001, 
****p<0.0001. 
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Some studies have found that CD28 is highly expressed on thymocytes (Gross et 
al., 1992), however others have not shown any impairment in the peripheral T 
cell repertoire in CD28-/- mice (Shahinian et al., 1993). The use of TCR transgenic 
T cells circumvents problems that may be associated with abnormal thymic 
development. Following i.v. transfer of TCR transgenic cells, the number of cells 
surviving after 24 hours has been described as the “park rate” (Hataye et al., 
2006). This has been shown to equal 10 % of the original population that was 
adoptively transferred (Hataye et al., 2006, Blattman et al., 2002). To test this 
using the SM1 TCR transgenic model WT mice were injected with 10 000 SM1 
CD4+ TCR transgenic T cells and the spleen and lymph nodes were analysed 24 
hours later to enumerate surviving cells. A median of around 600 SM1 CD4+ T 
cells were remaining following transfer, equalling 6 %, similar to previous 
reports (Figure 4.1 B). Injection with a low number of SM1 CD4+ T cells is 
designed to mimic the size of an endogenous T cell pool, which circumvents 
caveats associated with the transfer of large numbers of TCR transgenic T cells. 
Assuming a park rate of 10 %, this results in a naive starting population of 
around 1000 cells, which only modestly exceeds endogenous T cell pools, which 
have been measured at between 20-1500 cells per mouse (Moon et al., 2007, 
Obar et al., 2008, Kotturi et al., 2008). WT and CTLA4Ig mice were injected with 
10 000 SM1 CD4+ T cells and infected with Lm-FliC the following day. The 
number of SM1 CD4+ T cells in spleen was then enumerated.  The expansion of 
SM1 CD4+ T cells was significantly impaired in CTLA4Ig mice, by almost 9 fold 
(Figure 4.1 C; median for WT: 413 679, CTLA4Ig: 46 966). These data 
 
 
 
 
154 
demonstrate that constitutive expression of CTLA4Ig can significantly impair the 
primary expansion of antigen-specific CD4+ T cells in multiple model systems. 
Development of Treg cells in the thymus and their survival in the periphery are 
both thought to be CD28 dependent (Tai et al., 2005, Salomon et al., 2000, Tang 
et al., 2003). To evaluate how effective constitutive expression of CTLA4Ig fusion 
protein is at blocking signalling through CD28 we analysed the Treg population 
in CTLA4Ig mice. The total number of CD4+ Treg cells in the spleen was 
calculated from WT, CTLA4Ig and CD80-/-CD86-/- mice. Again CD80-/-CD86-/- mice 
were used as a control, in which Treg cell development would be severely 
impaired due to lack of CD28 signalling. As expected there was a significant 
reduction in the number of Treg cells in CD80-/-CD86-/- when compared to WT 
mice (Figure 4.1 D; median for WT: 848 998, CD80-/-CD86-/-: 74 078). This was 
also the case in CTLA4Ig mice, demonstrating that circulating CTLA4Ig fusion 
protein impairs Treg cell development or survival by blocking signals through 
CD28 (Figure 4.1 D; median for CTLA4Ig 182 043).  
To further assess the degree of impairment in the T cell response in CTLA4Ig 
mice, effector T cell populations were assessed in these animals. The generation 
of TFH cells has been shown to require signals through CD28; in the absence of 
this pathway TFH cell formation is impaired or abrogated (Salek-Ardakani et al., 
2011, Akiba et al., 2005).  For this reason the formation of 2W1S:I-Ab+ and SM1 
TFH was evaluated in CTLA4Ig mice. TFH cells were identified by expression of 
the highest levels of CXCR5 and PD-1 (as shown in Figure 3.4).  Both the number 
and the percentage of 2W1S:I-Ab+ TFH cells were significantly reduced in 
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CTLA4Ig mice compared to WT mice (Figure 4.2 A and B). TFH cells were also 
reduced in CTLA4Ig mice following adoptive transfer of SM1 CD4+ T cells and 
infection with Lm-FliC; the number and percentage of SM1 TFH cells were both 
significantly reduced (Figure 4.2 C and D).  
TFH cells have been shown to be essential for the maintenance of GC, providing 
surviving signals to B cells (de Vinuesa et al., 2000). Although spontaneous GC 
formation can occur in the absence of T cell help these are aborted early after 
induction (de Vinuesa et al., 2000). To investigate the effect of a reduced TFH cell 
population, spleen sections from WT and CTLA4Ig mice infected with Lm-2W1S 
7 days previously were cut and stained for confocal microscopy analysis. As 
described for Figure 3.9 in section 3.2.6, spleen sections were stained for Bcl-6 to 
identify GC and CD3 and CD4 to identify T cells. In WT mice large clusters of Bcl-
6+ cells were identified indicating GC are present at this timepoint (Figure 4.3 A). 
Consistent with the significant decrease in TFH cells observed in Figure 4.2, the 
size of GC in CTLA4Ig mice appeared reduced (Figure 4.3 A).  TFH cells can be 
identified by co-staining of CD3 and CD4 and nuclear staining of Bcl-6. A number 
of TFH cells were present in and around the GC in WT mice (Figure 4.3 B- 
identified by yellow circles). Some TFH cells could be identified in the follicle of 
CTLA4Ig mice however their number appeared to be reduced (Figure 4.3 B). 
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Figure 4.2: TFH cell formation is severely impaired in CTLA4Ig mice. WT and 
CTLA4Ig mice were infected with Lm-2W1S and analysed 7 dpi. (A) Flow cytometry 
plots showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells. (B) Number 
(top) and percentage (bottom) of 2W1S:I-Ab+  TFH cells. 
 
WT and CTLA4Ig mice were injected i.v. with 10 000 SM1 CD4+ T cells and infected 
with Lm-FliC the following day. Mice were analysed 7 dpi. (C) Flow cytometry plots 
showing expression of CXCR5 and PD-1 on SM1 CD4+ T cells (D) Number (top) and 
percentage (bottom) of SM1 TFH cells.  
(A and C) Plots are representative of ≥5 mice from 2 independent experiments. Values 
on plots are percentages. (B and D) Graphs show pooled data from 2 independent 
experiments. Bars show median. Mann-Whitney test: ***p<0.001.  
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Figure 4.3: GC are reduced in size in CTLA4Ig mice. WT and CTLA4Ig mice were 
infected with Lm-2W1S and analysed 7 dpi. (A) Spleen sections were cut and 
stained for expression of Bcl-6 (green), CD3 (blue) and CD4 (red) and 
counterstained with DAPI to identify GC. “GC” indicates germinal centre. “T” denotes 
T cell zone outlined by white dashed line. Magnification 25x, scale bar represents 50 
µm. White boxes indicate the area shown magnified in (B). (B) Spleen sections were 
cut and stained as in (A). Yellow circles indicate examples of TFH cells identified by 
nuclear Bcl-6 staining surrounded by CD3 and CD4 co-staining. Magnification 40x, 
scale bar represents 20 µm.  
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4.2.2 Migration of CD4+ T cells into the B cell follicle is 
impaired in CTLA4Ig mice 
To investigate the location of TFH cells further we used CD45.1+CD45.2+ TCR 
transgenic SM1 CD4+ T cells which could be identified in sections by allotype 
marking. Current limitations in tetramer staining methods mean it is not 
possible to identify 2W1S:I-Ab+ CD4+ T cells in tissue sections. WT (C57BL/6, 
CD45.2+) and CTLA4Ig (C57BL/6, CD45.2+) mice received an adoptive transfer of 
10 000 SM1 CD4+ T cells and were infected with Lm-FliC the following day. 
Sections of spleen were analysed 7 dpi for the location of responding SM1 CD4+ T 
cells within the white pulp areas. SM1 CD4+ T cells were identified by expression 
of CD45.1. B220 and CD4 were used to identify the B cell follicle and T cell zone 
respectively. For quantitation of SM1 CD4+ T cells in the B cell follicle, the area 
occupied by B220+ cells was marked and the number of CD45.1+ SM1 CD4+ T 
cells within were counted (Figure 4.4 A). This was repeated for the T cell zone 
and the percentage of total SM1 cells that were located in the follicle was 
calculated. In WT mice a high proportion of responding SM1 CD4+ T cells 
(around 80%) were located within the B cell follicle, however in CTLA4Ig mice 
this was significantly reduced to around 40% (Figure 4.4 C). It was observed that 
a large number of SM1 CD4+ T cells in CTLA4Ig mice were located around the 
border of the T cell zone and the B cell follicle, an area known as the B/T 
interface. To quantify this, a zone 20 μm either side of this border was 
designated as the B/T interface and the number of SM1 CD4+ T cells within it was 
counted.  
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Figure 4.4: Migration of SM1 CD4+ T cells to the follicle is impaired in CTLA4Ig 
mice. WT and CTLA4Ig mice were injected with 10 000 SM1 cells and infected with 
Lm-FliC the following day. Mice were analysed 7 dpi. (A) Spleen sections were cut 
and stained for expression of B220 (blue), CD4 (red) and CD45.1 (green) and 
counterstained with DAPI to identify white pulp areas. SM1 CD4+ cells were identified 
by co-staining for CD4 and CD45.1 in green. Yellow circles indicate examples of SM1 
cells located in or close to the B cell follicle. “F” denotes B cell follicle outlined by 
white dashed line. “T” denotes T cell zone. Magnification x10, scale bar represents 
100 µm. (B) Diagram showing how the B/T interface was designated. The solid yellow 
line marks the B/T border and the white dashed lines denotes the edge of the B/T 
interface 20 µm either side. (C) Percentage of SM1 CD4+ T cells located in B follicle 
of  splenic white pulp area. (D) Percentage of SM1 CD4+ T cells located at the B/T 
interface designated as shown in (B). 
 
(A) Confocal images are representative of 3 mice from 1 independent experiment. (C 
and D) Graphs show pooled data from 3 mice from 1 independent experiment. Each 
data point represents a white pulp area. Bars show median. Mann Whitney test: 
****p<0.0001.  
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A diagram describing how the B/T interface was designated is shown in Figure 
4.4 B.  In CTLA4Ig mice significantly more SM1 CD4+ T cells were located in this 
area than in WT mice (Figure 4.4 D) indicating a defect in the migration of these 
cells past this point. This is consistent with a lack of CXCR5 expression (shown in 
Figure 4.2 C), which is essential for the migration of CD4+ T cells into the B cell 
follicle (Breitfeld et al., 2000).  
 
4.2.3 ICOS expression is induced on antigen-specific 
CD4+ T cells following TCR stimulation 
ICOS is a member of the CD28 family of costimulatory receptors however, unlike 
CD28 it is not constitutively expressed on CD4+ T cells. Although the role for ICOS 
in the formation of TFH cells has been clearly identified (Akiba et al., 2005, Choi 
et al., 2011), it’s function for other CD4+ T cell subsets, including memory cells, is 
unclear. Conflicting reports have proposed a role for ICOS in the formation of 
Tem cells but not Tcm cells (Moore et al., 2011, Burmeister et al., 2008) and vice 
versa (Pepper et al., 2011). To dissect the role of ICOS:ICOSL signalling in the 
generation of CD4+ memory T cells we utilised ICOSL-/- mice in which all cells 
lack the ligand required to initiate the signalling cascade downstream of ICOS in 
CD4+ T cells. ICOS only interacts with ICOSL, which is expressed on APC, 
therefore these mice show impaired GC and humoral responses associated with a 
deficiency in T cell help (Yoshinaga et al., 1999, Hutloff et al., 1999). The naive 
2W1S:I-Ab+ CD4+ T cell population was analysed in these mice and found to be 
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similar to WT mice; a small population of tetramer binding CD4+ T cells could be 
identified that were CD44lo (Figure 4.5 A). The median size of this population in 
ICOSL-/- mice was around 100 cells, which is not significantly different from WT 
mice (Figure 4.5 D). Expression of ICOS is induced on activated CD4+ T cells 
following TCR stimulation and is dependent on signals through the costimulatory 
receptor CD28 (Yoshinaga et al., 1999, Tafuri et al., 2001, Hutloff et al., 1999, 
McAdam et al., 2001, Gonzalo et al., 2001, McAdam et al., 2000). Our data are 
consistent with this finding; expression of ICOS was detected on CD44hi CD4+ T 
cells in both WT and ICOSL-/- mice (Figure 4.5 B). 2W1S:I-Ab+ CD4+ T cells that 
had not been activated with antigen lacked expression of ICOS (Figure 4.5 C). An 
isotype control for anti-ICOS staining was found to have a high level of 
background staining and therefore under-represented the level of ICOS 
expression. As expression of ICOS is dependent on CD28 signalling (McAdam et 
al., 2000), CD80-/- CD86-/- mice were used as a negative control to set the gating 
for ICOS+ cells (Figure 4.5 E).  
To dissect the requirements for CD28 and ICOS signals during a CD4+ T cell 
response we used a combination of antigen-specific models. To analyse an 
endogenous polyclonal population, 2W1S:I-Ab+ CD4+ T cells were tracked from 
primary proliferation through to the memory stage of the response using MHC II 
tetramers. This was combined with the use of TCR transgenic SM1 cells as this 
method allowed us to generate memory cells in WT mice which could be 
transferred into genetically deficient hosts to monitor their persistence and re-
expansion upon challenge.  
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Figure 4.5: Naive 2W1S:I-Ab+ CD4+ T cells lack ICOS expression. Naive WT and 
ICOSL-/- mice were analysed for expression of CD44 and ICOS. (A) Expression of 
CD44 on 2W1S:I-Ab+ CD4+ T cells. Plots are gated on CD4+ T cells and show 2 mice 
pooled. (B) Expression of CD44 and ICOS by CD4+ T cells. (C) Expression of ICOS 
on 2W1S:I-Ab+ CD4+ T cells. Plots are gated on CD4+ T cells and show 2 mice 
pooled. (D) Number of 2W1S:I-Ab+ CD4+ T cells. 
 
(E) WT and CD80-/-CD86-/- mice were analysed for ICOS expression on 2W1S:I-Ab+ 
CD4+ T cells 28 dpi with Lm-2W1S. Gating for the ICOS- population was set using 
2W1S:I-Ab+ CD4+ T cells from CD80-/-CD86-/- mice which do not express ICOS.  
(A-C and E) Plots are representative of ≥4 mice from 2 independent experiments. 
(D) Graph shows pooled data from 2 independent experiments. Bars show median. 
Mann-Whitney test: ns= p>0.05.  
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 This approach allows a WT memory cell population to be studied, without the 
caveats associated with the sub-optimal generation of memory cells in 
costimulation deficient mice. Due to previous reports showing poor conversion 
to memory when large numbers of TCR transgenic cells are transferred (Hataye 
et al., 2006), we injected WT mice with 10 000 SM1 CD4+ T cells i.v. and infected 
mice with Lm-FliC to form a population of SM1 CD4+ memory T cells. SM1 CD4+ 
memory T cells were harvested from donor mice as described in section 2.9 and 
transferred into ICOSL-/-, CD80-/-CD86-/-, CTLA4Ig or WT mice for analysis.  
As we saw that OX40 expression was transient and closely linked to antigen 
exposure in the 2W1S model system we analysed ICOS expression on both 
2W1S:I-Ab+ CD4+ T cells and SM1 CD4+ T cells at different stages of the response. 
ICOS expression was examined on primary effector cells (7 dpi), memory cells 
(28 dpi), memory cells 4 hours post peptide restimulation and on recently 
activated memory cells (3 days post secondary challenge). Naive 2W1S:I-Ab+ 
CD4+ T cells do not express ICOS (shown in Figure 4.5) however at all 
subsequent timepoints analysed after activation with Lm-2W1S, ICOS was 
expressed by all or the majority of responding cells (Figure 4.6 A).  Unlike OX40, 
ICOS was expressed on resting memory cells, albeit at a lower level than primary 
effector cells or recently activated memory cells. ICOS expression on TCR 
transgenic SM1 CD4+ T cells responding to their antigen Lm-FliC was comparable 
to polyclonal 2W1S:I-Ab+ CD4+ T cells (Figure 4.6 B). Again the level of expression 
on resting memory cells was lower than SM1 cells at other stages of the 
response.  
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Figure 4.6: Timecourse of ICOS expression by 2W1S:I-Ab+ CD4+ T cells and 
TCR transgenic SM1 CD4+ T cells. (A) WT mice were infected with Lm-2W1S and 
analysed at the indicated timepoint. ICOS expression on 2W1S:I-Ab+ CD4+ T cells at 
7 dpi, on memory cells at 28 dpi, 4 hours post restimulation with 2W1S peptide and 
3 days post secondary challenge with Lm-2W1S 28 dpi. (B) WT mice received an 
adoptive transfer of 10 000 TCR transgenic SM1 CD4+ T cells and were infected the 
following day with Lm-FliC. ICOS expression was analysed at 7 dpi, on memory 
cells at 28 dpi, 4 hours post restimulation with FliC peptide and 4 days post 
secondary challenge with Lm-FliC 28 dpi.   
 
(A) Plots are representative of ≥8 mice from 2 independent experiments. (B) Plots 
are representative of ≥6 mice from 2 independent experiments except for 7 dpi and 
4 hours post challenge which represent 2 mice from 1 independent experiment.  
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4.2.4 ICOS is required for the formation of 2W1S:I-Ab+ 
TFH cells 
One of the key functions of the costimulatory receptor ICOS is in the 
differentiation of TFH cells (Choi et al., 2011, Akiba et al., 2005) and this has also 
been demonstrated in human patients (Bossaller et al., 2006). Expression of 
ICOSL on B cells is essential for the generation and maintenance of TFH cells 
(Nurieva et al., 2008, Choi et al., 2011). To test if ICOS is required for the 
generation of 2W1S:I-Ab+ CD4+ T cells, WT and ICOSL-/- mice were infected with 
Lm-2W1S. The CXCR5+PD-1+ TFH cell population was essentially absent in ICOSL-
/- mice and the Tcm precursor population was also significantly reduced (Figure 
4.7 A and B). There was however no significant effect seen on Teff cells (Figure 
4.7 B). These data are consistent with previous studies analysing the 2W1S:I-Ab+ 
CD4+ T cell response (Pepper et al., 2010, Pepper et al., 2011). Therapeutic 
targeting of the ICOS:ICOSL pathway has been successfully trialled to prolong 
cardiac allograft survival (Harada et al., 2003, Schenk et al., 2009). Combination 
of multiple pathways including ICOS and CD40L has been used to promote 
allograft tolerance and has prevented autoimmune diabetes in NOD mice (Ford 
et al., 2014, Orban et al., 2011).  We sought to test the efficacy of mAb blocking 
ICOS:ICOSL interactions by targeting the ICOS receptor. Blocking anti-ICOS mAb 
were provided by MedImmune and administered at 0 and 3 dpi. The half life of 
these mAb is 7-10 days (Gianluca Carlesso- unpublished observations) therefore 
these reagents could reasonably be expected to block ICOS:ICOSL signalling 
throughout the primary CD4+ T cell response.   
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Figure 4.7: 2W1S:I-Ab+ CD4+ TFH cells require ICOS signals for their formation. 
WT and ICOSL-/- mice were infected with Lm-2W1S and taken 7 dpi. (A) Flow 
cytometry plots showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells 
7 dpi. (B) Number of 2W1S:I-Ab+ CD4+ Teff, T central memory precursor (Tcm) and 
TFH cells.  
 
WT mice were infected with Lm-2W1S and taken 7 dpi. Mice received either blocking 
anti-ICOS or control mAb 0 and 3 dpi. (C) Flow cytometry plots showing expression 
of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ 
Teff, T central memory precursor (Tcm) and TFH cells.   
 
(A and C) Plots are representative of 12 mice from 3 independent experiments. 
Values on plots are percentages. (B and D) Graphs show pooled data from 2 
independent experiments. Values of 0 were assigned as 1. Bars show median. Mann-
Whitney test: **p<0.01, ***p<0.001, ****p<0.0001,  ns= p>0.05.  
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Blocking anti-ICOS mAb recapitulated the effects seen in ICOSL-/- mice; 
generation of TFH cells and Tcm precursors was significantly impaired, although 
the reduction in Tcm precursors was less dramatic than in TFH cells (Figure 4.7 
C and D). However unlike in ICOSL-/- mice, blocking anti-ICOS mAb caused a 
significant reduction in Teff cells. The blocking anti-ICOS mAb was made by 
linking the variable region sequences from Rat IgG2a anti-mouse ICOS with 
sequences of human IgG1-TM (Yusuf et al., 2014). The human IgG1 contains 3 
mutations in the Fc region that have been shown to significantly inhibit binding 
to Fcγ receptors and therefore prevent mAb dependent cytotoxicity (Herbst et 
al., 2010, Oganesyan et al., 2008). For this reason the blocking anti-ICOS mAb is 
not expected to deplete ICOS+ cells and is unlikely to account for the reduced 
population of Teff cells following mAb treatment.  
 
4.2.5 CD28 is required for the optimal expansion of all 
2W1S:I-Ab+ CD4+ T cell subsets in the primary response 
We sought to compare the effects of blocking ICOS signalling to another 
costimulatory receptor, CD28.  CD28 is well characterised as the 2nd signal 
required for T cell activation.  Interaction of CD28 with two B7 family member 
ligands, CD80 and CD86, provides an important signal to sustain T cell responses 
following TCR stimulation (Lenschow et al., 1996). CD80-/-CD86-/- mice were 
used to assess the primary 2W1S:I-Ab+ CD4+ T cell response in the absence of 
CD28 signalling. GC formation and immunoglobulin class switching are impaired 
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in these mice due to an absence of T cell help (Borriello et al., 1997). There was a 
significant reduction in all 2W1S:I-Ab+ CD4+ T cell subsets 7 dpi infection with 
Lm-2W1S and TFH cell formation was almost completely abrogated in the 
absence of CD28 signalling (Figure 4.8 A and B). Demonstrated in Figures 4.1 and 
4.2, CTLA4Ig mice can be used as a model of limited CD28 costimulation, such as 
experienced by patients receiving Abatacept therapy. Optimal expansion of all T 
cell subsets was also impaired in these mice and TFH cells were again the most 
severely affected (Figure 4.8 C and D).  
 
4.2.6 Generation of both Tcm and Tem populations 
requires signalling through ICOS as well as CD28 
Signals received in the primary response are key to the generation of a functional 
memory cell pool. Sub-optimal expansion at this early stage reduces both the 
size of the memory cell pool and it’s ability to rapidly expand upon secondary 
challenge and exhibit effector cell functions (Hataye et al., 2006, Blair and 
Lefrancois, 2007). Currently the literature surrounding the role of ICOS in the 
generation of CD4+ memory T cells is conflicted. Recently human ICOS-deficient 
patients have been identified and characterised. They were found to be deficient 
in both Tcm and Tem cell populations indicating that ICOS is involved in the 
generation or survival of CD4+ T cell memory (Takahashi et al., 2009).   
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Figure 4.8: CD28 signals are required for the optimal expansion of all 2W1S:I-Ab
+ CD4+ T cell subsets. WT and CD80-/-CD86-/- mice were infected with Lm-2W1S and 
taken 7 dpi. (A) Flow cytometry plots showing expression of CXCR5 and PD-1 on 
2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ Teff, T central memory 
precursor (Tcm) and TFH cells. 
 
WT and CTLA4Ig mice were infected with Lm-2W1S and taken 7 dpi. (C) Flow 
cytometry plots showing expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells. 
(B) Number of 2W1S:I-Ab+ CD4+ Teff, T central memory precursor (Tcm) and TFH 
cells.  
 
(A) Plots are representative of 12 mice from 3 independent experiments. Values on 
plots are percentages. (C) Plots are representative of 5 mice from 2 independent 
experiments. Values on plots are percentages.  (B and D) Graphs show pooled data 
from 2 independent experiments. Values of 0 were assigned as 1. Bars show median. 
Mann-Whitney test: **p<0.01, ***p<0.001.	
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Studies of ICOS-/- and ICOSL-/- mice however have noted a specific reduction in 
Tem cells, but identification of memory cells in these studies has relied upon the 
use of CD44 and CD62L as well as adoptive transfer of non-physiological 
numbers of TCR transgenic T cells (Moore et al., 2011, Burmeister et al., 2008). 
Another study utilising bone marrow chimeras reconstituted with an equal mix 
of WT and ICOS-/- bone marrow came to a different conclusion.  Using infection 
with Lm-2W1S they found that only Tcm cells were affected by the absence of 
ICOS (Pepper et al., 2011). Therefore we sought to clarify if CD4+ memory T cells 
require ICOS signals and whether there is a differential requirement for Tcm 
versus Tem cells.  
We tracked the 2W1S:I-Ab+ CD4+ T cell population at the memory cell timepoint 
in ICOSL-/- mice to identify which, if any, memory cell subsets were affected. As 
infection with Lm-2W1S induces a Th1 response, Tem cells were functionally 
identified by the rapid production of both IL-2 and IFN-γ upon restimulation 
with 2W1S peptide. Tcm cells were identified by the production of IL-2 only; 
they do not produce IFN-γ until after proliferation into effector cell types 
(Pepper et al., 2011). Strikingly, we found that the number of both Tcm and Tem 
cells were both significantly reduced in ICOSL-/- mice yet neither population was 
completely abrogated (Figure 4.9 A and B). At 28 dpi there was approximately a 
10-fold decrease in the total number of 2W1S:I-Ab+ CD4+ T cells compared to only 
a 3.5-fold difference at day 7 (Figure 4.9 C and D). This indicated that either 
ICOS:ICOSL signalling was required after day 7 or that ICOS signalling in the 
primary response is required to form an optimal CD4+ memory T cell pool.  
 
 
 
 
171 
 
Figure 4.9: Generation of both Tem and Tcm cells is impaired in the absence of 
signals through ICOS. WT and ICOSL-/- mice were infected with Lm-2W1S and 28 
dpi restimulated in vivo with 2W1S peptide and LPS. Spleen and lymph nodes were 
harvested 4 hours post restimulation for analysis. (A) Flow cytometry plots showing 
expression of IL-2 and IFN-γ on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ 
CD4+ Tcm (IL-2+ IFN-γ-) and Tem (IL-2+ IFN-γ+) cells. (C) Number of 2W1S:I-Ab+ 
CD4+ T cells at 7 and 28 dpi in WT and ICOSL-/- mice. (D) Fold difference in the 
median number of 2W1S:I-Ab+ CD4+ T cells at 7 and 28 dpi between WT and 
ICOSL-/- mice.  
 
(A) Plots are representative of 12 mice from 3 independent experiments. Values on 
plots are percentages. (B and C) Graphs show pooled data from ≥2 independent 
experiments. Bars show median. Mann-Whitney test: **p≤0.01, ***p≤0.001, 
****p≤0.0001, ns= p>0.05. (D) Graph shows pooled data from 3 independent 
experiments. Unpaired T-Test: **p≤0.01. 
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The extent to which 2W1S:I-Ab+ CD4+ memory T cell formation was impaired in 
the absence of ICOS was surprising as previously ICOS was thought to be 
involved in the generation of either Tem or Tcm cells only. Additionally, only a 
minimal impact was observed on non-TFH cells in the primary response. CD28 
however is a powerful costimulatory molecule involved in the activation of T 
cells and in the absence of CD28 T cell proliferation is significantly reduced. As 
CD80-/-CD86-/- mice show significant impairment in the expansion of CD4+ T cells 
in a primary response this will likely impact upon the memory cell pool. To 
compare memory cell generation in the absence of ICOS signals with a lack of 
CD28 signalling, WT and CD80-/-CD86-/- mice were infected with Lm-2W1S and 
the number of 2W1S:I-Ab+ CD4+ memory T cells analysed 28 dpi. The number of 
2W1S:I-Ab+ CD4+ memory T cells recovered from CD80-/-CD86-/- was significantly 
diminished compared to WT mice (Figure 4.10 A and B).  As well as a dramatic 
decrease in the number of 2W1S:I-Ab+ CD4+ memory T cells, they were also non-
functional in that they were unable to produce cytokines IL-2 and IFN-γ (Figure 
4.10 A and C).  
 
4.2.7 Blocking anti-ICOS mAb inhibits CD4+ memory T 
cell formation 
The ICOS:ICOSL pathway is a potential therapeutic target; in the primary 
response blocking ICOS impairs TFH cell development and therefore limits the 
humoral response. 
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Figure 4.10: Formation of functional 2W1S:I-Ab+ CD4+ memory T cells requires 
CD28 costimulation. WT and CD80-/-CD86-/- mice were infected with Lm-2W1S and 
restimulated in vivo with 2W1S peptide and LPS 28 dpi. Spleen and lymph nodes 
were harvested 4 hours post restimulation for analysis. (A) Flow cytometry plots 
showing expression of IL-2 and IFN-γ on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 
2W1S:I-Ab+ CD4+ memory T cells. (C) Number of 2W1S:I-Ab+ CD4+ Tcm (IL-2+ IFN-
γ-) and Tem (IL-2+ IFN-γ+) cells.  
 
(A) Plots are representative of 8 mice from 2 independent experiments except for 
cytokine staining which is representative of 4 mice from 1 independent experiment. 
Values on plots are percentages. (B) Graph shows pooled data from 2 independent 
experiments. Bars show median. (C) Graph shows data from 1 independent 
experiment. Bars show median. Mann-Whitney test: *p≤0.05, ***p≤0.001.  
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Blocking this costimulatory pathway may alleviate autoimmune diseases that are 
antibody mediated. Generation of the 2W1S:I-Ab+ CD4+ memory T cell population 
was severely impaired in ICOSL-/- mice and it is clear that memory T cells may 
play an important role in autoimmune diseases such as systemic lupus 
erythematosus and type 1 diabetes (Devarajan and Chen, 2013). Since blocking 
anti-ICOS mAb were successfully used to mimic the effect of genetic absence of 
ICOSL-/- on the primary CD4+ T cell response, the effect of these reagents on the 
memory cell response was investigated following infection with Lm-2W1S. 
Blocking anti-ICOS mAb were administered on day 0 and 4 following infection 
and mice were again analysed for 2W1S:I-Ab+ memory T cells 28 dpi. As seen in 
ICOSL-/- mice, although both functional populations of memory cells were 
present (Figure 4.11 A), there was a significant decrease in the overall number of 
2W1S:I-Ab+ CD4+ memory T cells (Figure 4.11 B). Again, this resulted from a 
significant decrease in both Tcm and Tem cell populations (Figure 4.11 C).    
 
4.2.8 The persistence of antigen-specific CD4+ memory T 
cells does not require ICOS or CD28 signalling 
2W1S:I-Ab+ CD4+ memory T cells clearly require signals through both ICOS and 
CD28 for their generation. It is less clear whether CD4+ memory T cells continue 
to require costimulatory signals once this population has formed. Cytokines such 
as IL-7 and IL-15 are known to be required for CD4+ memory T cell persistence 
(Purton et al., 2007, Kondrack et al., 2003).  
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Figure 4.11: Blocking anti-ICOS mAb prevents formation of 2W1S:I-Ab+ CD4+ 
memory T cells. WT mice were infected with Lm-2W1S and restimulated in vivo with 
2W1S peptide and LPS 28 dpi. Mice received either blocking anti-ICOS or control 
mAb 0 and 4 dpi. Spleen and lymph nodes were harvested 4 hours post restimulation 
for analysis. (A) Flow cytometry plots showing expression of IL-2 and IFN-γ on 
2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ memory T cells. (C) 
Number of 2W1S:I-Ab+ CD4+ Tcm (IL-2+ IFN-γ-) and Tem (IL-2+ IFN-γ+) cells. 
 
(A) Plots are representative of 12 mice from 3 independent experiments. Values on 
plots are percentages. (B and C) Graphs show pooled data from 3 independent 
experiments. Bars show median. Mann-Whitney test: **p≤0.01, ***p≤0.001, 
****p≤0.0001. 
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Whether CD4+ memory cells require periodic signals through costimulatory 
receptors for their continued survival is less well understood. OX40 has been 
suggested as a candidate for enhancing the survival of memory cells (Withers et 
al., 2009) however we were unable to see a significant effect on 2W1S:I-Ab+ CD4+ 
memory T cell survival in the absence of OX40 costimulation.  
To investigate the contribution of CD28 signals in CD4+ memory T cell 
persistence, the 2W1S:I-Ab+ CD4+ T cell population in CTLA4Ig mice was assessed 
following infection with Lm-2W1S. The number of 2W1S:I-Ab+ CD4+ T cells was 
tracked in WT and CTLA4Ig mice from the primary response through to the 
memory phase. 7 dpi there was around a 2.5 fold difference in the number of 
2W1S:I-Ab+ CD4+ T cells (Figure 4.12 A; median for WT: 44 221, CTLA4Ig: 
16495). This difference was increased to approximately 4-fold at day 28 but was 
then maintained until day 80 post infection indicating that partial blockade of 
the CD28 pathway with constitutive production of CTLA4Ig does not seem to 
impair the survival of an endogenous memory cell population (Figure 4.12 A; 
d28 median for WT: 12 415, CTLA4Ig: 3235; d80 median for WT: 9583, CTLA4Ig: 
2151).   
Blocking anti-ICOS mAb was effective in limiting the size of primary and memory 
CD4+ T cell populations when administered following antigenic stimulation. To 
determine if CD4+ memory T cells require continued interactions for survival, 
blocking anti-ICOS mAb was used to temporally block ICOS signalling in WT mice 
once memory T cells had been formed.  
 
 
 
 
 
177 
 
 
 
 
Figure 4.12: Combined blockade of ICOS and CD28 signals does not affect the 
persistence of 2W1S:I-Ab+ CD4+ memory T cells once formed. (A) WT and 
CTLA4Ig mice were infected with Lm-2W1S and 2W1S:I-Ab+ CD4+ T cells were 
enumerated 7, 28 and 80 dpi. (B) WT mice were infected with Lm-2W1S and at 28 
dpi blocking anti-ICOS or control IgG mAb were administered twice weekly for 4 
weeks. 2W1S:I-Ab+ CD4+ memory T cells were then enumerated from spleen and 
lymph nodes.  
 
 
(A and B) Graph shows pooled data from 2 independent experiments. Bars show 
median. Mann-Whitney test: *p≤0.05, ***p≤0.001, ns= p>0.05. 
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This approach would circumvent the problems associated with analysing 
memory T cell populations in mice where priming is impaired. For example 
experiments using CD30-/-OX40-/- mice concluded a problem with memory cell 
survival in the absence of these TNFR, however it is difficult to differentiate this 
from the effect of the absence of these receptors on the survival of effector CD4+ 
T cells following priming (Gaspal et al., 2005). CD4+ T cells responding to Lm-
2W1S undergo a period of intense proliferation peaking 7 dpi. The population 
then undergoes a massive contraction due to apoptosis ending around 20 dpi, 
before forming a stable population of memory cells that decrease gradually in 
number over the following year (Pepper et al., 2011). To model a lack of ICOS 
signals only after memory cell formation, WT mice were infected with Lm-2W1S 
and after 28 days blocking anti-ICOS or control mAb were administered twice 
weekly for 4 weeks. The number of 2W1S:I-Ab+ CD4+ memory T cells recovered 
from mice receiving blocking anti-ICOS or control mAb was not significantly 
different, indicating ICOS signals are not required for their survival in this time 
period (Figure 4.12 B).  
Since blocking ICOS mAb blockade may not be complete and CTLA4Ig is a model 
only of limited costimulation we sought to confirm these results using another 
model system that enables the survival of WT CD4+ memory T cells to be 
assessed. The transfer of tetramer specific CD4+ T cell populations is technically 
challenging due to their low frequency. Moreover, the magnetic enrichment 
method used to purify 2W1S:I-Ab+ CD4+ T cells binds via the TCR, adding 
additional caveats associated with TCR stimulation. For these reasons allotype 
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marked TCR transgenic SM1 CD4+ memory T cells were used to evaluate WT 
memory cell survival in genetically deficient hosts. Outlined in the schematic in 
Figure 4.13 A, 10 000 allotype marked SM1 CD4+ T cells were transferred into 
WT mice that were then immunised with Lm-FliC the following day to expand 
the SM1-specific population. Mice were left until day 28 post infection to form an 
SM1 CD4+ memory T cell population that was then harvested from spleen and 
lymph nodes and subsequently enriched using allotype markers. Approximately 
20 000- 40 000 SM1 CD4+ memory T cells were transferred into WT and 
genetically deficient hosts for comparison. SM1 CD4+ memory T cells were 
identified by the gating strategy shown in Figure 4.13 B.  SM1 CD4+ memory T 
cells are CD3lo so a large gate is drawn to take account of this; other cell lineages 
are excluded using the markers B220, CD11b and CD11c. They are then 
identified by expression of CD4, CD45.1 and CD45.2. All SM1 CD4+ memory T 
cells were checked for expression of CD44 and found to be CD44hi (Figure 4.13 
C). Following transfer of SM1 CD4+ memory T cells into WT, ICOSL-/-, CTLA4Ig 
and CD80-/-CD86-/- mice there were no significant differences in the number of 
memory cells recovered (Figure 4.13 D-F). Data shown in Figure 4.13 D and E are 
representative of 2 independent experiments, as due to the variable nature of 
memory cell transfers it was unfeasible to pool data. Within experimental 
repeats, no difference was observed in the number of recovered SM1 CD4+ 
memory T cells in costimulation deficient mice compared to WT controls. These 
data are consistent with our previous findings using endogenous 2W1S:I-Ab+ 
CD4+ T cells; blockade of ICOS or CD28 signals did not impair the persistence of 
established memory CD4+ T cells once formed. 
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Figure 4.13: Persistence of CD4+ memory T cells generated in WT mice is not 
dependent on ICOS or CD28 signals. WT mice were injected with 10 000 SM1 
CD4+ T cells and infected the following day with Lm-FliC. Mice were rested for 28 
days enabling formation of an SM1 CD4+ memory T cell population. Spleen and 
lymph nodes were harvested and enriched for SM1 CD4+ memory T cells, which were 
injected back into new hosts (approximately 25 000 SM1 memory cells per mouse). 
Mice were analysed 28 days post transfer. (A) Schematic showing the protocol for 
transfer of SM1 CD4+ memory T cells. (B) Flow cytometry plots showing the gating 
strategy for identification of SM1 CD4+ memory T cells; gated on lymphocytes, B220-
CD11b-CD11c-, CD4+CD8-, CD45.1+CD45.2+. (C) Representative plot showing 
expression of CD44 on SM1 CD4+ memory T cells. (D) Number of SM1 CD4+ memory 
T cells recovered from WT and ICOSL-/-. (E) Number of SM1 CD4+ memory T cells 
recovered from WT and CTLA4Ig mice. (F) Number of SM1 CD4+ memory T cells 
recovered from WT and CD80-/-CD86-/- mice.  
 
(B and C) Plots are representative of >12 mice from >3 independent experiments. 
Values on plots are percentages. (D-E) Graphs show representative data from 2 
independent experiments. (F) Graph shows pooled data from 2 independent 
experiments. Bars show median. Mann-Whitney test: ns= p>0.05. 
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4.2.9 Following secondary challenge ICOS is required for 
the generation of TFH cells 
Analysis of the requirements for the generation and survival of 2W1S:I-Ab+ CD4+ 
memory T cells following Lm-2W1S infection indicated that ICOS signals were 
required for the formation of this population, but not for subsequent survival 
following the contraction phase. Expansion of CD4+ memory T cells upon 
secondary challenge is thought to be less reliant on costimulatory signals due to 
the enhanced state of activation in which they reside (London et al., 2000, Croft 
et al., 1994). To investigate the specific requirement of antigen-specific CD4+ 
memory T cells for ICOS signals upon re-encounter of antigen, blocking mAb was 
used to temporally control ICOS signalling. WT mice were infected with Lm-
2W1S and challenged again with Lm-2W1S 28 dpi. Blocking anti-ICOS or control 
mAb were administered the day before and after secondary challenge to ensure 
blockade at the point of memory cell expansion. There was no difference in the 
expansion of Tcm cells, however a small, but significant, difference was observed 
in the expansion of Tem cells (Figure 4.14 A and B). Interestingly 2W1S:I-Ab+ 
TFH cell expansion was severely impaired by ICOS blockade, as was seen in the 
primary response (Figure 4.14 A and B).  
To additionally assess CD4+ memory T cell expansion in the genetic absence of 
ICOSL, SM1 CD4+ memory T cells were generated in WT mice and transferred 
into WT and ICOSL-/- hosts. Mice were then challenged with Lm-FliC 28 days post 
transfer and SM1 CD4+ T cells were enumerated 4 days post secondary 
challenge. 
 
 
 
 
182 
 
102
103
104
105
106
103
104
105
106
Figure 4.14: ICOS is required for the generation of TFH cells following 
secondary challenge. WT mice were infected with Lm-2W1S and at 28 dpi 
challenged with Lm-2W1S. Mice received blocking anti-ICOS or control mAb the day 
before and after challenge. 2W1S:I-Ab+ CD4+ T cells were enumerated from spleen 
and lymph nodes 3 days later. (A) Flow cytometry plots showing expression of 
CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ Tem, 
Tcm and TFH cells. 
 
(C) WT and ICOSL-/- received approximately 25 000 WT SM1 CD4+ memory T cells. 
Mice were then challenged with Lm-FliC 28 days post transfer. SM1 CD4+ memory T 
cells were enumerated from spleen and lymph nodes 4 days later. Shown is the 
number of SM1 CD4+ Tem, Tcm and TFH cells. 
 
(A) Plots are representative of 8 mice from 2 independent experiments. Values on 
plots are percentages. (B-C) Graphs show pooled data from 2 independent 
experiments. Bars show median. Mann-Whitney test: *p≤0.05, **p≤0.01, ***p≤0.001, 
ns= p>0.05. 
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As observed with blockade of ICOS, the generation of TFH cells from SM1 CD4+ 
memory cells was dependent upon ICOSL, however the expansion of the other T 
cell populations was not affected (Figure 4.14 C). Combined, these two 
approaches indicate that TFH cells remain reliant on ICOS for expansion 
following secondary challenge despite the convention that the costimulatory 
requirements of memory cells are reduced.  
To further investigate the costimulatory requirement of CD4+ memory T cells 
upon secondary challenge, the requirement for CD28 signals at this stage was 
also assessed. Previously it has been thought that the expansion of CD4+ memory 
T cells is independent of CD28 costimulation due to a reduced requirement for 
TCR stimulation for activation (Salomon and Bluestone, 2001). These ideas were 
mostly based on in vitro experiments showing that memory cells could 
proliferate in the absence of B7 ligands (London et al., 2000, Croft et al., 1994). 
However more recently published data has challenged this paradigm showing 
that influenza virus- and OVA-specific memory cell proliferation was inhibited by 
CTLA4Ig treatment (Ndejembi et al., 2006). SM1 CD4+ memory T cells generated 
in WT mice were transferred into WT and CD80-/-CD86-/- hosts then challenged 
28 days post transfer with Lm-FliC. The number of responding cells was 
enumerated from the spleen and lymph nodes 4 days post secondary challenge. 
Unlike in ICOSL-/- hosts, the expansion of all subsets of SM1 CD4+ memory T cells 
were reliant on signals through CD28, not just TFH cells  (Figure 4.15 A and B).  
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Figure 4.15: CD28 is required for the optimal generation of all T cell subsets 
following secondary challenge. WT and CD80-/-CD86-/- mice received 
approximately 25 000 SM1 CD4+ memory T cells.  Mice were challenged with Lm-
FliC 28 days post transfer. SM1 CD4+ T cells were enumerated from spleen and 
lymph nodes 4 days later. (A) Flow cytometry plots showing expression of CXCR5 
and PD-1 on SM1 CD4+ T cells. (B) Number of SM1 CD4+ Tem, Tcm and TFH cells. 
 
(A) Plots are representative of 8 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows representative data from 2 independent 
experiments. Bars show median. Mann-Whitney test: *p≤0.05. 
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These data are consistent with recent studies indicating that memory cells 
require costimulatory signals for optimal expansion upon re-encounter of 
antigen (Ndejembi et al., 2006).  
 
4.2.10 Combination of blocking anti-ICOS mAb and 
CTLA4Ig enhances blockade of CD4+ T cell response 
 Antibody mediated blockade of ICOS in the primary response comprehensively 
blocked TFH cell formation, however was not as effective at limiting proliferation 
of Teff cell and Tcm cell precursor populations. Despite this, the generation of 
memory cells was significantly impaired. Constitutive expression of CTLA4Ig 
inhibited the proliferation of all T cell subsets in the primary response but was 
not as effective as would be expected considering the potent effect of CD28 on T 
cell proliferation; 2W1S:I-Ab+ CD4+ T cells were reduced by only 2.5 fold. 
Surprisingly blocking anti-ICOS mAb caused a greater reduction in the memory 
cell population at day 28 than constitutive provision of CTLA4Ig (Figure 4.16 A; 
median for WT: 6076, CTLA4Ig: 2671, anti-ICOS: 377). There was a 10-fold 
reduction in the number of 2W1S:I-Ab+ CD4+ memory T cells following blocking 
anti-ICOS mAb compared to approximately 4-fold reduction in CTLA4Ig mice. A 
therapeutic approach combining these treatments may be the optimal way to 
effectively dampen CD4+ T cell responses. Furthermore, possible redundancy in 
the signalling cascades elicited by B7 family members may be circumvented by 
the combination of two blocking agents.  
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4.16: Blockade of ICOS and CD28 signalling does not impair 2W1S:I-Ab+ CD4+ 
memory cell T survival. (A) WT, CTLA4Ig and anti-ICOS mAb treated mice were 
infected with Lm-2W1S and analysed for enumeration of 2W1S:I-Ab+ CD4+ memory T 
cells 28 dpi. Blocking anti-ICOS mAb were administered at day 0 and 4 post 
infection. (B) CTLA4Ig mice were infected with Lm-2W1S and at 28 dpi blocking anti-
ICOS or control mAb were administered twice weekly for four weeks. 2W1S:I-Ab+ 
CD4+ memory T cells were then enumerated from spleen and lymph nodes.  
 
(A-B) Graph shows data pooled from 2 independent experiments. Bars show 
median. Mann Whitney test: ***p<0.001, ****p<0.0001, ns= p>0.05.  
**** 
ns 
*** 
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Previously, a combination of blocking anti-ICOS mAb and CTLA4Ig has been used 
to successfully prevent cardiac allograft rejection in transplant models (Kosuge 
et al., 2003). Blocking ICOS:ICOSL interactions also suppressed ongoing T cell 
responses in autoimmune EAE (Sporici et al., 2001). Combining blocking anti-
ICOS mAb and CTLA4Ig targets both cellular and humoral responses, through 
their impact on T cell responses.  Since the survival of 2W1S:I-Ab+ CD4+ memory 
T cells was not impaired in CTLA4Ig mice or with blocking anti-ICOS mAb alone 
we combined these approaches to investigate whether this reflected redundancy 
in the requirement for these signals. CTLA4Ig mice infected with Lm-2W1S 
received blocking anti-ICOS mAb for 4 weeks from 28 dpi, however the number 
of 2W1S:I-Ab+ CD4+ memory T cells recovered was not significantly different 
from control mice (Figure 4.16 B).  This demonstrates that the persistence of 
2W1S:I-Ab+ CD4+ memory T cells in the absence of either CD28 or ICOS is not due 
to compensatory signalling from ICOS or CD28 respectively. 
In the primary response to Lm-2W1S only a modest reduction in 2W1S:I-Ab+ 
CD4+ T cell number was observed in both CTLA4Ig mice and with the use of 
blocking anti-ICOS mAb. To investigate a dual therapeutic approach CTLA4Ig 
mice were infected with Lm-2W1S and received blocking anti-ICOS or control 
mAb. 7 dpi there was a significant decrease in all 2W1S:I-Ab+ CD4+ T cell subsets 
and TFH cells were absent (Figure 4.17 A and B). In CTLA4Ig mice treated with 
blocking anti-ICOS mAb there was a significant decrease in the number of 
2W1S:I-Ab+ CD4+ T cells compared to WT mice treated with anti-ICOS mAb alone 
(Figure 4.17 C).  There was a 9-fold decrease for CTLA4Ig anti-ICOS mAb treated 
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mice compared to only a 3.5-fold decrease for WT anti-ICOS mAb treated mice 
(Figure 4.17 D). This indicates that combined CTLA4Ig and anti-ICOS mAb 
treatment is superior to either reagent alone for therapeutic blockade of the 
primary CD4+ T cell response.  
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4.17: Therapeutic combination of blocking anti-ICOS mAb and CTLA4Ig 
enhances blockade of primary CD4+ T cell response. CTLA4Ig mice were 
infected with Lm-2W1S and analysed 7 dpi. Mice received either blocking anti-ICOS 
or control mAb 0 and 3 dpi. (A) Flow cytometry plots showing expression of CXCR5 
and PD-1 on 2W1S:I-Ab+ CD4+ T cells. (B) Number of 2W1S:I-Ab+ CD4+ Teff, T 
central memory precursor (Tcm) and TFH cells.  
 
WT and CTLA4Ig mice were infected with Lm-2W1S and analysed 7 dpi. Mice 
received blocking anti-ICOS or control mAb 0 and 3 dpi. (C) Number of 2W1S:I-Ab+ 
CD4+ T cells enumerated from the spleen. (D) Fold difference in median number of 
2W1S:I-Ab+ CD4+ T cells between mice treated with blocking anti-ICOS and control 
mAb for both WT and CTLA4Ig mice.   
 
(A) Plots are representative of 6 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 3 independent 
experiments. Bars show median. Mann-Whitney test: **p≤0.01, ***p≤0.001. (C) 
Graph shows pooled data from 2 independent experiments. Bars show median. 
Kruskal Wallis test with post host Dunn's test: *p<0.05. (D) Graph shows data from ≥ 
2 independent experiments. Bars show median.  
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4.3 Discussion 
Although there is a clear role for ICOS in the formation and maintenance of TFH 
cell populations, the importance of this receptor for other T cell subsets is less 
well defined, hindered by conflicting data. In this chapter I have dissected the 
requirement for ICOS during the generation and subsequent responses of 
antigen-specific CD4+ memory T cells and contrasted this with the role of CD28 
signals. These data show that, unlike CD28 which is required for the optimal 
expansion of all T cell subsets, ICOS is required only for the development of TFH 
cells in the primary response as well as following secondary challenge. Both Tcm 
and Tem cells are dependent on ICOS for their generation, but not for their 
subsequent persistence once formed. The combination of blocking anti-ICOS 
mAb and CTLA4Ig was more effective at blocking antigen-specific CD4+ T cell 
expansion than either reagent alone, indicating this may provide a useful 
therapeutic option.  
Originally thought to control the differentiation of Th2 cells, ICOS is now thought 
to have a more general role in controlling cytokine production by effector cells 
(McAdam et al., 2000, Tafuri et al., 2001, McAdam et al., 2001). However, the 
exact time in the response at which ICOS is required for an endogenous antigen-
specific CD4+ T cell population responding to infection has not been dissected. In 
addition there are conflicting reports for the requirement of ICOS signalling for 
memory cell populations. Conventionally, memory cells are thought to be less 
reliant on costimulation for reactivation than naive T cells, however in Chapter 1 
I have demonstrated that a lack of signalling through OX40 specifically impacts 
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upon the Tem cell population. Therefore in this chapter we sought to determine 
when and which memory cell subsets require signalling through ICOS and 
compare this to CD28, the molecule on which much of the early work suggesting 
costimulation is dispensable for memory cells was performed.   
As observed previously, ICOS was not present on naive T cells but following 
activation expression of ICOS was detected at all timepoints analysed on both 
2W1S:I-Ab+ and SM1 CD4+ T cells, with a slightly lower level observed on 
memory cells (Hutloff et al., 1999, Mages et al., 2000). This expression of ICOS 
after TCR engagement indicates a prominent role for this costimulatory receptor 
in effector T cell responses. Unlike OX40, ICOS was expressed on 2W1S:I-Ab+ 
CD4+ memory T cells at low levels suggesting they may receive either continuous 
or periodic signals through this receptor that contribute to their survival. To 
precisely dissect the requirements for ICOS, a combination of ICOSL-/- mice and 
blocking anti-ICOS mAb were used, alongside the models established in the 
previous chapter, to investigate the role of this costimulatory receptor in CD4+ T 
cell responses. Formation of TFH cells was significantly impaired in the absence 
of ICOS for both 2W1S:I-Ab+ and SM1 CD4+ T cells, consistent with previous data 
(Akiba et al., 2005, Nurieva et al., 2008, Choi et al., 2011). Teff cell formation was 
not affected in ICOSL-/- mice suggesting that ICOS functions specifically to 
promote the generation or survival of TFH cells. As a comparison CD80-/-CD86-/- 
mice were used to show the effect of a lack of signalling through CD28. As 
expected from previous studies all CD4+ T cell subsets are reliant on CD28 for 
optimal primary expansion (Akiba et al., 2005, Shahinian et al., 1993). 
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The data surrounding the requirement of ICOS for CD4+ memory T cells is 
unclear since different studies have made conflicting conclusions on whether 
Tcm or Tem require ICOS signals for their development or survival. One study 
found a significant reduction of Tem cells in the steady state in ICOS-/- mice, an 
effect which was amplified with age (Burmeister et al., 2008). However, this 
conclusion was drawn from the analysis of memory phenotype cells, which have 
been shown to be an independent population from antigen-specific memory cells 
with different requirements for survival signals (Purton et al., 2007, Lenz et al., 
2004).  These findings were corroborated by an antigen-specific study showing 
Tem cells depend on ICOS for survival (Moore et al., 2011). Adoptive transfer of 
TCR transgenic cells and influenza-specific tetramers were used to show ICOS 
was required specifically for the long-term survival of Tem cells and not their 
development. In contrast, a study by Pepper et al. revealed dependence on ICOS 
signals for generation of Tcm precursors and maintenance of this population 
once formed (Pepper et al., 2011).  
My data demonstrate a clear role for ICOS signals in the generation of both 
2W1S:I-Ab+ CD4+ Tcm and Tem cell populations. Further experiments are 
required to conclusively dissect whether this requirement is during the initial 
formation of these populations, or in the maintenance during the contraction 
phase of the response. Notably, amongst the small 2W1S:I-Ab+ CD4+ memory T 
cell population formed in the absence of ICOS signals, the percentage of 
functional Tcm and Tem cells was not altered in comparison to WT mice.  This is 
consistent with data described for human patients with ICOS deficiency; 
 
 
 
 
193 
peripheral blood T cells were found to contain a reduced percentage of both Tcm 
and Tem cells (Takahashi et al., 2009). The 2W1S:I-Ab+ CD4+ memory T cell pool 
was significantly more impaired than at 7 dpi; a 10 fold reduction in the number 
of memory cells in ICOSL-/- mice was observed compared to a 3.5 fold reduction 
at day 7. This finding suggests that ICOS signals may support the generation of 
CD4+ memory T cells by enhancing the initial development of antigen-specific 
cells that will survive long-term. Alternatively, ICOS signals may be required 
after initial proliferation to directly support the survival of cells that will enter 
the memory cell pool. Both of these effects could be achieved through the 
upregulation of anti-apoptotic molecules, such as Bcl-2, that permit survival 
through the contraction phase. Further careful manipulation of the timing of 
blocking anti-ICOS mAb administration could be used to dissect this. 
Previous data have suggested there may be a role for costimulatory signals in the 
long-term persistence of memory CD4+ T cells. RORt-/- mice infected with Lm-
2W1S showed normed CD4+ T cell expansion in the primary response, but had a 
significantly reduced memory cell pool indicating a role for RORt+ ILC in 
memory cell survival (Withers et al., 2012). Constitutive expression of OX40L by 
ILC prompted us to test this observation in Chapter 3, however expression of 
OX40 was tightly linked to antigen-exposure.  ICOSL is expressed by ILC3, (D. 
Withers unpublished observations), which are absent in ROR-/- mice, making 
ICOS:ICOSL interactions a possible mechanism enhancing memory CD4+ T cell 
survival.  
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We observed that ICOS, and also CD28, signals were dispensable for the 
persistence of both polyclonal 2W1S:I-Ab+ CD4+ memory T cells once formed and 
TCR transgenic SM1 memory cells formed in WT mice and transferred into new 
hosts. Furthermore a combined approach using blocking anti-ICOS mAb in 
CTLA4Ig mice did not affect memory cell survival, indicating that the lack of 
effect is not due to redundancy in these pathways. These data suggest that it is 
likely that signals from costimulatory molecules received during priming impact 
upon the survival of CD4+ T cells through the latter stages of the primary 
response, to form a functional memory cell pool. Clear evidence that periodic 
signals through costimulatory receptors regulate the survival of the memory cell 
population once formed is lacking and at present cytokines such as IL-7 and IL-
15 appear to play the dominant role (Kondrack et al., 2003, Purton et al., 2007).  
Upon secondary challenge we observed that antigen-specific CD4+ memory T 
cells show a differential requirement for signals through CD28 and ICOS. 
Although many studies have previously thought CD28 to be unnecessary for 
reactivation of memory cells (Croft et al., 1994, London et al., 2000), here we 
show for WT TCR transgenic SM1 memory cells proliferation is significantly 
impaired in the absence of B7 ligands CD80 and CD86. These data are consistent 
with a study showing blocking CD28 signalling through injection of CTLA4Ig 
inhibited the expansion of CD4+ T cells following secondary challenge (Ndejembi 
et al., 2006). However in the absence of ICOS signals only SM1 TFH cells were 
significantly reduced with Tcm and Tem cells both expanding normally. This was 
also the case for polyclonal 2W1S:I-Ab+ CD4+ memory T cells, which showed a 
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significant impairment in TFH cell expansion when blocking anti-ICOS mAb were 
administered at secondary challenge. Secondary expansion of tetramer-specific 
CD4+ T cells has previously been shown to be impaired in ICOS-/- mice (Mahajan 
et al., 2007). In this study mice were immunised s.c. with peptide in CFA, a robust 
adjuvant, which may account for the differences seen in our study. It is not yet 
known if the initial priming of CD4+ T cells impacts upon the costimulatory 
requirements of the resulting memory cell population upon secondary challenge.  
We explored the use of mice constitutively expressing CTLA4Ig fusion protein as 
a model of limited costimulation analogous to treatment of human patients with 
Abatacept. Abatacept has had some success in the treatment of RA and has been 
promising in clinical trials to treat psoriasis (Ruderman and Pope, 2005, Kremer 
et al., 2003, Abrams et al., 1999). However other disease models have not been 
ameliorated by CTLA4Ig treatment, for example type 1 diabetes and ulcerative 
colitis (Orban et al., 2014, Orban et al., 2011, Sandborn et al., 2012). We sought to 
clarify the efficacy of CTLA4Ig in a mouse model by analysing the endogenous 
2W1S:I-Ab+ CD4+ T cell population and comparing this to adoptively transferred 
SM1 CD4+ T cells. CTLA4Ig mice exhibited a reduced Treg cell compartment and 
impaired primary CD4+ T cells responses to infection with L. moncytogenes, both 
CD28 dependent processes. These mice also had smaller GC than WT mice 
following immunisation with Lm-2W1S and migration of SM1 CD4+ T cells to the 
follicle was impaired. CD80-/-CD80-/- mice analysed as a control in which CD28 
signalling is absent were significantly more impaired, indicating that CTLA4Ig 
fusion protein causes a partial blockade. These data show that constitutive 
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expression of CTLA4Ig is effective in limiting CD28 costimulation and therefore 
provides a mouse model of Abatacept treatment. 
As we observed that blocking anti-ICOS mAb were highly efficient at 
recapitulating the phenotype of ICOSL-/- mice, we explored their potential for use 
as a therapeutic to limit CD4+ T cell responses.  Following infection with Lm-
2W1S, TFH cell formation was abrogated but non-TFH cells were largely 
unaffected. As constitutive expression of CTLA4Ig resulted in only partial 
blockade, we investigated whether combination of CTLA4Ig and anti-ICOS mAb 
could enhance immune blockade. Previously, combination of CTLA4Ig and anti-
ICOS mAb have been used to successfully prevent cardiac allograft rejection in 
transplant models indicating this may be a possible way to enhance immune 
blockade (Kosuge et al., 2003). Following treatment of CTLA4Ig mice with anti-
ICOS mAb a further reduction in the primary effector responses was seen 
compared to the use of either therapeutic alone.  
In summary, unlike OX40 ICOS expression is maintained on 2W1S:I-Ab+ CD4+ T 
cells throughout the course of the response. This prompted us to investigate 
when ICOS signals are required by CD4+ T cells for either generation or survival 
and if there is a preferential requirement among T cells subsets. I have shown a 
clear role for ICOS signals in the generation of both Tcm and Tem cells alongside 
CD28. Although required for their initial formation, ICOS and CD28 were 
dispensable for the persistence of memory cells.  The re-expansion of memory 
cells upon secondary challenge was dependent on CD28 but not ICOS, except for 
TFH cells, which remained ICOS dependent. Furthermore, therapeutic targeting 
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using anti-ICOS mAb was superior to CTLA4Ig in limiting memory cell 
generation. Dual targeting of CD28 and ICOS was more effective at blocking the 
primary response than using CTLA4Ig alone, highlighting the need for 
combinatorial approaches in the treatment of disease.   
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CHAPTER 5: INVESTIGATING THE MIGRATION OF 
CD4+ MEMORY T CELLS 
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5.1 Introduction 
Memory T cells have distinct migratory patterns from their naive counterparts. 
Naive T cells are thought to recirculate throughout the lymph system, ready to 
encounter cognate antigen. Within 24 hours 70% of naive lymphocytes within a 
lymph node will have exited and migrated to other sites (Tomura et al., 2008). 
Tcm cells also recirculate through lymphoid tissue and blood due to their 
expression of CCR7 and CD62L while Tem cells are thought to recirculate 
between the blood and non-lymphoid tissues providing a rapid response to 
reinfection. A third subset of memory cells, Trm, has recently been described 
which do not recirculate but are maintained within tissues (Masopust et al., 
2010, Gebhardt et al., 2009). This population does not exhibit the recirculating 
properties characteristic of conventional memory cell subsets, but reside in non-
lymphoid sites to mediate rapid responses to pathogenic challenge. A population 
of CD4+ memory T cells found in the skin appear to recirculate; exit from this 
tissue is mediated by low level expression of CCR7 therefore these cells are 
distinct from recirculating CCR7- Tem cells (Bromley et al., 2013). This 
population has been termed recirculating memory T cells (Trcm) and also 
express CD62L and E-selectin ligand to enable recirculation between lymph 
nodes and peripheral tissue.   
The migration of effector and memory CD4+ T cells is thought to be more diverse 
than their naive counterparts. This is due to a range of surface molecules that 
mediate their entry into peripheral tissues. CD44, LFA-1, α4β1-integrin and P-
selectin glycoprotein ligand (PSGL-1) are more highly expressed on antigen-
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experienced T cells than naive T cells (Ostermann et al., 2002, Hirata et al., 2000, 
Bonder et al., 2006, Shimizu et al., 1990). Other adhesion molecules and 
chemokine receptors are expressed on specific subsets of memory cells, which 
direct their migration to distinct sites. For example expression of cutaneous 
lymphocyte-associated antigen (a modified form of PSGL-1) and CCR4 enable T 
cells to home to the skin (Fuhlbrigge et al., 1997, Campbell et al., 1999).  
Although Tcm cells have been defined by expression of CCR7 and CD62L, 
memory cells have been identified in lymph nodes that express a low or 
undetectable level of these molecules (Brinkman et al., 2008, Unsoeld and 
Pircher, 2005, Marzo et al., 2005). Therefore the composition of memory cell 
populations in the lymph node may be more complex than just Tcm cell alone. 
The entry of effector and memory cells into lymph nodes may be less dependent 
on CCR7 than for naive T cells due to the expression of additional surface 
molecules. E-selectin and α4β1 integrin were found to enable CD8+ effector and 
memory T cells to enter lymph nodes even though they displayed low expression 
of CD62L (Brinkman et al., 2013). The convention that memory cells can be 
divided into Tcm and Tem based on expression of CD62L and CCR7, molecules 
that determine their migration patterns, has been questioned by a study 
analysing CD8+ memory T cells responding to infection with LCMV (Unsoeld and 
Pircher, 2005). Not only were expression of CD62L and CCR7 mixed, they also 
found significant number of Tcm cells present in non-lymphoid tissues. Many 
human memory cells expressing adhesion molecules required for entry into non-
lymphoid tissues, such as α4β7, were found to also express CCR7 (Campbell et 
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al., 2001).  In addition, another study found that entry of CD4+ memory T cells 
into the lymph nodes from the blood did not require expression of CCR7 (Vander 
Lugt et al., 2013). Using mixed bone marrow chimeras to circumvent anomalies 
seen in CCR7-/- mice, they showed that expression of CCR7 on antigen-
experienced CD4+ T cells did not increase their representation in lymph nodes 
compared to CCR7- cells. Antigen experienced cells were defined by expression 
of CD44 so this population will likely contain a mixture of effector cells and true 
memory cells that persist in the absence of antigen.  
In Chapters 3 and 4 we noted that both Tcm and Tem cells defined functionally 
by cytokine production were present in secondary lymphoid tissue. This is 
despite the conventional definition of these subsets by differential expression of 
lymphocyte homing molecules, indicating they are located in distinct areas.  This 
prompted us to investigate the location of Tem cells in secondary lymphoid 
tissue, specifically lymph nodes, and if these cells were recirculating through 
these areas or residing here. To this end we analysed the migratory behaviour of 
CD4+ T cells to determine the movement of naive, Tcm and Tem cells, using 
Kaede transgenic mice. These mice express the photoconvertible Kaede protein 
in every cell, which upon exposure to violet light irreversibly switches to red 
fluorescence. Unlike previous studies analysing memory T cell migration this 
method allows us to track the migration of a labelled population of antigen-
specific that have originated from a known site. Utilising the model to track 
antigen-specific CD4+ T cells established in Chapters 3 and 4, our aim was to 
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better understand the composition of CD4+ memory T cell populations within 
secondary lymphoid tissue.  
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5.2 Results 
5.2.1 Exploring the location of 2W1S:I-Ab+ CD4+ memory 
T cells 
Following i.v. infection with Lm-2W1S two distinct memory cell populations 
have been identified that can be subdivided into Tcm and Tem cells based on 
their production of cytokines (Pepper et al., 2011). Conventionally Tcm cells 
have been identified as CCR7+CD62L+ cells, therefore express the molecules 
required for trafficking into lymph nodes and white pulp areas in the spleen 
(Sallusto et al., 1999, Forster et al., 1999). Tem cells however are CCR7-CD62L-, 
therefore should lack this ability, and are usually considered to traffic through 
peripheral, non-lymphoid tissues (Sallusto et al., 1999). Homing of lymphocytes 
to lymphoid tissue is an essential function required for immunosurveillance and 
is regulated by the expression of surface molecules such as integrins and L-
selectin (CD62L) (Weninger et al., 2001, Stein et al., 2000). Entry of lymphocytes 
into lymph nodes takes place through HEV and this process is mediated by 
CD62L, which allows lymphocytes to roll on HEV (Marchesi and Gowans, 1964). 
Lymphocytes expressing CD62L bind PNAd expressed by endothelial cells, which 
halts their circulation in the blood stream. In previous experiments we identified 
the presence of IL-2+ IFN-γ+ 2W1S:I-Ab+ CD4+ Tem cells in lymph nodes and 
spleen. This was surprising, as Tem cells do not express CD62L and CCR7, 
markers required to enter these tissues. The presence of Tem cells in lymph 
nodes raises two possibilities. Firstly they are generated in this location 
following interaction with antigen, proliferation and differentiation and have 
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remained resident since. Secondly they have migrated into lymphoid tissue by an 
alternate mechanism independent of CCR7 and CD62L. This observation 
prompted us to further investigate the migratory properties of CD4+ memory T 
cells. To establish where 2W1S:I-Ab+ CD4+ memory T cells are located following 
infection with Lm-2W1S, tissues were analysed from WT mice 28 dpi. Previous 
studies found that the majority of 2W1S:I-Ab+ CD4+ memory cells were located in 
secondary lymphoid tissue but a small population were identified in the bone 
marrow (Pepper et al., 2010). Therefore in addition to lymph nodes and spleen, 
the lungs were chosen to analyse as a representative non-lymphoid tissue. As 
memory cells have been shown to express a number of integrins that enable 
homing to specific tissues including CD11b (Sallusto et al., 1999, Baron et al., 
1993), we excluded anti-CD11b and anti-CD11c from the stain to ensure we were 
not selectively gating out cells. Anti-B220 was retained to exclude B cells and 
anti-MHC II was included to label and gate out APC (Figure 5.1 A). After gating on 
CD3+B220-MHCII- cells they were checked for expression of TCRβ to ensure only 
T cells were analysed. 2W1S:I-Ab+ cells were then identified as CD4+CD8-CD44hi 
(Figure 5.1 A). This gating strategy was used for the analysis of spleen and lymph 
node tissues and blood. To analyse lung tissue addition of a Live/Dead marker 
and anti-CD45.2 antibody were used to gate on viable lymphocytes before gating 
on CD3+B220-MHCII-, CD4+CD8-CD44hi 2W1S:I-Ab+ T cells (Figure 5.1 B). This 
was necessary due to a high proportion of non-lymphoid cells present in the 
lungs and increased cell death in the preparation of lung tissue. To identify Tem 
and Tcm cells based on their cytokine production mice were restimulated in vivo 
with 2W1S peptide and LPS as described in section 2.9.2.  
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Figure 5.1: 2W1S:I-Ab+ CD4+ memory T cell populations are present in the 
spleen, lymph nodes and lungs but not in the blood. (A) Gating strategy for 
analysis of 2W1S:I-Ab+ CD4+ memory T cells in spleen, lymph nodes and blood. 
Gated on CD3+ B220- MHCII-; TCRβ+; CD4+CD8-; 2W1S:I-Ab+ CD44hi cells.(B) 
Gating strategy for analysis of 2W1S:I-Ab+ CD4+ memory T cells in the lungs. Gated 
on viable CD45.2+ cells using Live/Dead marker then CD3+ B220- MHCII-; 
CD4+CD8-; 2W1S:I-Ab+ CD44hi cells.  
 
WT mice were infected i.v. with Lm-2W1S and analysed 28 dpi for location of 
2W1S:I-Ab+ CD4+ memory T cells. Mice were restimulated in vivo with 100 µg 2W1S 
peptide and LPS and analysed after 4 hours to identify Tcm and Tem cells based on 
cytokine production. (C) IL-2 and IFN-γ production by 2W1S:I-Ab+ CD4+ memory T 
cells in the spleen, (D) lymph nodes, and (E) lungs. Values on plots are percentages. 
(F) Absence of 2W1S:I-Ab+ CD4+ memory T cells in blood. (G) Number of 2W1S:I-Ab+ 
CD4+ memory T cells in the spleen, lymph nodes and lungs. (H) Number and ;(I) 
Percentage of 2W1S:I-Ab+ CD4+ Tcm and Tem cells in the spleen, lymph nodes and 
lungs.  
 
(A-F) Plots are representative of  ≥9 mice from ≥2 independent experiments except E 
which is representative of 6 mice. Values on plots are percentages. (G) Graph shows 
pooled data from ≥2 independent experiments. Bars show median. (H and I) Graphs 
show pooled dated from ≥2 independent experiments. Bars show mean and error 
bars show SEM. Mann Whitney Test: *p≤0.05, ****p≤0.0001, ns= non-significant.   
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As mice were infected with Listeria monocytogenes, which elicits a Th1 response, 
Tcm cells were identified as IL-2+IFN-γ- and Tem cells were identified as IL-2+ 
IFN-γ+. A population of CD44hi 2W1S:I-Ab+ CD4+ memory T cells could be 
identified in spleen, lymph node and lung tissue, however none were present in 
the blood samples analysed (Figure 5.1 C-G). A population of Tcm and Tem cells 
were present in the spleen and lymph nodes however were less clear in the lungs 
(Figure 5.1 C-F and H). In the spleen and lymph nodes there was a significantly 
higher proportion of Tcm cells (Figure 5.1 I). Lung tissue showed a bias towards 
Tem cells however this was not a significant increase (Figure 5.1 I). Although 
there appeared to be a bias toward IFN-γ+ cells in the lungs the overall number 
of 2W1S:I-Ab+ CD4+ T cells was very low making analysis of memory cell 
populations somewhat unreliable. Furthermore the method to stimulate 
cytokine produce in spleen and lymph node cells through i.v. injection may not 
be appropriate for use when trying to stimulate cells in the lung. Intranasal 
instillation with LPS has been shown to be more reliable in targeting the lungs 
than by the i.v. route (Szarka et al., 1997).  
Analysis of CCR7 expression on 2W1S:I-Ab+ CD4+ T cells from spleen, peripheral 
lymph nodes and lungs was performed, as this chemokine receptor is required 
for entry into lymphoid tissue (Forster et al., 1999). Tcm cells have been defined 
by their expression of CCR7 and Tem cells by its absence (Sallusto et al., 1999). 
Expression of CCR7 was more widespread in lymphoid tissues. In the spleen and 
lymph nodes around 70% of 2W1S:I-Ab+ CD4+ T cells are CCR7+ whereas in the 
lungs only 25-45% are CCR7+(Figure 5.2 A and B).  
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Figure 5.2: CCR7 expression does not correlate with Tcm cell phenotype. WT 
mice were infected i.v. with Lm-2W1S and analysed 28 dpi. Mice were restimulated in 
vivo with 100 µg 2W1S peptide and LPS and analysed after 4 hours to identify Tcm 
and Tem cells based on cytokine production. (A) Expression of CCR7 on 2W1S:I-Ab+ 
CD4+ memory T cells from the spleen, lymph nodes and lungs. (B) Percentage of 
2W1S:I-Ab+ CD4+ memory T cells expressing CCR7 in the spleen, lymph nodes and 
lungs. (C) Percentage of 2W1S:I-Ab+ CD4+ Tcm and Tem cells expressing CCR7 from 
spleen and lymph nodes. (D) Expression of IFN-γ and CCR7 on 2W1S:I-Ab+ CD4+ 
memory T cells from the spleen and lymph nodes. 
 
(A and D) Plots are representative of 15 mice from 3 independent experiments except 
for lungs which are representative of 9 mice from 2 independent experiments. Grey 
shaded areas on histograms represent relevant isotype control and values show 
percentage of CCR7+ cells. (B-C) Graphs show pooled data from ≥ 2 independent 
experiments. Bars show median. Mann Whitney Test: ns= non-significant.   
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This finding is consistent with previous data showing Tcm cells recirculate 
through lymph nodes, not through non-lymphoid sites (Reinhardt et al., 2001, 
Masopust et al., 2001). However, within the 2W1S:I-Ab+ CD4+ T cell population 
no significant difference in CCR7 expression was observed between IL-2+IFN-γ- 
Tcm cells and IL-2+IFN-γ+ Tem cells, with IFN+CCR7+ cells evident (Figure 5.2 C 
and D). Thus, expression of CCR7 on CD4+ memory T cells following Lm-2W1S 
infection does not seem to correlate with a Tcm phenotype. 
 
5.2.2 Establishing a model to investigate the location 
and migration of 2W1S:I-Ab+ CD4+ memory T cells 
To further investigate the location and migration of CD4+ memory T cells, a 
model in which antigen-specific cells could be tracked from their point of origin 
through different lymphoid and non-lymphoid tissues was required. To this end 
local immunisation in the paw pad was used, which initiates an immune 
response in the draining brachial and axillary lymph nodes. This method would 
allow us to track CD4+ T cells responding to cognate antigen in the brachial 
lymph node and their movement to other lymph nodes and the spleen. Previous 
observations in our laboratory have shown that infection with attenuated Lm-
2W1S in the foot pad (an approach that can be used to model a local route of 
immunisation) did not elicit a large 2W1S:I-Ab+ CD4+ T cell response, perhaps 
due to a combination of the attenuated nature of the antigen and a non-
physiological infection route (Emma Mackley- unpublished observations). 
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Therefore, immunisation with 2W1S peptide precipitated with aluminium was 
used given the robust response induced by this adjuvant (Glenny et al., 1931, 
Brewer et al., 1996).  
WT mice were immunised in the right paw pad only, with 20 μg 2W1S peptide 
alum ppt or PBS as a control. 8 dpi draining brachial lymph node, contralateral 
lymph nodes (consisting of a pool of brachial, axillary and inguinal lymph nodes), 
mesenteric lymph node and spleen were harvested for analysis. This timepoint 
was chosen as aluminium precipitation of peptide has been shown to produce a 
prolonged response (Kool et al., 2008). This study found that after immunisation 
with alum ppt OVA, antigen-specific T cells were present in the draining lymph 
node at 7 dpi, however these cells were virtually absent at this timepoint after 
immunisation with OVA alone. We found that OX40 expression was maintained 
at day 9 following immunisation with alum ppt 2W1S peptide, indicating the 
possible continued presence of antigen (Chapter 3, Figure 3.15). Contralateral 
lymph nodes were analysed to assess trafficking from the site of immunisation 
via the bloodstream. This would exclude possible drainage solely through the 
lymphatics to lymph nodes that are connected in chains (Tomura et al., 2008, 
Braun et al., 2011).  
Following immunisation in the paw pad with 20 μg 2W1S peptide, the 2W1S:I-
Ab+ CD4+ T cell population was analysed for expression of CXCR5 and PD-1 to 
monitor the migration of different T cell subsets. A large population of 2W1S:I-
Ab+ CD4+ T cells could be identified in the draining brachial lymph node and 
within this Teff, T central memory precursors and TFH cells were present 
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(Figure 5.3 A and B; median for bLN 29 799). There was also a considerable 
population of 2W1S:I-Ab+ CD4+ T cells in the spleen and a smaller number in the 
contralateral and mesenteric lymph nodes (Figure 5.3 A and B; median for cLN 
502, mLN 526, spleen 18 177). TFH cells could be identified in all tissues, with 
the majority found in the draining brachial lymph node and the spleen (Figure 
5.3 A, C and D). TFH cells are thought to differentiate in the presence of antigen 
and reside in the follicle without migrating to other tissues (Suan et al., 2015). 
The presence of a small number of TFH cells in the contralateral and mesenteric 
lymph nodes and a large population in the spleen suggested that antigen had 
disseminated beyond the draining lymph node. Therefore this method cannot be 
used as a model of local immunisation to study the migration of 2W1S:I-Ab+ CD4+ 
T cells, as their origin would be unknown. 
To refine this approach, the quantity of 2W1S peptide was reduced to 5 μg to 
restrict dissemination from the site of immunisation. Also, the injection site was 
moved further towards the palm of the paw to ensure the antigen would be 
contained within this area and not enter the circulation through blood vessels in 
the wrist. Following immunisation with 5 μg alum ppt 2W1S peptide a 
population of 2W1S:I-Ab+ CD4+ T cells could be identified in the draining brachial 
lymph node, contralateral lymph nodes, mesenteric lymph node and spleen 
(Figure 5.4 A and B; median for bLN 8334, cLN 537, mLN 652, spleen 4370).  The 
number of 2W1S:I-Ab+ CD4+ T cells in the draining brachial lymph node was 
reduced compared to mice that were immunised with 20 μg 2W1S peptide 
(median 8334 compared to 29 799).  
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Figure 5.3: A model to investigate the location and migration of 2W1S:I-Ab+ 
CD4+ memory T cells. WT mice were immunised with 20 µg alum ppt 2W1S peptide 
in the right paw pad. Draining brachial lymph node, contralateral lymph nodes 
(brachial, axillary and inguinal), mesenteric lymph node and spleen were analysed 8 
dpi. (A) Expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells from each 
tissue respectively. (B) Number of 2W1S:I-Ab+ CD4+ T cells from each tissue. (C) 
Number and ;(D) Percentage of 2W1S:I-Ab+ CD4+ TFH cells from each tissue.  
 
(A) Plots are representative of 3 mice from 1 independent experiment. Values on 
plots are percentages. (B-D) Graphs show data from 1 independent experiment. 
Bars show median.  
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Figure 5.4: Optimising a model to investigate the location and migration of 
2W1S:I-Ab+ CD4+ memory T cells. WT mice were immunised with 5 µg alum ppt 
2W1S peptide in the right paw pad. Draining brachial lymph node, contralateral lymph 
nodes (brachial, axillary and inguinal), mesenteric lymph node and spleen were 
analysed 8 dpi. (A) Expression of CXCR5 and PD-1 on 2W1S:I-Ab+ CD4+ T cells from 
each tissue respectively. (B) Number of 2W1S:I-Ab+ CD4+ T cells from each tissue. (C) 
Number of 2W1S:I-Ab+ CD4+ TFH cells from each tissue.  
 
(A) Plots are representative of 6 mice from 2 independent experiments. Values on plots 
are percentages. (B-C) Graphs show pooled data from 2 independent experiments. 
Values of 0 were assigned 1. Bars show median. Mann Whitney test: **p<0.01. 
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The number of 2W1S:I-Ab+ CD4+ T cells was also reduced in the spleen, however 
the number of cells found in the contralateral and mesenteric lymph nodes were 
comparable.  Despite this, TFH cells were only found in significant numbers in 
the draining brachial lymph node and were almost absent in non-draining 
tissues (Figure 5.4 A, C and D). These findings indicated that antigen had not 
disseminated beyond the draining lymph nodes, as was the case when mice were 
immunised with 20 μg 2W1S peptide and that this method could be used as a 
model of local immunisation to monitor the migration of antigen-specific CD4+ T 
cells.  
 
5.2.3 The presence of 2W1S:I-Ab+ CD4+ T cells in distal 
tissues from the site of immunisation is not due to 
dissemination of antigen 
To further assess whether antigen had disseminated beyond the draining 
brachial lymph node, fluorescently labelled antigen was injected to enable direct 
analysis of its spread.  Injection with chicken OVA labelled with Alexa Fluor 647 
(AF647) was used to fluorescently label cells that bind or phagocytose antigen. 
DC take up antigen by phagocytosis and present peptides on MHC molecules to 
activate naive T cells. DC can express several integrins and chemokine receptors 
on their surface, which determine their migration into secondary lymphoid 
tissue (Guermonprez et al., 2002). OVA-AF647 was aluminium precipitated as 
performed for the 2W1S peptide in an attempt to maintain the nature of the 
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immunisation. After injection of alum ppt OVA-AF647 into the right paw pad we 
analysed the draining brachial lymph node, contralateral lymph nodes, 
mesenteric lymph node and spleen for the presence of AF647+ DC.  The 
timepoints we chose to analyse were 6 and 24 hours post injection of OVA, as the 
movement of DC from the site of immunisation to lymphoid tissues has been 
shown to occur within this period (Kool et al., 2008, Ciabattini et al., 2011).  The 
gating strategy used to identify AF647+ DC is defined in Figure 5.5 A. As DC are 
larger than T cells the forward scatter gate was extended. Putatively DC were 
then positively identified based on expression of CD11c and MHCII. CD3+ and 
B220+ cells were gated out to remove contaminating T and B cells.  In the 
draining brachial lymph node 6 hours post injection a population of OVA+ DC 
could be identified which constituted approximately 40% of total DC (Figure 5.5 
A). A control mouse receiving PBS in the right paw pad was used to set the gating 
and eliminate the possibility of background staining (Figure 5.5 B). 6 hours post 
injection of OVA in the right paw pad, none of the distal tissues analysed 
contained a population of OVA+ DC (Figure 5.5 B). This was also the case 24 
hours post injection, yet a population could still be identified in the draining 
brachial lymph node (Figure 5.5 C). These data indicate that antigen does not 
reach other lymphoid tissues within the initial 24 hours post immunisation, an 
observation consistent with the restriction of TFH cells to the draining lymph 
node at 8 dpi (Figure 5.4 A and C).  
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Figure 5.5: Antigen does not disseminate beyond the draining lymph node. WT 
mice were injected with 5 µg alum ppt OVA  Alexa Fluor 647 in the right paw pad. 
Draining brachial lymph node, contralateral lymph node, mesenteric lymph node and 
spleen were then analysed 6 and 24 hours later as indicated. (A) Gating strategy to 
identify OVA+ DC in the draining brachial lymph node 6 hours post injection. Gated 
on extended lymphocyte gate, MHCII+CD11c+, B220-CD3-, OVA+. (B) OVA+ DC gated 
as shown in (A) from the draining brachial lymph node PBS control, contralateral 
lymph nodes, mesenteric lymph node and spleen 6 hours post injection. (C) OVA+ 
DC gated as shown in (A) from the draining brachial lymph node, contralateral lymph 
nodes, mesenteric lymph node and spleen 24 hours post injection.  
 
(A-C) Plots are representative of 3 mice from 1 independent experiment. Values on 
plots are percentages.   
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5.2.4 Analysing the migration of 2W1S:I-Ab+ CD4+ 
memory T cells 
Having assessed the 2W1S:I-Ab+ CD4+ T cell response at 8 dpi during the primary 
phase we sought to investigate the migration of memory cell populations. Whilst 
memory cells may be present 8 dpi, identification of these cells is challenging due 
to a lack of specific surface markers. Therefore, memory cells were defined by 
time since immunisation and we analysed the migration of this population at 
later timepoints when definition of this population is more reliable. To directly 
study antigen-specific CD4+ memory T cell migration is technically challenging 
due to low cell frequency, which is exacerbated in a local immunisation model 
where only one lymphoid site is responding. Mice were immunised with 5 μg 
2W1S peptide in the right paw pad and analysed 21 dpi. This timepoint was 
chosen as following systemic immunisation with Lm-2W1S effector cells have 
contracted to form a memory cell population by this stage (Pepper et al., 2010). 
As we would expect a very low cell frequency at this time, gating for 2W1S:I-Ab+ 
CD4+ T cells was set using a control mouse that received PBS in the right paw 
pad and therefore will not have a 2W1S:I-Ab+ CD4+ memory T cell population 
(Figure 5.6 A). Draining brachial, contralateral, mesenteric lymph node and 
spleen were analysed for the presence of a 2W1S:I-Ab+ CD4+ memory T cell 
population. The low frequency of cells at this timepoint made conclusions of 
phenotype based on cytokine secretion unreliable, so this approach was not 
used. Therefore, surface markers CD44 and CD62L were used to putatively 
define Tcm and Tem cells.  
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Figure 5.6:  Investigating the migration of 2W1S:I-Ab+ CD4+ memory T cells. WT 
mice were immunised with 5 µg alum ppt 2W1S peptide in the right paw pad. 
Draining brachial lymph node, contralateral lymph nodes (brachial, axillary and 
inguinal), mesenteric lymph node and spleen were analysed 21 dpi. (A) Expression of 
CD44 and CD62L on 2W1S:I-Ab+ CD4+ T cells from each tissue respectively. PBS 
control shows how gating was set for 2W1S:I-Ab+ cells. (B) Number of 2W1S:I-Ab+ 
CD4+ T cells from each tissue. (C) Number (left) and percentage (right) of 2W1S:I-Ab+ 
CD4+ CD62L+ and CD62L- cells from each tissue. (D) Expression of OX40 on 
2W1S:I-Ab+ CD4+ T cells from each tissue.  
 
(A) Plots are representative of 6 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 2 independent 
experiments. Bars show median. (C) Graphs show pooled data from 2 independent 
experiments. Bars show mean and error bars show SEM. (D) Plots are 
representative of 3 mice from 1 experiments. Values on plots are percentages. Grey 
shaded areas on histograms represent CD4+ T cells, the majority of which are OX40-. 	
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Both populations of memory cells express the activation marker CD44; Tcm cells 
are defined by expression of CD62L, required for entry into lymph nodes, while 
Tem cells lack this molecule (Sallusto et al., 1999). Therefore Tcm phenotype 
cells were identified as CD62L+ and Tem phenotype cells were CD62L- cells. A 
population of 2W1S:I-Ab+ CD4+ memory T cells could be detected in all tissues, 
however this was very small in the contralateral and mesenteric lymph nodes 
(Figure 5.6 A and B; median for bLN 4567, cLN 164.4, mLN 277, spleen 1460). In 
the draining lymph node and spleen there was a significantly higher proportion 
of CD62L- Tem cells (Figure 5.6 A and C). This and the high cell number 
suggested that the response may be ongoing and that the 2W1S:I-Ab+ CD4+ T cell 
population might contain both effector and memory cells. To further investigate 
this, 2W1S:I-Ab+ CD4+ T cells were stained for expression of OX40. OX40 
expression is thought to be tightly linked to antigen exposure and in the acute 
response to attenuated Lm-2W1S OX40 expression is transient and lost by 4 dpi 
(Chapter 3, Figure 3.3). Since in chronic responses expression of OX40 can be 
maintained until 20 dpi (Boettler et al., 2013), it was possible that alum ppt 
2W1S peptide may persist for several weeks at the site of immunisation, driving 
a sustained primary response (Glenny et al., 1931, Ghimire et al., 2012). Total 
CD4+ T cells were used as a negative control for OX40 staining as the isotype 
control under-represents the background level. OX40 expression was detected 
on the majority of 2W1S:I-Ab+ CD4+ T cells from all tissues (Figure 5.6 D). This 
indicated that the kinetics of the response to alum ppt 2W1S peptide are 
different to that of attenuated Lm-2W1S and analysis at a later timepoint would 
likely enrich for only memory 2W1S:I-Ab+ CD4+ T cells. 
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A caveat of defining T cell populations by expression of CD62L and CCR7 is that 
they are intrinsically linked to their ability to enter lymphoid tissue (Forster et 
al., 1999, Marchesi and Gowans, 1964). Analysis of Tem cell migration would be 
enhanced by identification of other surface markers expressed specifically by 
these cells. To this end we investigated other possible phenotypic markers that 
could be used to identify Tcm and Tem cells. Killer cell lectin-like receptor G 1 
(KLRG1) and CD27 have both been used in the study of CD8+ memory T cells. 
KLRG1 expression is associated with short-term survival and is therefore 
present at lower levels on CD8+ T cells that will enter the memory cell pool 
(Sarkar et al., 2008). CD27- CD8+ memory T cells showed an enhanced ability to 
produce effector cytokines, characteristic of Tem cells (De Jong et al., 1992). In 
addition CD27- cells were found to be enriched in CCR7- and CD62L- human 
memory T cell populations suggesting lack of this receptor is correlated with an 
inability to home to secondary lymphoid tissue (Campbell et al., 2001). Therefore 
we analysed expression of these makers on 2W1S:I-Ab+ CD4+ T cells to determine 
if they could also be applicable to CD4+ memory T cells. Following immunisation 
with alum ppt 2W1S peptide in the paw pad the majority of CD62L+ and CD62L- 
cells were KLRG1- indicating this would not be a useful phenotypic marker 
(Figure 5.7 A).  The majority of both CD62L+ and CD62L- cells were CD27+; there 
was a small population of CD27- cells within the CD62L- cell population which 
was not seen within CD62L+ cells (Figure 5.7 A). This was consistent in all tissues 
analysed where a proportion of CD62L- cells, but not CD62L+ cells, were CD27-  
(Figure 5.7 B).  These data indicate that any CD27- 2W1S:I-Ab+ CD4+ T cells 
identified were likely Tem cells.  
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Figure 5.7: Investigating alternative phenotypic markers for Tem cells. WT mice 
were immunised with 5 µg alum ppt 2W1S peptide in the right paw pad. Draining 
brachial lymph node, contralateral lymph nodes (brachial, axillary and inguinal), 
mesenteric lymph node and spleen were analysed 21 dpi. (A) Expression of CD27, 
KLRG1 and CXCR5 on 2W1S:I-Ab+ CD4+ CD62L+ and CD62L- cells from the draining 
lymph node. (C) Percentage of 2W1S:I-Ab+ CD4+ CD62L+ and CD62L- cells that are 
CD27- in each tissue. 
 
(A) Plots are representative of 6 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 2 independent 
experiments. Bars show mean and error bars show SEM.  
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We and others have used CXCR5 to subdivide 2W1S:I-Ab+ CD4+ T cells into Teff 
cells and Tcm precursor cells following infection with Lm-2W1S (Marriott et al., 
2014, Marriott et al., 2015, Pepper et al., 2011). For this reason we looked for 
expression of CXCR5 following immunisation with alum ppt 2W1S peptide. 
However the majority of 2W1S:I-Ab+ CD4+ T cells did not express CXCR5 
indicating this cannot be used as a marker to differentiate Tcm and Tem 
populations (Figure 5.7 A).  
Since OX40 expression on 2W1S:I-Ab+ CD4+ T cells at 21 dpi indicated that the 
response was still in the effector phase we waited a further 3 weeks before 
analysing the memory cell population; mice were immunised with alum ppt 
2W1S peptide and analysed at 42 dpi. A population of around 3000 2W1S:I-Ab+ 
CD4+ T cells could be recovered from the draining brachial lymph node at this 
time, however, in the contralateral and mesenteric lymph nodes the population 
was very small (Figure 5.8 A and B; median for bLN 2806, cLN 192, mLN 296). 
There was also a significant population recovered from the spleen (Figure 5.8 A 
and B; median for spleen 9909). Similar to what was observed at 21 dpi the 
number and proportion of CD62L- cells were higher than CD62L+ cells in the 
draining brachial lymph node and the spleen (Figure 5.8 A, C and D). However, 
the proportion of 2W1S:I-Ab+ CD4+ T cells expressing OX40 was decreased 
compared to 21 dpi in the draining, contralateral and mesenteric lymph nodes 
and the spleen indicating the response has entered the memory phase (Figure 
5.8 E).  
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Figure 5.8: 2W1S:I-Ab+ CD4+ Tcm and Tem phenotype cells can be identified in 
draining and contralateral tissues following local immunisation. WT mice were 
immunised in the right paw pad with 5 µg 2W1S alum ppt peptide. Draining brachial 
lymph node, contralateral lymph nodes, mesenteric lymph node and spleen were 
analysed 42 dpi. (A) Expression of CD44 and CD62L on 2W1S:I-Ab+ CD4+ T cells 
from each tissue respectively. (B) Number of 2W1S:I-Ab+ CD4+ T cells from each 
tissue. (C) Number of 2W1S:I-Ab+ CD4+ CD62L+ and CD62L- cells from each tissue. 
(D) Percentage of 2W1S:I-Ab+ CD4+ T cells that are CD62L+ and CD62L- from each 
tissue. (E) Expression of OX40 on 2W1S:I-Ab+ CD4+ T cells from each tissue. 
 
(A ) Plots are representative of 6 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 2 independent 
experiments. Bars show median. (C-D) Graphs show pooled data from 2 
independent experiments. Bars show mean and error bars show SEM. (E) Plots are 
representative of 3 mice from 1 experiment. Values on plots are percentages. Grey 
shaded areas on histograms represent CD4+ T cells. Mann Whitney Test: *p<0.05, 
**p<0.01, ns= non-significant. 
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In the contralateral lymph nodes the proportion of CD62L+ cells was significantly 
higher than CD62L- cells, consistent with their migratory roles, however this was 
not the case in the mesenteric lymph node where the ratio was around 50:50 
(Figure 5.8 A and D). However previous studies have shown that entry into the 
mesenteric lymph node is mediated by surface molecule such as α4β7, in 
addition to CD62L (Hamann et al., 1994, Gorfu et al., 2009).  
We further analysed the phenotype of 2W1S:I-Ab+ CD4+ memory T cells 42 dpi to 
determine if other surface markers correlated with CD62L expression. 
Expression of CCR7 was not restricted to CD62L+ cells, again indicating that on 
memory cells CCR7 may be expressed by both Tcm and Tem cell populations 
(Figure 5.9 A and B). This is in contrast to initial studies that defined Tcm cells 
based on expression of CD62L and CCR7 and Tem cells on their absence (Sallusto 
et al., 1999), however another study has indicated that expression of CCR7 may 
be more complex (Unsoeld and Pircher, 2005). Expression of CCR7 may not be 
exclusive to CD62L+ cells or alternatively changes in expression of CCR7 may 
occur depending upon location.  As seen at 21 dpi, in all lymph nodes, the 
majority of both CD62L+ and CD62L- cells were CD27+ but a small number of 
CD62L- cells were CD27- (Figure 5.9 A and C). Between 21-43% of CD62L- cells 
were CD27- depending upon the tissue, with the highest number found in the 
spleen (Figure 5.9 C). CD27- cells were essentially absent from the CD62L+ 
population, but clearly detected amongst CD62L- cells, independent of CCR7 
expression (Figure 5.9 A and C). 
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Figure 5.9: Phenotype of 2W1S:I-Ab+ CD4+ Tcm and Tem cells following local 
immunisation. WT mice were immunised in the right paw pad with 5 µg 2W1S alum 
ppt peptide. Draining brachial lymph node, contralateral lymph nodes, mesenteric 
lymph node and spleen were analysed 42 dpi. (A) Expression of CD27 and CCR7 on 
2W1S:I-Ab+ CD4+ CD62L+ and CD62L- cells from each tissue respectively. (B) 
Percentage of 2W1S:I-Ab+ CD4+ CD62L+ and CD62L- cells expressing CCR7 from 
each tissue. (C) Percentage of 2W1S:I-Ab+ CD4+ CD62L+ and CD62L- cells that are 
CD27- from each tissue. 
 
(A) Plots are representative of 6 mice from 2 independent experiments. Values on 
plots are percentages. (B-C) Graphs show pooled data from 2 independent 
experiments. Bars show mean and error bars show SEM.  
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5.2.5 Utilising photoconvertible Kaede protein to track 
cell migration 
Having established a model to track an antigen-specific response to local 
immunisation we further refined this approach to investigate the migration of 
cells from the site of immunisation within a distinct period of time. This key 
additional information would better establish trafficking of cells from a given 
site. We used Kaede transgenic mice, which are genetically modified to express 
the fluorescent Kaede protein in every cell (Ando et al., 2002). This Kaede 
protein fluoresces green at 518 nm under normal conditions, however following 
exposure to violet light (wavelength 350-400 nm) formation of a double bond 
within the structure causes a change in fluorescence to red (wavelength 582 nm) 
(Mizuno et al., 2003, Ando et al., 2002).  This irreversible reaction labels cells 
exposed to violet light and the red Kaede protein has a long half-life in vivo 
enabling their migration to be tracked (Tomura et al., 2008).   
To enable us to specifically label only the cells in the draining brachial lymph 
node we developed a surgical technique to expose this site to violet light. Under 
anaesthesia a small incision was made in the armpit area of the mouse and the 
brachial lymph node was located. This site was then exposed to violet light for 3 
minutes, following testing in vitro and on sacrificed mice to determine the 
optimal time for photoconversion. Mice were then sacrificed immediately post 
photoconversion to analyse the efficacy of this method. Mice undergoing 
photoconversion (switched) were compared to control mice (unswitched) that 
had not been photoconverted. Following 3 minutes of exposure to violet light 
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almost 100 % of lymphocytes were converted to Kaede red (Figure 5.10 A and 
B). Consistent with other reports (Ando et al., 2002, Tomura et al., 2008), we 
have found that even with prolonged exposure to violet light, not all of the Kaede 
green protein is converted to red and therefore “switched” cells are defined as 
double positive for Kaede green and red protein.  
As local immunisation in the paw pad not only targets the draining brachial 
lymph node but also the axillary lymph node we assessed the level of 
photoconversion in this tissue. Surgical exposure of the brachial lymph node 
resulted in variable labelling of the axillary lymph node due to scatter of light 
(Figure 5.10 C and D). For this reason the axillary lymph node was excluded and 
only the brachial lymph node was analysed. We then investigated the level of 
photoconversion in different cell subsets. B cells, CD4+ and CD8+ T cells were all 
equally efficient at photoconverting with over 99 % of cells switched in the 
brachial lymph node (Figure 5.10 E-G).  
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Figure 5.10: Photoconversion of Kaede protein. Kaede mice underwent surgery to 
expose the brachial lymph node which was then exposed to violet light for 3 minutes. 
Mice were sacrificed and analysed immediately post surgery to assess switching in 
brachial and axillary lymph nodes. (A) Gated on total lymphocytes to show the level of 
expression of Kaede red protein in the brachial lymph node of control mice 
(unswitched- left) and following exposure to violet light (switched-right). (B) Percentage 
of switched lymphocytes in the brachial lymph node following violet light exposure. (C) 
Gated on total lymphocytes to show the level of expression of Kaede red protein in the 
axillary lymph node of control mice (unswitched- left) and in 2 mice following exposure 
to violet light (switched-right). (D) Percentage of switched lymphocytes in the axillary 
lymph node following violet light exposure. (E) Plot showing level of Kaede red 
expression in B cells following violet light exposure. (F) Plot showing level of Kaede red 
expression in CD4+ T cells following violet light exposure. (G) Plot showing level of 
Kaede red expression in CD8+ T cells following violet light exposure.  
 
(A, C, E-G) Plots are representative of 4 mice from 1 independent experiment. Values 
on plots are percentages. (B and D) Graphs show data from 1 experiment.   
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5.2.6 Tracking the migration of cells in 24 hours 
following photoconversion 
An initial step in tracking the migration of antigen-specific CD4+ T cells was to 
first analyse total lymphocytes to validate the method on a large population of 
cells.  The left brachial lymph node was exposed to violet light using the surgical 
technique described in section 5.2.5 and the wound was sutured and the mice 
left to recover. Mice were sacrificed 24 hours after photoconversion and the 
brachial lymph node was analysed. Approximately 15 % of lymphocytes in the 
brachial lymph node were positive for Kaede red (switched) indicating that 
around 85 % of lymphocytes had migrated into or out of the lymph node in the 
previous 24 hours (Figure 5.11 A and B). These data were highly reproducible 
between mice; consistently between 10 and 20 % of cells within the brachial 
lymph node were switched (Figure 5.11 B). This was also the case for B cells or 
CD4+ T cells which show similar kinetics of migration; around 85 % of cells in the 
brachial lymph node were unswitched indicating a large migration has taken 
place (Figure 5.11 C-F). CD8+ T cells however showed much faster kinetics of 
migration as less than 1 % of cells in the lymph node were switched after 24 
hours (Figure 5.11 G and H). This is in contrast to a previous study monitoring 
the migration of lymphocytes from the inguinal lymph node, where the kinetics 
of migration of CD8+ T cells were similar to CD4+ T cells (Tomura et al., 2008).  
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Figure 5.11: Migration of cells to and from the brachial lymph node in 24 hours. 
The left brachial lymph node was exposed to violet light for 3 minutes then analysed 
24 hours later for migration of lymphocytes. (A) Expression of Kaede green and 
Kaede red protein in lymphocytes from the brachial lymph node. (B) Percentage of 
switched (resident) and unswitched (migrating) lymphocytes from the brachial lymph 
node. (C) Expression of Kaede green and Kaede red protein in B220+ B cells from 
the exposed brachial lymph node. (D) Percentage of switched (resident) and 
unswitched (migrating) B cells from the brachial lymph node. (E) Expression of 
Kaede green and Kaede red protein in CD4+ T cells from the brachial lymph node. 
(F) Percentage of switched (resident) and unswitched (migrating) CD4+ T cells from 
the brachial lymph node. (G) Expression of Kaede green and Kaede red protein in 
CD8+ T cells from the brachial lymph node. (H) Percentage of switched (resident) 
and unswitched (migrating) CD8+ T cells from the brachial lymph node.   
 
(A, C, E, G) Plots are representative of 8 mice from 2 independent experiments. 
Values on plots are percentages. (B, D, F, H) Graphs show pooled data from 2 
independent experiments.  
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Using this method we can track the migration of cells that were in the brachial 
lymph node at the time of photoconversion to other tissues in the body. The 
presence of any switched cells in the spleen and lymph nodes indicates that their 
point of origin was the brachial lymph node 24 hours previously. In both the 
contralateral lymph nodes and the spleen a small proportion of lymphocytes, 
around 2-3 %, were switched, validating the use of this method to investigate cell 
migration (Figure 5.12 A). Around 2.5 % of B cells in the contralateral lymph 
nodes and spleen were switched (Figure 5.12 B), however this was less than 0.5 
% for CD8+ T cells  (Figure 5.12 C).  This could not be accounted for by cells 
remaining in the brachial lymph node as CD8+ T cells showed faster kinetics of 
migration. It is possible that CD8+ T cells preferentially migrate to a tissue that 
we have not analysed.  
Approximately 2 % of CD4+ T cells in the contralateral lymph nodes and spleen 
were switched indicating similar migratory properties to B cells (Figure 5.13 A 
and B). Again the number of switched cells was highly reproducible between 
mice, indicating that this will be a reliable method when analysing smaller, 
antigen-specific populations. Naive T cells are CD44loCD62L+ while Tcm and Tem 
phenotype cells were defined as CD44hi cells that were CD62L+ or CD62L- 
respectively. Based on their lack of CD62L and CCR7 expression it is assumed 
that Tem cells are unable or less efficient at entering lymph nodes through HEV. 
We investigated the migratory capacity of T cell subsets by analysing their 
proportions within the switched and unswitched populations of CD4+ T cells 24 
hours post photoconversion of the brachial lymph node.  
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Figure 5.12: Migration of cells from the brachial lymph node to contralateral 
lymph nodes and spleen in 24 hours . The left brachial lymph node of Kaede mice 
was exposed to violet light for 3 minutes. Mice were analysed 24 hours later for 
migration of lymphocytes to the contralateral lymph nodes and spleen. (A) 
Expression of Kaede green and Kaede red protein in lymphocytes each tissue. (B) 
Expression of Kaede green and Kaede red protein in B cells from each tissue. (C) 
Expression of Kaede green and Kaede red protein in CD8+ T cells from each tissue. 
 
(A-C) Plots are representative of 8 mice from 2 independent experiments. Values on 
plots are percentages.  
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Figure 5.13: Migration of CD4+ T cell subsets 24 hours following 
photoconversion of the brachial lymph node. The left brachial lymph node of 
Kaede mice was exposed to violet light for 3 minutes. Mice were analysed 24 hours 
later for migration of CD4+ T cells. (A) Expression of Kaede red and Kaede green in 
CD4+ T cells from the contralateral lymph nodes and spleen. (B) Percentage of 
switched CD4+ T cells in the contralateral lymph nodes and spleen. (C) Expression of 
CD44 and CD62L on CD4+ T cells from the contralateral lymph nodes that are 
switched (left) and unswitched (right). (D) Percentage of switched and unswitched 
cells that are either naive T cells, CD62L+ or CD62L- cells in the contralateral lymph 
node. (E) Expression of CD44 and CD62L on CD4+ T cells from the spleen that are 
switched (left) and unswitched (right). (F) Percentage of switched and unswitched 
cells that are either naive T cells, CD62L+ or CD62L- cells in the spleen. (G) 
Expression of CD44 and CD62L on CD4+ T cells from the exposed brachial lymph 
node that are switched (left) and unswitched (right). (H) Percentage of switched and 
unswitched cells that are either naive T cells, CD62L+ or CD62L- cells in the exposed 
brachial lymph node. 
 
(A, C, E, G) Plots are representative of 8 mice from 2 independent experiments. 
Values on plots are percentages. (B, D, F, H) Graphs showed pooled data from 2 
independent experiments. Bars show median. Mann Whitney Test: *p≤0.05, 
**p≤0.01, ***p≤0.001, ns= non-significant.   
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In the contralateral lymph nodes naive T cells constitute the majority of CD4+ T 
cells for both switched and unswitched populations (Figure 5.13 C and D). There 
was a small proportion of CD62L+ cells in both switched and unswitched 
populations indicating that cells with Tcm phenotype have migrated from the 
exposed brachial lymph node into the contralateral lymph node (Figure 5.13 C 
and D). CD62L- cells however are significantly reduced in the switched 
population compared to the unswitched (Figure 5.13 D), consistent with a 
significant impairment in their ability to migrate into the contralateral lymph 
nodes. It is possible that the small population of Tem cells in the lymph node, 
identified by lack of CD62L, are actually Tcm cells that have down-regulated this 
molecule following lymph node entry. Alternatively, it is possible that Tem cells 
express other surface molecules that enable inefficient entry into lymph nodes 
from the blood. In the spleen there were similar proportions of T cell subsets to 
the contralateral lymph nodes; naive T cells were most abundant and there was a 
small population of CD62L+ cells in both the switched and unswitched 
populations (Figure 5.13 E and F).  
 In the exposed brachial lymph node the switched population are cells that are 
resident and have not migrated in the previous 24 hours. Within this population 
the proportion of naive T cells was much lower than in the migrating unswitched 
cells (Figure 5.13 G and H; median for switched 47 %, unswitched 89 %). This is 
consistent with naive CD4+ T cells being highly migratory, patrolling through 
secondary lymphoid tissue in search of cognate antigen. In the brachial lymph 
node CD62L- cells were significantly enriched in the switched population 
 
 
 
 
240 
suggesting these cells are resident within this lymph node, however, there is also 
an increase in CD62L+ cells which may indicate that memory cells in general 
show slower kinetics of emigration than naive cells (Figure 5.13 G and H).  
  
5.2.7 Tracking the migration of cells in CCR7-/- mice 
To extend our analysis of cell trafficking we crossed Kaede mice with CCR7-/- 
mice to create a model in which we could track the migration of cells that lack 
the chemokine receptor CCR7. CCR7 is important for several immune functions 
including the trafficking of leukocytes, establishing cognate interactions between 
cells and the organisation of lymphocytes to form lymphoid structures such as 
spleen and lymph nodes.  The movement of naive CD4+ T cells (Campbell et al., 
1998a, Campbell et al., 1998b, Gunn et al., 1999) and Tcm cells (Sallusto et al., 
1999) from blood into lymph nodes is dependent on CCR7, although this has 
been disputed for antigen-experienced T cells (Vander Lugt et al., 2013). CCR7-/- 
mice display impaired immune phenotypes including T cell responses due to the 
absence of distinct microenvironments within secondary lymphoid tissue 
(Forster et al., 1999).  These secondary lymphoid structures are small and do not 
have distinct T and B cell zones which are required for the correct positioning of 
lymphocytes during an immune response. Therefore although the phenotypic 
defects observed in CCR7-/- mice have been attributed to impairment in cell 
trafficking they may be due to development within abnormal secondary 
lymphoid structures.  
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Cohorts of CCR7-/- Kaede mice were analysed and compared to WT mice that 
were previously photoconverted and analysed after 24 hours. Photoconversion 
of the brachial lymph node of CCR7-/- Kaede mice and analysis 24 hours later 
revealed a significantly increased proportion of switched CD4+ T cells residing 
here compared to WT Kaede mice (Figure 5.14 A and B). This demonstrates that 
there is an impairment in the movement of CD4+ T cells into or out of lymph 
nodes in these mice. Naive T cells were significantly reduced in the unswitched 
CD4+ T cell population that is migrating into the brachial lymph node of CCR7-/- 
Kaede mice (Figure 5.14 D). The proportion of CD62L+ and CD62L- memory 
phenotype cells however was increased compared to WT Kaede mice, indicating 
that naive T cells are more reliant on CCR7 for entry into the lymph node (Figure 
5.14 C and D). The total number of naive, CD62L+ and CD62L- T cells migrating 
into this tissue was decreased in CCR7-/- mice showing that all these population 
utilise CCR7 to some extent to enter lymph nodes (Figure 5.14 E). The switched 
(resident) CD4+ T cell population was altered in constitution compared to WT 
Kaede mice; the proportion of CD62L- cells was significantly increased with 
corresponding decreases in naive T cells and CD62L+ T cells (Figure 5.14 C and 
F). When analysing total number of cells it is important to consider that the naive 
CD4+ T cell population is significantly reduced in the lymph nodes of CCR7-/- 
mice (Forster et al., 1999). This is due to their inability to enter through HEV, 
therefore the number of CD4+ T cells that were exposed to violet light and initial 
number of switched cells would be decreased in CCR7-/- Kaede mice. For this 
reason it was not informative to analyse the number of switched (resident) cells 
present in the brachial lymph node.  
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(A and C) Plots are representative of 5 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graph shows pooled data from 4 independent experiments. 
Bars show median. (D-F) Graphs show pooled data from 4 independent experiments. 
Bars show mean and error bars show SEM. Mann Whitney Test: **p≤ 0.01, ***p≤ 0.001.  
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Both the proportion and the number of switched CD4+ T cells that had migrated 
into the contralateral lymph nodes and spleen were significantly reduced in 
CCR7-/- Kaede mice, consistent with a defect in the migration of these cells into 
lymphoid tissue (Figure 5.15 A and B). The fold change in the proportion of 
switched CD4+ T cells appeared to be greater in the contralateral lymph nodes 
than in the spleen (Figure 5.15 C). This is consistent with the requirement for 
CCR7 to enter lymph nodes and white pulp areas in the spleen but not for entry 
into the red pulp (Forster et al., 1999). The switched CD4+ T cell population in 
the contralateral lymph nodes of CCR7-/- Kaede mice contained a smaller 
proportion of naive T cells than in WT mice (Figure 5.15 D and E). There was also 
a significant decrease in the number of naive T cells entering the contralateral 
lymph nodes in CCR7-/- mice (Figure 5.15 F; mean for naive T cells: WT 19511, 
CCR7-/- 899). However as a number of naive T cells were able to enter the lymph 
node this shows that expression of CCR7 isn’t an absolute requirement for entry. 
There was a small, but statistically significant, increase in the proportion of 
switched CD62L+ Tcm phenotype cells and CD62L- Tem phenotype cells, again 
indicating a higher reliance on CCR7 for naive T cells (Figure 5.15 E). Consistent 
with this, the fold change in number of cells entering the contralateral lymph 
nodes between WT and CCR7-/- Kaede mice was higher for naive T cells than for 
CD62L+ or CD62L- CD44hi cells (Figure 5.15 G).  
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5.2.8 Tracking the migration of 2W1S:I-Ab+ CD4+ T cells 
24 hours following photoconversion 
To assess migration of CD4+ memory T cell populations, we combined the use of 
our local immunisation model and Kaede transgenic mice to track the migration 
of antigen-specific CD4+ T cells. Previously it has been difficult to elucidate the 
migration patterns of antigen-specific T cells due to their low frequency. 
Experiments have been carried out using TCR transgenic cell transfers, however 
injection with abnormally high numbers of cells may not represent the normal 
migratory behaviour of endogenous T cell populations. Additionally lymphoid 
tissues contain populations of T cells that are resident, as well as recirculating T 
cells that have altered expression of adhesion molecules upon entry to these 
sites (Luettig et al., 2001) . Therefore cell suspensions prepared from lymphoid 
tissues will contain cells that are not ready to leave and may not display normal 
migration (Westermann et al., 2003). To establish a model to investigate CD4+ T 
cell migration in Kaede mice, we immunised the left paw pad with 5 μg 2W1S 
peptide alum ppt. Surgery was performed to expose the draining lymph node to 
violet light and therefore switch all 2W1S:I-Ab+ CD4+ T cells contained within in it 
8 dpi. We chose this timepoint as this is the peak of the effector response and 
therefore a large 2W1S:I-Ab+ CD4+ T cell population will be present to aid in 
analysis of migrating cells.  
Twenty four hours following photoconversion 80 % of 2W1S:I-Ab+ CD4+ T cells in 
the exposed brachial lymph node were switched (Figure 5.16 A and B). This is a 
significant inhibition of migration compared to total CD4+ T cells in the naive 
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state where only 15 % remained switched after 24 hours (Figure 5.16 B). During 
an immune response lymph node shutdown describes the process whereby 
lymphocyte egress is inhibited to concentrate cells in the draining lymph node 
(Hall and Morris, 1965, Cahill et al., 1976). The mechanisms of this process are 
unknown but it is thought to increase the likelihood of cognate interactions 
occurring. Lymph node shutdown has been reported to last for 24 hours 
following antigen exposure, after which egress of lymphocytes is increased 
(Mackay et al., 1992). Another possibility is that there is antigen still present in 
the lymph node as alum ppt peptide can induce a prolonged immune response, 
demonstrated by maintained expression of OX40 following immunisation with 
2W1S alum ppt peptide (Chapter 3, Figure 3.18). To determine if the migration of 
non-antigen specific T cells was also affected we determined the percentage of 
total CD4+ T cells that were switched in the brachial lymph node 8 dpi. 20 % of 
CD4+ T cells were switched which was significantly increased from 15 % seen in 
the naive state (Figure 5.16 A and B). This implies that the egress of multiple cell 
populations from the draining lymph node is inhibited due to the ongoing 
immune response. The percentage of 2W1S:I-Ab+ CD4+ T cells that were switched 
was higher still, indicating fundamental changes in antigen-specific cells that are 
responsible for their residency within the draining lymph node. It is also possible 
that the number of recirculating of 2W1S:I-Ab+ CD4+ T cells at this timepoint is 
very low due to their residence in the draining lymph node where cognate 
antigen is present. This would mean there are few incoming unswitched 2W1S:I-
Ab+ CD4+ T cells to decrease the proportion of switched cells, as is the case for 
total CD4+ T cells.  
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Figure 5.16: Tracking the migration of 2W1S:I-Ab+ CD4+ T cells from the 
brachial lymph node. Kaede mice were immunised in the left paw pad with 5 µg 
2W1S alum ppt peptide. 8 dpi mice underwent surgery to photoconvert the left 
brachial lymph node which was then analysed 24 hours later. (A) Expression of 
Kaede green and Kaede red protein in 2W1S:I-Ab+ CD4+ T cells (left) and total CD4+ 
T cells (right). (B) Percentage of switched CD4+ T cells from naive mice, CD4+ T cells 
8 dpi and  2W1S:I-Ab+ CD4+ T cells 8 dpi. (C) Expression of CD44 and CD62L on 
2W1S:I-Ab+ CD4+ T cells that are switched (left) and unswitched (right). (D) 
Percentage of 2W1S:I-Ab+ CD4+ T cells that are switched and unswitched that are 
either CD62L+ or CD62L-. (E) Expression of CCR7 on total CD4+ T cells, unswitched 
and switched 2W1S:I-Ab+ CD4+ T cells. (F) Percentage of switched and unswitched 
2W1S:I-Ab+ CD4+ T cells that are CCR7+.  
 
(A, C, E) Plots are representative of 7 mice from 2 independent experiments. Values 
on plots are percentages. Fluorescence minus one control is represented by solid 
grey peak. (B, D, F) Graphs show pooled data from 2 independent experiments. Bars 
show median. Mann Whitney Test: **p≤ 0.01, ***p≤ 0.001, ns=non-significant. 
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We examined the expression of CD44 and CD62L on switched and unswitched 
2W1S:I-Ab+ CD4+ T cells in the brachial lymph node to see if these surface 
markers determine their migratory capabilities (Figure 5.16 C). Eight dpi 
2W1S:I-Ab+ CD4+ T cells have not yet undergone the contraction phase therefore 
the CD62L- population will consist of effector cells and those that will survive as 
Tem phenotype cells. Unswitched 2W1S:I-Ab+ CD4+ T cells that have migrated 
into the brachial lymph node in the previous 24 hours are enriched in CD62L+ 
cells and have fewer CD62L- cells compared to switched cells, which are resident 
in the lymph node (Figure 5.16 C and D). Although expression of CCR7 could be 
detected on 70 % of total CD4+ T cells, the majority of which are naive cells that 
highly express CCR7, the level of expression on activated 2W1S:I-Ab+ CD4+ T cells 
was very low (Figure 5.16 E). Due to the presence of two endogenous fluorescent 
markers in Kaede transgenic mice that cause bleed over into other channels, the 
fluorochromes that can be used to label surface markers are more limited. 
Combined with this CCR7 is notably difficult to detect upon the cell surface hence 
staining is performed at 37 °C to enhance detection. The percentage of switched 
and unswitched 2W1S:I-Ab+ CD4+ T cells that were CCR7+ was calculated and was 
highly variable between two experimental repeats (Figure 5.16 F). Therefore 
within Kaede transgenic mice detection of CCR7 expression by 2W1S:I-Ab+ CD4+ 
T cells was beyond the technical limits of the experiment.  
A population of 2W1S:I-Ab+ CD4+ T cells could be detected in the contralateral 
lymph nodes, mesenteric lymph node and spleen (Figure 5.17 A).  
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Figure 5.17: Tracking the migration of 2W1S:I-Ab+ CD4+ T cells 
throughout the body. Kaede mice were immunised in the left paw pad with 5 
µg 2W1S alum ppt peptide. 8 dpi mice underwent surgery to photoconvert the 
left brachial lymph node and were analysed 24 hours later. (A) Expression of 
Kaede green and Kaede red protein in 2W1S:I-Ab+ CD4+ T cells from the 
contralateral lymph nodes, mesenteric lymph node and spleen. (B) 
Percentage of switched 2W1S:I-Ab+ CD4+ T cells from the exposed brachial 
lymph node, contralateral lymph nodes, mesenteric lymph node and spleen. 
(C) Number of 2W1S:I-Ab+ CD4+ T cells from the exposed brachial lymph 
node, contralateral lymph nodes, mesenteric lymph node and spleen.  
 
(A) Plots are representative of 7 mice from 2 independent experiments. 
Values on plots are percentages. (B-C) Graphs show pooled data from 2 
independent experiments. Bars show median.  
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The level of Kaede green expression was variable between experiments so gating 
was set on a larger population (CD4+ T cells) where positive and negative 
populations could be more easily delineated. A small proportion of 2W1S:I-Ab+ 
CD4+ T cells were switched in all contralateral tissues (Figure 5.17 A). Migration 
of 2W1S:I-Ab+ CD4+ T cells into these tissues appeared to be higher than for total 
CD4+ T cells in the naive state (contralateral LNs median: 7% compared to 2% 
and spleen median: 22 % compared to 2%- see Figure 5.13 A). For the 
contralateral lymph nodes this may be confounded by the very low cell number, 
resulting in an inflated percentage of switched cells (Figure 5.17 C; contralateral 
LNs median: 183). In the spleen however a significant population of 2W1S:I-Ab+ 
CD4+ T cells was identified (Figure 5.17 C: spleen median 2219).  Approximately 
22 % of these cells had migrated into the spleen in the previous 24 hours, a 
significantly higher migration than for total CD4+ T cells in the naive state.  
The majority of switched cells in the contralateral lymph nodes and mesenteric 
lymph nodes were CD62L+ (Figure 5.18 A and B). Although this observation is 
consistent with their ability to migrate into lymphoid tissue, the number of 
2W1S:I-Ab+ CD4+ T cells present was very low. In the spleen there was a more 
even split between CD62L+ and CD62L- cells with a slight bias towards the latter 
(Figure 5.18 A and B).  
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Figure 5.18: Phenotyping migrating 2W1S:I-Ab+ CD4+ T cells. Kaede mice were 
immunised in the left paw pad with 5 µg 2W1S alum ppt peptide. 8 dpi mice underwent 
surgery to photoconvert the left brachial lymph node and contralateral lymph nodes, 
mesenteric lymph nodes and spleen were analysed 24 hours later. (A) Expression of 
CD44 and CD62L on switched 2W1S:I-Ab+ CD4+ T cells from each tissue respectively. 
(B) Percentage of switched 2W1S:I-Ab+ CD4+ T cells that are CD62L+ or CD62L- from 
each tissue.  
 
(A) Plots are representative of 7 mice from 2 independent experiments. Values on 
plots are percentages. (B) Graphs show pooled data from 2 independent experiments. 
Bars show median.  
C
D
62
L 
CD44 
Contralateral LNs Mesenteric LN Spleen 
88.9 
11.1 
90 
10 
42.4 
56.8 
 
 
 
 
253 
To extend our analysis to CD4+ memory T cells we immunised Kaede mice with 
2W1S alum ppt peptide in the left paw pad and rested for 42 days. This 
timepoint was chosen as we have previously shown in WT mice the response to 
alum ppt 2W1S peptide takes longer to enter the memory phase than with Lm-
2W1S infection (Figures 5.5 and 5.6).  At 42 dpi mice underwent surgery to 
photoconvert the draining brachial lymph node and were analysed 24 hours 
later. In the exposed brachial lymph node approximately 70 % of 2W1S:I-Ab+ 
CD4+ memory T cells were switched indicating that there had been little 
migration of these antigen-specific CD4+ T cells when compared to migration of 
total CD4+ T cells in a naive mouse where the percentage of switched cells 
remaining after 24 hours was only 15 % (Figure 5.19 A; naive CD4+ T cell 
migration shown in Figure 5.11 E and F). The reduced proportion of 2W1S:I-Ab+ 
CD4+ T cells expressing OX40 at this timepoint indicated that the response may 
have entered the memory phase, however this lack of migration indicated that 
cell movement might still be restricted. To determine if this lack of migration 
was due to prolonged effects of lymph node shutdown, we analysed the 
migration of total CD4+ T cells in Kaede mice that had been immunised 42 days 
previously. The median percentage of switched CD4+ T cells in the brachial 
lymph node was 7 % demonstrating that migration of naive cells has been 
restored to normal levels (Figure 5.19 A and B).  This suggests that that the lack 
of migration in 2W1S:I-Ab+ CD4+ T cells is due to fundamental differences 
between naive and memory cells. 
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Figure 5.19: Tracking the migration of 2W1S:I-Ab+ CD4+ memory T cells. Kaede 
mice were immunised in the left paw pad with 5 µg 2W1S alum ppt peptide. 42 dpi 
mice underwent surgery to photoconvert the left brachial lymph node and were 
analysed 24 hours later. (A) Expression of Kaede green and Kaede red protein in 
2W1S:I-Ab+ CD4+ T cells (left) and total CD4+ T cells (right) from the exposed brachial 
lymph node. (B) Percentage of switched 2W1S:I-Ab+ CD4+ T cells and total CD4+ T 
cells from the exposed brachial lymph node. (C) Expression of Kaede green and 
Kaede red protein in 2W1S:I-Ab+ CD4+ T cells from the contralateral lymph nodes; 
(D) mesenteric lymph node and (E) spleen. (F) Number of 2W1S:I-Ab+ CD4+ T cells 
from the exposed brachial lymph node, contralateral lymph nodes, mesenteric lymph 
node and spleen. (G) Percentage of switched 2W1S:I-Ab+ CD4+ T cells from the 
exposed brachial lymph node, contralateral lymph nodes, mesenteric lymph node 
and spleen. 
 
(A, C-E) Plots are representative of 7 mice from 2 independent experiments. Values 
on plots are percentages. (B, F and G) Graphs show pooled data from 2 independent 
experiments. Bars show median. Mann Whitney Test: ***p≤ 0.001 
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A population of 2W1S:I-Ab+ CD4+ memory T cells could be clearly identified in 
contralateral lymph nodes, mesenteric lymph node and spleen but as expected 
was small in contralateral and mesenteric lymph nodes (Figure 5.19 C-F).  Nearly 
all 2W1S:I-Ab+ CD4+ memory T cells identified in these tissues were unswitched 
meaning they had not migrated from the draining brachial lymph node in the 
previous 24 hours (Figure 5.19 C-E and G). However their presence at these sites 
indicated that 2W1S:I-Ab+ CD4+ memory T cells are migrating but perhaps 24 
hours is not a sufficient amount of time for them to move from the draining 
brachial lymph node.  Alternatively, as the most switched cells could be found in 
the spleen, it may be that there is not a large enough population circulating 
through the lymph nodes to detect. Fundamentally, these data indicate that a 
CD4+ memory T cell population in the draining lymph node is maintained which 
displays very limited migration within 24 hours.  
Again we investigated the phenotypic makeup of the switched and unswitched 
populations in the exposed brachial lymph node using expression of CD62L. 
Unswitched 2W1S:I-Ab+ CD4+ memory T cells that had migrated into the lymph 
node in the previous 24 hours contained a higher proportion of CD62L+ cells, 40 
% compared to 14 %, than switched cells that were resident (Figure 5.20 A and 
B). Switched 2W1S:I-Ab+ CD4+ memory T cells that are resident in the draining 
lymph node were enriched for CD62L- cells (Figure 5.20 A and B; median for 
switched Tem 85 %, unswitched Tem 56 %). Approximately 56% of unswitched 
2W1S:I-Ab+ CD4+ T cells in the brachial lymph node were CD62L- and therefore of 
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Tem phenotype indicating that CD62L- cells do recirculate through lymph nodes 
(Figure 5.20 B).  
Nearly all 2W1S:I-Ab+ CD4+ memory T cells in the contralateral lymph node were 
unswitched meaning that these cells had not migrated from the brachial lymph 
node in the previous 24 hours, but must still be a recirculating population to 
have reached this distal site. We analysed this population for expression of 
CD62L and CD27. Although there was a significantly higher proportion of CD62L+ 
cells, around 35 % of this population was CD62L- (Figure 5.20 C and D). In 
addition a proportion of this population were CD27- and therefore defined as 
Tem cells (Figure 5.20 E and F). These data indicate that although the majority of 
recirculating 2W1S:I-Ab+ CD4+ memory T cells are of the conventional CD62L+ 
Tcm phenotype, a small proportion are Tem cells, which are not thought to 
recirculate through lymph nodes.    
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Figure 5.20: Phenotyping migrating 2W1S:I-Ab+ CD4+ memory T cells. Kaede 
mice were immunised in the left paw pad with 5 µg 2W1S alum ppt peptide. 42 dpi 
mice underwent surgery to photoconvert the left brachial lymph node and were 
analysed 24 hours later. (A) Expression of CD44 and CD62L on switched and 
unswitched 2W1S:I-Ab+ CD4+ memory T cells from the exposed brachial lymph node. 
(B) Percentage of 2W1S:I-Ab+ CD4+ memory T cells that are switched and 
unswitched that are either CD62L+ or CD62L- phenotype from the exposed brachial 
lymph node. (C) Expression of CD44 and CD62L on unswitched 2W1S:I-Ab+ CD4+ 
memory T cells from the contralateral lymph nodes. (D) Percentage of 2W1S:I-Ab+ 
CD4+ memory T cells that are CD62L+ and CD62L- from the contralateral lymph 
nodes. (E) Expression of CD27 on unswitched 2W1S:I-Ab+ CD4+ memory T cells from 
the contralateral lymph nodes. (F) Percentage of 2W1S:I-Ab+ CD4+ memory T cells 
that are CD27+ and CD27- from the contralateral lymph nodes.  
 
(A, C and E) Plots are representative of 8 mice from 2 independent experiments. 
Values on plots are percentages. (B, D and F) Graphs show pooled data from 2 
independent experiments. Bars show median. Mann Whitney Test: ***p≤ 0.001 
C D
*** 
Exposed brachial LN 
unswitched 
Contralateral LNs 
60.7 
36 
CD44 
C
D
62
L 
*** 
E F
25 
CD27 
2W
1S
:I-
A
b 
unswitched 
Contralateral LNs 
 
 
 
 
259 
5.3 Discussion 
Throughout my analysis of CD4+ memory T cell populations, a surprising 
observation was the location of cells possessing a Tem phenotype within 
secondary lymphoid tissue. These data suggested that some Tem cells might 
persist within secondary lymphoid tissue rather than traffic through non-
lymphoid tissue as is conventionally thought. To further investigate this, in this 
chapter I have established a novel model to track the migration of an antigen-
specific CD4+ T cell population in photoconvertible Kaede transgenic mice. This 
model clearly demonstrates that, following immunisation with alum ppt peptide, 
a population of CD4+ memory T cells displaying a non-circulatory phenotype 
within the draining lymph node is generated and persists at this site for an 
extended period of time.  
Both Tcm and Tem cells, identified by cytokine secretion, could be found in 
secondary lymphoid tissue following systemic infection with Lm-2W1S. To 
better understand the distribution of CD4+ memory T cells following infection 
with Lm-2W1S, I looked in the lymph nodes, spleen, lungs and blood samples. 
Within the spleen and lymph nodes the 2W1S:I-Ab+ CD4+ memory T cell 
population was enriched in Tcm cells as would be expected for lymphoid sites. In 
contrast to this memory cells in the lung were biased towards IFN-γ producing 
Tem cells. Although expression of CCR7 was more prevalent in lymphoid tissues 
it was not restricted to Tcm cells as would be expected based on their definition 
(Sallusto et al., 1999). This raises the possibility that CCR7 is not only expressed 
by Tcm cells, at least in the context of some responses. A recent paper assessing 
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the contribution of CCR7 in competitive mixed bone marrow chimeras found that 
expression of CCR7 conferred no advantage for CD4+ memory T cells entering 
lymph nodes from the blood (Vander Lugt et al., 2013). This, combined with my 
data, is suggestive that CCR7 may not be the most useful marker for functionally 
defining Tcm cells. 
To further investigate the migratory capacity of CD4+ memory T cells, I have 
established a local immunisation model in which an antigen-specific population 
of CD4+ T cells was expanded in the draining lymph node and their subsequent 
migration into contralateral tissue then tracked. This model assessed the 
movement of CD4+ T cells from the blood through HEV into lymph nodes and is 
not influenced by intra-nodal migration of cells through the lymph system. The 
amount of antigen administered was central to the success of this model; low 
quantities of peptide restricted the immune response to the draining lymph node 
and antigen was not disseminated beyond this within 24 hours. Crucially this 
meant that the differentiation of Teff, Tcm precursors and TFH cells took place 
only in the draining lymph node and the migratory component of these 
populations could be followed in contralateral tissues. Evidence for this was 
generated through the use of OVA AF647, which indicated that antigen did not 
disseminate beyond the draining lymph node 24 hours after immunisation. 
Although it cannot be ruled out that small quantities of antigen may be dispersed 
after this time, the absence of TFH formation in contralateral lymph nodes, 
mesenteric lymph node and spleen indicates that little antigen spreads beyond 
the draining lymph node.   
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We then extended this model to investigate the migration of antigen-specific 
CD4+ memory T cells. As there are caveats associated with the study of memory 
phenotype cells we followed the endogenous 2W1S:I-Ab+ CD4+ T cell population 
and defined memory cells based on time since immunisation. Due to the 
prolonged response induced by alum ppt peptide memory cells were studied 42 
dpi, a later timepoint than in the systemic response to Lm-2W1S. Conventional 
definition of Tcm and Tem cells by CD62L and CCR7 has recently been 
questioned by several studies (Unsoeld and Pircher, 2005, Vander Lugt et al., 
2013, Brinkman et al., 2013, Debes et al., 2004). CD8+ memory T cells responding 
to LCMV were frequently found to be CD62L-CCR7+ in both lymphoid and non-
lymphoid tissue, a phenotype not classically associated with Tcm or Tem cells 
(Unsoeld and Pircher, 2005). Following i.v. infection with Lm-2W1S CCR7 
expression was more widespread in lymphoid tissue however a proportion of 
CCR7+ cells were present in the lungs. This indicates that expression of lymph 
node homing surface molecules cannot solely be used to predict the localisation 
of CD4+ memory T cells. IFN-γ+ Tem cells that expressed CCR7 at a similar level 
to IFN-γ- Tcm cells could be identified, as has been described for IFN-γ+ cells in 
the lung draining mediastinal lymph nodes following influenza infection (Debes 
et al., 2004). At 42 dpi with alum ppt 2W1S peptide, CCR7+CD62L- cells could 
also be identified in the lymph nodes and spleen demonstrating that CCR7 
expression is not restricted to CD62L+ cells. Although it is possible that these 
represent Tcm cells that have down-regulated CD62L, co-expression of IFN-γ and 
CCR7 suggest CCR7 expression is more widespread than previously thought. 
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For the reasons outlined above, reliance on CD62L and CCR7 for the definition of 
CD4+ memory T cell populations may be unreliable.  Furthermore these 
molecules mediate the entry of CD4+ T cells into lymph nodes, therefore 
investigation of migration may be confounded by definition of memory T cells by 
these markers. For this reason we investigated alternative markers that could be 
used to define Tem cells. KLRG1 has been used to discriminate CD8+ memory T 
cells with the ability to rapidly produce effector cytokines (Sarkar et al., 2008). 
However KLRG1 was not expressed by 2W1S:I-Ab+ CD4+ T cells and therefore is 
not useful for discrimination of memory cell populations. CD27- cells are 
contained within CCR7- and CD62L- circulating human memory T cell 
populations suggesting lack of this TNF receptor correlates with Tem phenotype 
(Campbell et al., 2001). Consistent with this we found that a population of CD27- 
cells was present in the CD62L-, but not CD62L+, 2W1S:I-Ab+ CD4+ T cell 
population, indicating that CD27- cells are Tem cells.  
To study the migration of 2W1S:I-Ab+ CD4+ memory T cells we used 
photoconvertible Kaede transgenic mice.  Irreversible photoconversion of cells 
upon exposure to violet light labels these cells and their migration can be tracked 
throughout the body. We have successfully developed a surgical model to expose 
the brachial lymph node to violet light and combined this with local 
immunisation to track the migration of photoconverted 2W1S:I-Ab+ CD4+ T cells. 
This method is highly advantageous compared to previous studies of memory 
cell migration as it enables antigen-specific cells to be tracked from a known 
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origin in a specified period of time. This model allowed us to better establish the 
kinetics of cell trafficking to and from lymphoid sites.   
Initial analysis of CD4+ T cells in a resting state revealed that these cells are 
highly migratory; in a 24 hour period approximately 85 % of the cells present at 
the time of photoconversion had exited the lymph node. Analysis of 8 similarly 
treated mice showed little variation indicating that this is a robust model for 
tracking cell migration. A small, but consistent, population of switched cells 
could then be identified in the contralateral lymph nodes and spleen 
demonstrating that these cells have migrated from the brachial lymph node and 
validating this model as a method to track CD4+ T cell migration from a given 
site. Among the migrating switched cells found in the contralateral lymph node 
the CD62L- population are under-represented, consistent with the role of this 
molecule in lymph node entry. Within the switched population resident in the 
exposed brachial lymph node CD44hi cells are enriched, indicating that the 
antigen-experienced population is less likely to or less efficient at recirculating 
than naive T cells. 
To track the migration of an antigen-specific CD4+ T cell population mice were 
immunised with alum ppt 2W1S peptide and underwent surgery to expose the 
draining lymph node to violet light 8 dpi or 42 dpi to study memory T cells. 
Previously it has been difficult to study the migration of antigen-specific CD4+ 
memory T cell populations due to their low frequency. The development of 
photoconvertible proteins has provided new ways to investigate cell trafficking 
(Tomura et al., 2008).  Targeted exposure to violet light allows cells within a 
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given site to be irreversibly labelled at a specific point in time. Photoconversion 
of the draining lymph node 8 dpi and analysis after 24 hours revealed that 80 % 
of 2W1S:I-Ab+ CD4+ T cells were switched, showing that the kinetics of migration 
of responding antigen-specific cells in an inflamed lymph node are much slower 
than CD4+ T cells in the steady state. This could be due to a number of reasons; 8 
dpi with alum ppt 2W1S peptide there may still be antigen present within the 
draining lymph node which is inhibiting the egress of T cells from this site. In 
support of this the egress of naive CD4+ T cells was also decreased compared to 
the steady state indicating that this effect is not restricted to responding antigen-
specific cells. Alternatively, or in addition, the number of circulating 2W1S:I-Ab+ 
CD4+ T cells will likely be low as the majority are contained within the draining 
lymph node, actively involved in a response. Therefore there are few migrating 
cells to replace the switched cells within the draining lymph node. 
 The migration of 2W1S:I-Ab+ CD4+ T cells out of the draining lymph node 
remained low for memory cells; at 42 dpi 70 % of cells within this site were 
switched. OX40 expression at this timepoint was significantly reduced compared 
to 21 dpi, however was still present on a number of 2W1S:I-Ab+ CD4+ T cells. This 
may suggest that there is still antigen present, but the migration of total CD4+ T 
cells was restored to the level observed in the steady state, indicating they were 
not under the effect of lymph node shutdown. It is possible that expression of 
OX40 in the response to alum ppt 2W1S peptide shows different kinetics to 
infection with Lm-2W1S, independent of antigen availability. Unexpectedly there 
appears to be a resident population of 2W1S:I-Ab+ CD4+ memory T cells present 
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in the lymph node 42 dpi. Conventional recirculating Tcm and Tem populations 
may have been expected to leave the lymph node by this point. This resident 
population was composed of significantly more CD62L- cells, a characteristic 
displayed by tissue resident CD8+ T cells in the small intestine (Schenkel and 
Masopust, 2014). Trm cells have been described for both CD4+ (Teijaro et al., 
2011) and CD8+ (Schenkel and Masopust, 2014) T cell populations, poised to 
respond to infection at non-lymphoid sites. Also using photoconversion to label 
cells, a recent study has described a resident population of CD4+ T cells in the 
mesenteric lymph node and Peyer’s patches (Ugur et al., 2014). These cells were 
also CD62L- and accumulated in response to chronic antigen administered orally 
(Ugur et al., 2014). This population included TFH cells as well as other T cell 
subsets and expressed CD69, a commonly used marker of CD8+ Trm cells 
(Schenkel and Masopust, 2014). This suggests that lymph node resident 
populations may form in response to persistent antigen, however resident CD8+ 
T cells have also been described in the absence of antigen using parabiosis 
experiments. A small population in the spleen and lymph nodes, between 1-5 % 
of CD8+ memory cells, remained within these tissues and were phenotypically 
similar to resident cells in the small intestine (Schenkel et al., 2014). The 
function of a lymph node resident population is unknown and presumably would 
have to decrease in size over time to make way for subsequent responses. CD8+ 
Trm cells were found to be positioned at sites of pathogen entry in the spleen 
and lymph nodes (Schenkel et al., 2014), perhaps located here to most effectively 
activate immune responses for pathogen control. 
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Although the proportion of switched cells in the draining lymph node 8 dpi is 
high suggesting slow egress of cells, 2W1S:I-Ab+ CD4+ T cells appear to migrate 
into contralateral lymph nodes and the spleen at a higher rate that naive T cells 
in the steady state. This is likely because these sites originally contain very few 
2W1S:I-Ab+ CD4+ T cells and they are being seeded with circulating cells from the 
draining lymph node. The majority of these cells in contralateral lymph nodes 
are CD62L+ as would be expected for cells able to enter the lymph node from the 
bloodstream. At 42 dpi switched 2W1S:I-Ab+ CD4+ memory T cells could not be 
detected in the contralateral lymph nodes. This could be because 24 hours is not 
sufficiently long enough for memory cells to migrate from the brachial lymph 
node, however the presence of switched 2W1S:I-Ab+ CD4+ memory T cells in the 
spleen argues against this notion. It is more likely that the number of 2W1S:I-Ab+ 
CD4+ memory T cells migrating into contralateral lymph nodes is below our limit 
of detection, as a small population could be identified in the spleen, which is a 
larger tissue. There were however many unswitched 2W1S:I-Ab+ CD4+ memory T 
cells present in the contralateral lymph nodes that represent a recirculating 
population, although they were not in the brachial lymph node at the time of 
photoconversion. As expected this population was enriched in CD62L+ cells, 
however contained a significant proportion, around 35 %, of CD62L- cells. 
Furthermore a small proportion of these cells were CD27- and therefore 
displayed the phenotype of Tem cells, which are not thought to recirculate 
through lymph nodes. Unswitched cells migrating into the brachial lymph node 
contained an increased proportion of CD62L+ cells compared to cells resident in 
the lymph node at both primary and memory timepoints. Yet approximately half 
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of this population was CD62L-, again indicating that recirculating effector and 
memory 2W1S:I-Ab+ CD4+ memory T cells may enter lymph nodes from the 
bloodstream using a CD62L independent mechanism as well as through afferent 
lymph.  
CCR7-/- Kaede transgenic mice were used to study the migration of T cells that 
lack this chemokine receptor, thought to be required for multiple immune 
functions including entry into lymph nodes (Forster et al., 1999). Consistent with 
a defect in migration, the exposed brachial lymph node of CCR7-/- Kaede mice 
contained an increased proportion of switched cells. As the number and 
proportion of naive T cells migrating into lymph nodes was reduced this was due 
to impaired entry, not exit. The proportion of CD44hi cells was increased in 
lymph nodes implying that memory cells are less reliant on CCR7 than naive T 
cells. This is consistent with a study showing that CCR7 confers no advantage for 
entry of Tcm cells into lymph nodes (Vander Lugt et al., 2013). The migration of 
CD4+ T cells into contralateral lymph nodes was more impaired than their 
migration into spleen. Entry into the spleen is not impaired in the absence of 
CCR7 but T cell localisation is severely perturbed (Forster et al., 1999).  
In summary I have developed a robust method to track the migration of both 
CD4+ T cells and 2W1S:I-Ab+ T cells using photoconvertible Kaede transgenic 
mice. Migration of naive T cells into lymph nodes is CCR7 dependent and is 
significantly impaired in mice that lack this chemokine receptor. However 
antigen-experienced cells are less reliant on CCR7 for entry into lymph nodes 
and likely use other CCR7-independent mechanisms. Expression of CCR7 was not 
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restricted to Tcm and was also found on Tem cells, both functionally defined by 
cytokine secretion. Following local immunisation migration of 2W1S:I-Ab+ CD4+ T 
cells, the majority of which were CD62L-, out of the draining lymph node was low 
at both 8 and 42 dpi. This suggests that a population of cells with Tem phenotype 
persist in the draining lymph node and do not recirculate as classical Tcm and 
Tem cells do.  
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CHAPTER 6: GENERAL DISCUSSION 
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6.1 Discussion 
Vaccines have been highly successful in reducing morbidity and mortality since 
they were first developed by Edward Jenner in 1796. Major diseases that used to 
cause significant mortality such as smallpox, measles and diphtheria are now 
eradicated or reported rarely in vaccinated populations (Hilleman, 2000). 
Underpinning the success of vaccines is the induction of long-term 
immunological memory. Although the driving force behind the development of 
many vaccines was the induction of a high-titre antibody response, the role that 
the cell-mediated arm plays in protective immunity is now better understood. 
Conventionally, vaccines have been effective as the pathogens they target have 
been antigenically stable therefore have induced robust antibody responses, as 
for smallpox and polio. The majority of currently licensed vaccines induce 
antibody responses, which are reliant on T cell help (Esser et al., 2003). These 
vaccines are successful at providing long-term protection against viruses such as 
influenza and smallpox. However, vaccine development for chronic infections or 
those able to evade immune recognition through switching of surface antigens 
has been more problematic, as in the case of Mycobacterium tuberculosis (TB), 
human immunodeficiency virus (HIV) and hepatitis C virus (HCV). The protective 
responses to these pathogens are cell mediated and consist of both CD4+ and 
CD8+ T cells.  
Thus, memory T cells play a key role in protective immunity and are the 
cornerstone of successful vaccines. CD4+ memory T cells are a fundamental 
aspect of recall immunity as they activate and recruit other components of the 
 
 
 
 
271 
immune response to clear pathogens before they are able to spread systemically. 
Elucidating the mechanisms involved in the generation and subsequent survival 
of memory cells is vital to the understanding and production of more efficient 
vaccination strategies. To date this has been challenging due to the lack of 
sensitive methods to track antigen-specific memory T cells in vivo, impeding our 
understanding of the precise mechanisms controlling their generation and 
survival.  
The division of CD4+ memory T cells from primary effector cells has been 
problematic due to a deficit of distinctive surface receptors. Upregulation of 
CD44 following antigen recognition is often used to distinguish antigen-
experienced T cells from naive T cells, however this marker is unable to 
differentiate between effector cells in an active response from memory cells 
persisting in the absence of antigen. Other activation markers such as CD69 and 
CD25 have also been employed to identify recently activated cells, however 
expression of these molecules can be transient and therefore their absence does 
not necessarily identify memory cells (Sallusto et al., 1999, Dutton et al., 1998). 
Furthermore memory phenotype cells defined by these criteria have been shown 
to possess different survival and homeostatic properties from antigen-specific T 
cells (Purton et al., 2007, Lenz et al., 2004). For this reason the study of antigen-
specific memory T cells that have proliferated in response to a known antigen 
and undergone contraction to form a stable memory cell population is necessary. 
TCR transgenic cells have been employed to enhance detection however studies 
have now found they may not be representative of endogenous, polyclonal 
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memory cell populations (Marzo et al., 2005, Foulds and Shen, 2006). For this 
reason tracking endogenous populations using MHC II tetramers has become the 
“gold standard” for analysis of CD4+ memory T cells. Amongst these endogenous 
populations, CD4+ T cells responsive to 2W1S peptide have been demonstrated 
as a robust model due to reliable detection methods and the development of an 
infectious agent expressing the 2W1S peptide (Pepper et al., 2010, Pepper et al., 
2011). Infection with Lm-2W1S induces expansion of CD4+ T cells responding to 
the 2W1S peptide, a larger than average endogenous T cell pool that facilitates 
the study of this population. Combination of magnetic enrichment and MHC II 
tetramers enable this population to be tracked in naive mice, following infection 
through the primary response and after contraction of the effector population 
into the memory cell phase. Detailed analysis of the kinetics of this response by 
the Jenkins laboratory has facilitated the definition of memory T cells by time 
since infection. This stable population consists of cells undergoing slow 
homeostatic proliferation, persisting in the absence of antigen (Pepper et al., 
2010, Pepper et al., 2011). The establishment of this model now enables the role 
of multiple molecules and signalling pathways to be investigated for their 
involvement in CD4+ memory T cell generation and survival.  
Memory cells have been broadly divided into subsets based upon expression of 
key lymph node homing molecules CCR7 and CD62L (Sallusto et al., 1999). Tcm 
cells were defined by their expression of CCR7 and CD62L, circulating through 
lymphoid tissue. Upon activation they produce IL-2 and proliferate to produce 
numerous effector cells to respond to reinfection. Tem cells lack these lymph 
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node homing receptors, instead circulating through blood and non-lymphoid 
tissue. Upon activation they rapidly produce effector cytokines such as IFN-γ to 
eliminate threats. However since their description it has been shown that these 
definitions are not absolute; memory T cells lacking CCR7 and CD62L have been 
observed within lymphoid tissue (Unsoeld and Pircher, 2005). Additionally, the 
recent identification of Trm cells has shown that memory cell populations may 
be more complex than this simple definition based upon expression of homing 
molecules. It is becoming increasingly clear that Trm cells, which are not present 
in human peripheral blood samples, are an important part of adaptive immunity 
and protection against infection. The requirements for survival and maintenance 
of these populations are yet to be defined, but may be different to those of 
circulating Tcm and Tem cells. Development of new vaccines may hinge upon a 
greater understanding of how protective immunity is initiated at specific sites, 
whether this is due to migration of memory cells or tissue resident populations. 
The putative resident CD4+ memory T cell population that we have identified 
within a peripheral skin draining lymph node following local immunisation may 
represent a Trm cell population found within secondary lymphoid organs. This 
population is similar to a recently described resident population located in 
Peyer’s patches and mesenteric lymph node (Ugur et al., 2014). These cells did 
not recirculate and were found to accumulate in the Peyer’s patches following 
chronic antigen exposure. Although the function of such a population is currently 
unclear, it may be poised at sites of pathogen entry to efficiently recruit other 
immune cells to this site and rapidly clear pathogens before they can spread 
systemically. The goal of vaccine design will be to induce high numbers of both 
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Tem and Trm cells, to provide immediate effector responses, and Tcm cells to 
provide a pool of new effector cells through proliferation. A greater 
understanding of the factors that govern the generation and survival of each of 
these populations is essential to improved vaccine design in the future. 
Definition of these populations based on chemokine receptors, cytokine 
secretion and adhesion molecules will help to determine what type of response a 
vaccine is eliciting and therefore be tailored to provide the most efficacious 
combination. 
The generation of a functional memory cell pool is defined by the integration of 
numerous signals received during T cell priming. CD4+ T cells undergo 3 distinct 
phases after encounter of cognate antigen: extensive proliferation and 
differentiation, contraction due to cell death and the memory phase, which is 
maintained by slow homeostatic proliferation. Signals received during priming 
dictate the differentiation pathway and are determined by the context in which 
antigen is recognised, which will shape the response due to activation of 
different PRR, and the duration of antigen contact (Iezzi et al., 1998). CD4+ T cells 
then integrate signals from a number of different costimulatory receptors to 
determine the differentiation of T cell subsets. Costimulatory molecules can act 
to enhance signalling through the TCR or may provide additional signals that 
affect the proliferation or differentiation of T cells. There may be temporal 
separation of these signals; for example CD28 is constitutively expressed on 
naive T cells therefore acts immediately upon antigen recognition to influence 
TCR signalling (Tuosto and Acuto, 1998). Other receptors such as OX40 and ICOS 
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are upregulated following T cell activation therefore may exert their influence in 
the days following initial antigen recognition (Gramaglia et al., 1998, Hutloff et 
al., 1999, Mages et al., 2000). When analysing the costimulatory requirements of 
CD4+ T cell populations it will be important to consider the nature of the 
response. Monoclonal TCR transgenic populations will likely show different 
requirements to endogenous polyclonal populations, due to the presence of T 
cells with a range of affinities. Therefore a better understanding of how the 
resulting memory cell pool is affected by signals received in the primary 
response may require the study of endogenous populations, as they most closely 
resemble those in a human patient.  
Previous studies have shown a clear role for ICOS in the generation of TFH cells 
but its importance for other T cell subsets was less clear (Akiba et al., 2005, 
Bossaller et al., 2006). My studies have shown that ICOS signals received during 
the primary response to Lm-2W1S enable the optimal formation of the memory 
cell pool. Importantly, ICOS signals were required for the generation of both Tcm 
and Tem cells subsets. Human patients with ICOS deficiency have been reported 
to show a similar defect in both Tcm and Tem cell populations indicating our 
murine studies show close parallels to human immunity (Takahashi et al., 2009).  
Additionally, signals received through OX40 appeared to specifically benefit the 
Teff cell population and were actually detrimental to TFH cells when given in 
excess. Agonistic anti-OX40 mAb caused the vast expansion of Teff cells in the 
primary response and skewed the memory cell pool towards Tem cells. 
Understanding the role these different costimulatory molecules play in 
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controlling T cell differentiation and memory cell formation will enable the 
manipulation of vaccine responses to achieve the desired T cell response. 
The factors mediating the long-term survival of memory T cells have been a 
contentious issue; initial ideas suggested that continuous provision of TCR 
signals through peptide:MHC sustained memory cells (Gray and Matzinger, 
1991). However studies in MHC II-/- mice have shown normal survival of CD4+ 
memory T cells (Swain et al., 1999). Since CD8+ memory T cells are more 
abundant and therefore easier to study much work has revolved around signals 
regulating the survival of this population. It was determined that the cytokines 
IL-7 and IL-15 were essential for the persistence of this population (Schluns and 
Lefrancois, 2003), so these were proposed as likely candidates regulating the 
survival of CD4+ T cells. However contradictory studies found that the survival of 
CD4+ memory T cells was not impaired in common γ chain-/- mice (Lantz et al., 
2000) and also that memory cell survival was impaired in IL-7-/- mice (Kondrack 
et al., 2003, Purton et al., 2007). This confusion was perhaps partly explained by 
studies showing that memory phenotype cells, classically used in the study of 
memory cell survival, showed different signalling requirements to antigen-
specific memory cells (Purton et al., 2007, Lenz et al., 2004). IL-7 and IL-15 were 
both found to play a role in both CD4+ and CD8+ memory T cell survival in non-
lymphopenic mice. Following on from this it was suggested that periodic signals 
from costimulatory molecules might enhance memory cell survival. Clearly the 
generation and survival of memory cells through the contraction phase of the 
response is dependent on signals from costimulatory molecules such as OX40, 
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but whether they are involved in long-term persistence once they are formed is 
unknown. Impaired survival of CD4+ memory T cells in CD30-/-/OX40-/- mice and 
RORγt-/- mice suggested a possible mechanism where interactions between ILC 
and CD4+ memory T cells supported survival. ILC3 are strategically located in the 
lymph nodes to interact with cells trafficking through this tissue (Mackley et al., 
2015). Constitutive expression of OX40L (Kim et al., 2003) and ICOSL (Maazi et 
al., 2015) on some ILC prompted us to investigate the role of these receptors, 
OX40 and ICOS, in CD4+ memory T cell survival. The kinetics of expression of 
OX40 and ICOS were distinctive; OX40 expression was transient and tightly 
linked to antigen availability, whereas ICOS expression was more sustained once 
initial TCR activation had taken place. This suggested a temporal separation of 
the roles of OX40 and ICOS in CD4+ T cell responses. Although not detected 
directly ex vivo, expression of OX40 could be upregulated on 2W1S:I-Ab+ CD4+ 
memory T cells following culture with IL-7. ICOS expression was maintained at 
low levels on memory cells, from both endogenous and TCR transgenic 
populations.  Despite this, the survival of antigen-specific CD4+ memory T cells 
was not impaired by the specific absence of signalling through OX40, ICOS or 
CD28. To date there is no clear evidence that, once formed, CD4+ memory T cells 
require costimulatory signals for their long-term persistence.  
The response of T cells upon secondary challenge is an important consideration 
for boosting of protective immunity through multiple dose vaccination. Prime-
boost vaccination can be used to generate a large population of memory T cells. 
Initial priming with antigen is done in one vector, distinct from the 2nd vector 
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used for boosting. This approach is more effective at generating antigen-specific 
memory T cells than repeated doses of the same vaccine as antigen presentation 
and inflammatory signals are not impaired by existing immunity (Woodland, 
2004). Although conventionally considered dispensable for expansion of 
memory cells, costimulation was an important dictator of the secondary 
response to Lm-2W1S. CD28 was required for the optimal expansion of all 
subsets following challenge, while OX40 and ICOS again appeared to exert effects 
on specific subsets. ICOS was not required for expansion except for TFH cells, 
similar to what was observed in the primary response. Again OX40 signalling 
specifically benefited the effector cell population by enhancing expansion of Tem 
cells. Understanding what costimulatory signals are required upon recall will aid 
in the development of optimal vaccination strategies for control of diseases in 
which traditional humoral vaccines have been unsuccessful.   
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6.2 Concluding remarks 
Through the use of a model to track an antigen-specific CD4+ T cell population 
we have elucidated the differing requirements for costimulatory molecules and 
the migratory behaviour of T cell subsets. The formation of an optimal memory T 
cell pool was dependent upon signals through CD28, ICOS and OX40. However 
these costimulatory signals were not required for the long-term persistence of 
memory cells once formed. Upon secondary challenge a differential requirement 
is seen; CD28 is important for the expansion of all T cell subsets whereas OX40 
and ICOS were important for Tem cell and TFH cell expansion respectively. We 
have identified a putative lymphoid tissue resident memory cell population that 
does not appear to recirculate from the draining lymph node.  
 
 
6.3 Future Work 
To fully elucidate the mechanisms regulating the long-term persistence of CD4+ 
memory T cells once formed more refined methods are required. Ideally this 
would include the use of inducible conditional knockout mice to selectively 
remove costimulatory receptors, OX40 and ICOS, from CD4+ memory T cells once 
the primary response has resolved. For example CD4 cre/ERT2 mice, which have 
a tamoxifen inducible Cre recombinase under the control of the Cd4 promoter, 
crossed with either OX40 fl/fl or ICOS fl/fl mice. This would directly assess 
whether CD4+ memory T cells require continuous or periodic signals through 
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costimulatory receptors for their persistence. This strategy can be employed to 
dissect the role of costimulatory receptors in multiple CD4+ T cell responses. 
Understanding the precise requirements of different responses will facilitate 
therapeutic manipulation for clinical benefit.  
Fundamentally, it is still unclear whether signals through the TCR are required 
for the persistence of CD4+ memory T cells; experiments in MHC-/- mice 
demonstrating TCR signals are dispensable used adoptive transfer of TCR 
transgenic T cells into T cell deficient mice. Therefore more sophisticated 
methods such as inducible conditional knockout mice could again be applied to 
induce deletion of MHC II expression after the formation of CD4+ memory T cells 
in WT mice.  
In this thesis I have identified a putative resident CD4+ memory T cell population 
in a peripheral skin draining lymph node. The function of this population is 
currently unknown. Thus experiments to test whether this population persists 
for the lifetime of the mouse or occupies a niche that will be vacated upon 
subsequent responses should be performed. For example, mice could be 
immunised as presented in Chapter 5 with 2W1S peptide in the paw pad and 
following formation of the memory cell population immunised with a distinct 
antigen, listeriolysin (LLO) peptide for which MHC II tetramers are available. 
Analysis of the draining lymph node 42 days after this second immunisation 
would then identify if the original 2W1S:I-Ab+ CD4+ T cell population remains or 
if this has been replaced by a LLO:I-Ab+ CD4+ T cell population. Additionally I 
would like to assess if these resident cells display Tem cell like functions upon 
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immunisation. To do this mice will be re-immunised at a distal site with cognate 
antigen and the migration of 2W1S:I-Ab+ CD4+ T cells away from the resident site 
will be assessed. These experiments would provide key further data on the 
function of this putative lymph node resident CD4+ memory T cell population.  
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Papers arising from this thesis: 
Marriott, C. L., Mackley, E. C., Ferreira, C., Veldhoen, M., Yagita, H. and Withers, D. 
R. (2014), OX40 controls effector CD4+ T-cell expansion, not follicular T helper 
cell generation in acute Listeria infection. Eur. J. Immunol., 44: 2437–2447. 
doi: 10.1002/eji.201344211 
Marriott, C. L., Carlesso, G., Herbst, R. and Withers, D. R. (2015), ICOS is required 
for the generation of both central and effector CD4+ memory T-cell populations 
following acute bacterial infection. Eur. J. Immunol., 45: 1706–1715. 
doi: 10.1002/eji.201445421 
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